Advances in the Diagnosis and Treatment of Amyloidosis and Related Disorders by Sayed, Rabya Hussain
1 
 
 
Advances in the Diagnosis and Treatment of 
Amyloidosis and Related Disorders 
 
Rabya Hussain Sayed 
 
Doctor of Medicine 
University College London 
 
UK National Amyloidosis Centre 
Department of Medicine 
Royal Free Hospital 
Rowland Hill Street 
London NW3 2PF 
 
MD (Res) Thesis 
2018 
2 
 
 
Declaration 
 
I, Rabya Hussain Sayed, confirm that the work presented in this thesis is my own.  
I have declared where information has been derived from other sources. 
 
 
 
Signature: (electronically signed)  
 
Name: Rabya Hussain Sayed    Date: 7th December 2017 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Abstract 
Background 
Amyloidosis is a disorder arising from the variable physiological effects of dysregulated, 
extracellular protein deposition. There are >30 different subtypes, all possessing the same 
histological characteristics and the two major organs affected are the kidneys and the heart.  
Aims and Hypothesis  
➢ To evaluate current UK histological practices leading to a misdiagnosis of amyloidosis  
➢ To establish proteomics as a new diagnostic technique for identifying amyloid, in the 
UK  
➢ To investigate the usefulness of a relatively new biomarker i.e. Retinol Binding Protein 
(RBP), across amyloid subtypes and correlate values with biopsy findings, which has 
not previously been done 
➢ To identify the cause of death in patients with Stage III/ IV cardiac amyloidosis using, 
for the first time, Implantable Loop Recorders. 
➢ To present the first comprehensive review of Light Chain Deposition Disease 
highlighting the relationship between haematological response and overall prognosis 
 
Results 
In 65% of cases where renal amyloidosis was misdiagnosed as minimal change disease, 
Congo red staining was not undertaken and in 35% of cases neither Congo red staining, 
with cross-polarised light visualisation, nor electron microscopy was undertaken.  
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Proteomics has now been established as a specific and sensitive technique by which to 
diagnose amyloid and the subtype, demonstrated by distinguishing Fibrinogen Aα-Chain 
(AFib) renal biopsies from other subtypes.  
 
Urinary RBP/Creatinine (RCR) correlated with the: degree of tubular atrophy, number of light 
chains, eGFR, presence of glycosuria and degree of tubular phosphate reabsorption. RCR 
values were especially high in AFib and AA amyloidosis. 
 
Pulseless Electrical Activity was identified as the terminal rhythm in patients with Stage III/IV 
cardiac amyloidosis and this was preceded by a high degree AV block. 
 
Deep clonal responses to chemotherapy are associated with improved renal and overall 
outcomes in LCDD and should be pursued even in advanced chronic kidney disease. 
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Chapter One 
 Introduction 
This chapter is, in part, based on the publication below: 
Emerging treatments for amyloidosis. Sayed RH, Hawkins PN, Lachmann HJ. 
Kidney Int. 2015 Mar; 87(3):516-26. Review 
The term amyloidosis encompasses a group of diseases caused by the pathogenic 
misfolding and aggregation of specific proteins, resulting in the formation of insoluble fibrils 
and their accumulation in the extracellular space, ultimately causing organ dysfunction and 
death. The term amyloid or starch-like was first coined by Virchow in 1858 following the 
reaction of tissue deposits to iodine and sulfuric acid, this mixture conventionally being used 
to identify starch in plants [1]. Since then, more than 30 different amyloid fibril precursor 
proteins have been identified, but all types of amyloid fibril share an essentially similar 
ultrastructure [2].  This acquired highly characteristic β pleated conformation of amyloid 
fibrils is associated with specific biophysical properties, including the ability to bind Congo 
red dye in a spatially ordered fashion that produces diagnostic green birefringence when 
viewed under cross-polarised light [3, 4]. Under electron microscopy, amyloid deposits 
appear as randomly arranged, rigid nonbranching fibrils of ∼10 nm in diameter and of 
indeterminate length [5]. All subtypes also contain Serum amyloid P component (SAP) which 
is a normal serum, non-fibrillar plasma glycoprotein, specifically concentrated in amyloid 
deposits as it binds avidly and reversibly to all types of amyloid fibrils [6]. This component 
plays a crucial role in an exciting new treatment strategy for amyloidosis and is also used 
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for binding purposes in SAP scintigraphy and in confirming amyloid deposition in proteomic 
analysis [7]. 
 
Recent diagnostic developments have improved disease recognition and the incidence of 
systemic amyloidosis is estimated to be at least c.8 per million per year although likely to be 
higher [8].  Untreated, the prognosis for the commonest amyloid subtype is only 12 months 
and the prognosis in treated individuals, after 20 years of drug development, now exceeds 
3 years [9]. It is estimated to be the cause of death in 0.58/1000 cases and is responsible 
for 0.8% of cases of end-stage renal disease [8, 10]. It remains critically important that we 
strive to further lessen the morbidity and mortality burden that accompanies the diagnosis 
of such a potentially debilitating disease. 
 
Pathogenesis 
Essentially there are understood to be 4 main settings in which amyloid formation can occur: 
 
Persistently high levels of a normally present protein due to either increased 
production, as in AA amyloidosis where serum amyloid A (SAA) levels are increased 
or high levels secondary to decreased elimination e.g. β2-microglobulin in Aβ2m in 
end-stage renal failure (ESRF). 
 
Short term exposure to a highly amyloidogenic precursor protein such as light chains 
(LCs) in light chain (AL) amyloidosis or variant proteins in hereditary amyloidosis. 
 
When there is normal abundance of a ‘normal’, but to some extent inherently 
amyloidogenic protein over a very prolonged period which undergoes remodelling, 
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such as transthyretin in wild type TTR amyloidosis (ATTRwt), formerly known as 
senile systemic amyloidosis. 
 
When the mechanism is as yet unknown e.g. in Leukocyte chemotactic factor 2 
amyloidosis (ALECT2), where raised levels, mutations or proteolytic remodelling 
have not yet been identified as a possible cause [11].  
 
However, clearly only a small percentage of patients in such circumstances go on to develop 
amyloidosis i.e. not everyone with a long term inflammatory process or plasma cell dyscrasia 
(PCD) or advancing age will develop AA, AL or ATTRwt (respectively) amyloidosis. 
Additionally, in the hereditary amyloidosis, even in kindred with the same genetic mutation 
there can be great variability in penetrance and severity, perhaps related to the size of the 
precursor protein fragment [12]. Hence there are genetic and environmental factors at play 
that we do not fully comprehend. 
 
The exact mechanisms by which amyloid deposits, once formed, cause tissue damage have 
not yet been fully elucidated. It is generally believed that large amounts of insoluble amyloid 
fibril aggregates deposit extracellularly, disrupt tissue architecture and mechanically 
interfere with the physiologic function of affected organs [13]. These pathological fibrils arise 
due to ‘misfolding’ of the precursor proteins into a β- sheet structure as opposed to the usual 
α helical structure formed by most proteins [14]. However, the reason for this propensity 
towards abnormal fibril formation is poorly understood. Additionally, once formed, amyloid 
fibrils act as a nidus encouraging the exponential accumulation of further amyloid- as 
demonstrated by experimental mice models in whom amyloid tissue was injected. They 
developed AA amyloidosis within days of an acute inflammatory stimulus unlike ‘unprimed’ 
mice who developed amyloid weeks after an ongoing inflammatory stimulus. Amyloid thus 
23 
rapidly accumulates once this amyloid enhancing factor / template is established. 
Furthermore, prefibrillar oligomeric species may also be toxic and contribute to organ 
dysfunction; cytoxicity, in these cases, seems to be related to structural flexibility and 
exposure of hydrophobic residues [15]. Once formed, interactions with other moieties 
renders the amyloid fibril resistant to degradation, notably glycosaminoglycans, such as 
heparan and dermatan sulphate, as well as SAP [16]. These promote misfolding and SAA 
aggregation both in vitro and in vivo and accelerate the process through acting as a scaffold 
for polymerisation.  Heparan sulfate is thought responsible for the stability of SAA2, the 
immediate precursor to AA amyloid, in adopting the β-sheet structure [17]. In the case of 
transthyretin amyloidosis, the conversion of circulating TTR protein into amyloid requires 
dissociation of the normal tetrameric protein into monomers, and a massive change in 
conformation and assembly to form the fibrils [18]. The stability of the tetramer and transition 
to amyloid are influenced by disease-associated mutations and environmental factors such 
as pH and oxidative stress [19, 20].  
 
Overall, fibrillation is an unfavourable process in which proteins overcome a thermodynamic 
and kinetic barrier and, therefore, it is not unexpected that it occurs over a long time [21]. 
Increasing evidence supports the possibility that multiple, morphologically distinct forms of 
amyloid fibrils may be generated from a single amyloidogenic protein through different 
aggregation pathways.  Some of the risk factors leading to the formation of pathological, 
misfolded and insoluble fibres are known to us: time and a sustained, critical concentration 
of the precursor protein, changes in amino acids leading to variant protein production as 
seen in the hereditary amyloidosis and proteolytic remodelling of the protein precursor, as 
in the case of β-amyloid precursor protein in Alzheimer's disease [22]. These mechanisms 
can occur independently or in association with one another.  
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Amyloid regression has occasionally been seen post treatment, as evidenced by functional 
testing, imaging and blood tests. The exact mechanism is unknown but macrophages and 
the complement pathway are both believed to play a role, with the former identified around 
amyloid deposits [23]. Studies suggest that macrophages have both a role in the formation 
and the degradation of amyloid deposits. In amyloid AA and AL amyloid, the precursor 
protein is proteolysed by macrophages prior to its deposition as an amyloid fibril and hence 
macrophages are involved in amyloid formation.  With regards to degradation, macrophages 
form multinucleate giant cells whose increased surface area, arising from membrane ruffles, 
aids in the phagocytosis of large C3 opsonised objects [23].   Macrophage depletion with 
liposomal clodronate, has been shown to retard amyloid regression in vivo [24]. It may be 
that differences in rates of amyloid regression are secondary to differences in the phenotype 
and function of macrophages or monocytes, as well as the success of treatment in 
suppressing amyloidogenic precursor protein production. The net effect of amyloid 
regression is stabilisation or improvement of organ function coupled with increased patient 
survival.  
 
Amyloid Subtypes 
 
 As mentioned above there are >30 different types of fibril precursor protein giving rise to 
varying amyloid subtypes, although not all cause overt disease. The current nomenclature 
consists of the first letter, A (for amyloid), followed by a description of the precursor protein 
e.g. primary or AL associated amyloidosis which arises from a PCD. The subsequent 
disorders can be divided according to distribution type (systemic/ localised) or depending 
upon whether they are acquired or hereditary. The more common of these are listed in Table 
1.1, followed by a brief description of some of the subtypes. 
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Table 1.1. The major amyloid subtypes 
 
Amyloid 
Subtype 
 
Fibril 
Precursor 
 
Treatment 
 
Organs Involved 
 
AL 
 
Monoclonal  
free 
immunoglobulin  
light chains 
 
Chemotherapy directed at   
the underlying plasma cell 
dyscrasia 
Potentially novel agents 
 
Renal (50-80%), cardiac, 
liver, spleen, bones, GI, 
autonomic and peripheral 
neuropathy, soft tissue 
 
AA 
 
Serum amyloid A 
protein  
 
Treatment aimed at 
specific underlying  
inflammatory condition 
Potentially eprodisate 
 
Renal (>95%), liver, 
spleen, adrenals, 
autonomic neuropathy 
TTR: Senile   
Systemic 
 
TTR: Hereditary 
 
Wild type 
transthyretin  
 
 
Variant 
transthyretin 
(more than 100 
different variants)  
Cardiac transplantation 
Potentially novel agents 
 
Liver +/- cardiac +/-renal 
transplantation 
Tafamadis 
Potentially novel agents 
Cardiac, soft tissue 
 
Dominant neurological+/- 
cardiac involvement 
(dependent upon specific 
TTR variant) 
 
A Fib 
(hereditary) 
 
Variant Fibrinogen 
Aα  
 
Renal ± liver 
transplantation 
Potentially novel agents 
 
Renal 
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Apolipoprotein 
AI 
(hereditary) 
Variant 
Apolipoprotein AI 
 
Renal +/- Liver 
transplantation 
Potentially novel agents 
Renal (mainly medullary), 
liver, heart, skin, larynx 
 
Apolipoprotein 
AII 
(hereditary) 
Variant 
Apolipoprotein AII      
 
Renal transplantation 
 
Potentially novel agents 
Renal 
 
 
AGel 
 
Variant gelsolin 
 
Renal transplantation 
Cranial nerve. 
involvement 
Lattice corneal dystrophy 
Lysozyme 
(hereditary) 
 
Variant lysozyme   
Renal transplantation 
Potentially novel agents 
Renal, liver, GI, spleen, 
lymph nodes, lung, 
thyroid, salivary glands 
 
Abbreviations: AA, amyloid A; AFib, fibrinogen Aα-chain; AL, immunoglobulin light chain 
amyloidosis; ATTR, amyloidogenic transthyretin; β2M, β2-microglobulin; GI, 
gastrointestinal; TTR, transthyretin
27 
 Systemic Amyloidosis 
AL amyloidosis 
AL amyloidosis, otherwise known as immunoglobulin LC amyloidosis, taking its name from 
the amyloidogenic LCs, more commonly λ than κ, which are almost invariably produced from 
an underlying B-cell dyscrasia [25]. Rarely, a combination of heavy and LCs cause the 
disease, or just heavy chains alone can cause systemic amyloidosis, termed AHL and AH 
amyloidosis respectively [26]. The LCs themselves, which are most commonly part of the 
variable domain, are inherently pathogenic and propagate fibril formation leading to systemic 
amyloidosis [27]. There is evidence of differences in the amino acid substitution in this 
variable region between those patients with a PCD who go on to develop amyloidosis and 
those patients who do not [28] . The most severe manifestation is cardiac amyloidosis, 
occurring to some degree in >70% of patients and largely determining both treatment 
tolerance and outcome [29]. This most commonly manifests as a restrictive cardiomyopathy 
ultimately resulting in congestive cardiac failure, at which point median survival is only 4-6 
months [30]. A cohort of patients thus affected are investigated further in the Implantable 
Loop Recorder Study, as described in Chapter 6. Equally frequently the kidneys have also 
been found to be affected which gives rise to proteinuria, progressing in some patients to 
nephrotic syndrome [31]. The pathognomonic periorbital purpura and macroglossia actually 
occurs in only <15% of patients with systems, such as the hepatic (22%), autonomic and 
peripheral nervous system (15%) and soft tissues (15%) being involved more commonly 
[32]. The brain is not affected. 
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AA Amyloidosis 
In AA amyloidosis, the amyloid deposits are derived from the circulating acute phase 
protein, serum amyloid A (SAA), an apolipoprotein of HDL type, whose N-terminal 
fragments spanning the first 66-76 amino acids form the actual protein precursors  [33]. 
SAA levels range between 1 to >3,000 mg/L, with higher levels occurring when production 
is upregulated to potentially a 1000-fold during acute inflammation [34, 35]. SAA is 
synthesised by hepatocytes under regulatory control of proinflammatory cytokines such as 
tumour necrosis factor (TNF), interleukin 1 (IL-1), interleukin 6 (IL-6) and transcription 
factors such as SAA activating factor and lipopolysaccharide [36-38]. Additionally, the 
hepatic clearance of SAA during both acute and chronic inflammation is reduced, adding 
to the elevated levels seen [39]. Although SAA’s exact function as an acute phase reactant 
remains unclear, persistently elevated SAA levels are a ubiquitous feature noted in all 
established human cases of SAA amyloidosis.  
 
The onset of organ dysfunction is usually acute, suggesting the presence of a triggering 
event in patients who do develop amyloidosis; the major target organs involved are the 
spleen and kidneys with progressive proteinuric renal dysfunction being the most clinically 
relevant common presenting feature with approximately 25% of cases progressing to ESRF. 
Cardiac involvement and neuropathy are only ever very rarely reported and hepatic 
involvement, a feature of advanced disease, confers a poor prognosis [40]. 
In the developed world, the most frequent predisposing conditions are the inflammatory 
arthritides, followed by chronic sepsis, inflammatory bowel disease and the hereditary 
periodic fever syndromes (Table 1.2): Familial Mediterranean Fever (FMF), hyper-
immunoglobulin D syndrome (HIDS), TNF receptor associated periodic fever syndrome 
(TRAPS), familial cold urticaria (FCU) and Muckle-Wells syndrome (MWS) [40]. 
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Tuberculosis still remains the commonest cause overall although AA amyloidosis may occur 
in association with any kind of chronic inflammatory disorder and the lifetime incidence of 
AA amyloidosis in those with chronic inflammatory conditions is 1-5%. In 6% of patients 
there is no clinically evident underlying inflammatory disorder [40, 41].  
Table 1.2. Inflammatory disorders potentially resulting in SAA protein amyloidosis 
Disorder 
Chronic Inflammatory Disorder: 
Rheumatoid arthritis  
Juvenile Inflammatory Arthritis   
Ankylosing Spondylitis 
Psoriasis and Psoriatic Arthropathy 
Reiter’s Syndrome 
Adult Still’s Disease 
Behcet’s Syndrome 
Crohn’s Disease  
Ulcerative Colitis 
Gout 
 
Chronic Microbial Infections 
Leprosy 
Tuberculosis 
Bronchiectasis 
Cystic Fibrosis 
Decubitus ulcers 
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Complications of paraplegia 
Osteomyelitis 
Whipple’s Disease   
Infections in intravenous drug abusers 
Ciliopathies 
Neoplastic Disease 
Hodgkin’s lymphoma 
Non-Hodgkin’s Lymphoma 
Renal carcinoma 
Carcinomas of gut, lung, urogenital tract 
Basal Cell Carcinoma 
Hairy Cell Leukaemia 
Castleman’s Syndrome 
 
Autoinflammatory Diseases 
Familial Mediterranean Fever 
TNF receptor-associated periodic fever syndrome  
Hyper-IgD syndrome 
Cryopyrin-associated periodic syndrome  
Familial Cold Autoinflammatory Syndrome 
Muckle-Wells Syndrome 
Neonatal-onset multisystem inflammatory disease 
Mevalonate kinase deficiency 
Schnitzler Syndrome 
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Systemic Vasculitis 
Behcet’s Disease 
Polyarteritis Nodosa 
Giant cell arteritis 
Takayasu’s arteritis 
Polymyalgia Rheumatica 
 
Others 
? Obesity 
Sarcoidosis 
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) 
 
Although the median latency between onset of inflammation and diagnosis is approximately 
17 years, some individuals develop amyloid within months [40]. Outcome in AA amyloidosis 
is favourable when SAA concentrations remain below 10mg/l and correspondingly, it is the 
control of inflammation and hence of SAA production in patients with AA amyloidosis which 
arrests amyloid accumulation [42]. Although outcomes have improved markedly in recent 
years through better control of inflammation, AA amyloidosis is still a potentially fatal 
complication of chronic inflammatory states and there remain important lacunae in our 
understanding of its pathogenesis, including: the factors which predispose only certain 
individuals to developing amyloidosis, the exact mechanism by which inflammation leads to 
amyloid deposition and why the distribution, severity and progression of amyloid deposition 
differs in those affected. 
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Transthyretin (ATTR) Amyloidosis 
Transthyretin (TTR) is a 55kDa homotetrameric plasma protein almost exclusively produced 
from the liver, save for 5% from the choroid plexus and retina. It transports thyroxine and 
retinol (hence transthyretin) and is associated, in its wild-type (wt) form, with acquired 
amyloidosis of the senile systemic type, now termed wild-type transthyretin amyloidosis or 
ATTRwt [43]. More than 100 genetic variants of TTR are associated with autosomal 
dominant hereditary amyloidosis, the most common inherited amyloidosis worldwide, and 
these mutations may increase TTR’s predisposition to misfold into an insoluble β-pleated 
sheet. 
 
Wild-type transthyretin (ATTRwt) amyloid  
ATTRwt amyloidosis is being ever more increasingly diagnosed and is an important 
differential in elderly patients with putative hypertensive or hypertrophic cardiomyopathy, 
especially in cases where there is heart failure with a preserved ejection fraction. ATTRwt 
can be associated with hypotension, aortic stenosis with a paradoxical slow flow and atrial 
fibrillation [44-46]. It is much less rapid in progression than AL or AA amyloidosis, but is 
more common, especially in elderly white men with a 25 to 50:1 male: female preponderance 
[47]. Approximately 25% of patients >80 years had amyloid detected in a cardiac autopsy 
study, although only two-thirds of these patients actually had left ventricular involvement and 
50% of these had any significant level of involvement- placing the prevalence at 8-16%  [47-
49] . ATTRwt presents as restrictive cardiomyopathy, congestive cardiac failure, arrhythmias 
and/or conduction defects with patients having a better median survival than that in cardiac 
AL amyloidosis [50]. Cardiac symptoms are preceded by a history of carpal tunnel 
syndrome, with the incidence being 48% in one study and onset a median of 8 years prior 
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to the diagnosis of heart failure; amyloid deposits have been found on palmer fascia biopsies 
post carpal tunnel release surgery [51]. 4% of patients presented with haematuria and 
evidence of bladder amyloid, with other non-clinically significant deposits in ATTRwt 
frequently being present in the lungs, gut and small arteries [52].  
 
A left bundle branch pattern on ECG is seen more commonly in ATTRwt and small QRS 
complexes are seen in other subtypes of cardiac amyloid too [53]. Echocardiography 
demonstrates a markedly thickened myocardium, more so than that typically found in 
cardiac AL amyloidosis [54]. In a study of 18 patients with ATTRwt the mean interventricular 
septal thickness was 17.8mm in the ATTRwt group as compared to 14.3mm in the AL group 
(P=0.002) [47]. The identification of ATTRwt has lately increased due to the advent of CMR 
imaging but diagnosing the exact amyloid subtype on CMR alone is difficult.  Although 
99mTc-DPD scintigraphy is a sensitive imaging technique in diagnosing cardiac 
transthyretin amyloidosis especially where Perugini high grade imaging is present, there are 
cases of DPD positive scans in AL amyloidosis [55]. Such cases cannot be differentiated 
through biomarkers alone i.e. 7.5% of patients >85 years old have a monoclonal 
gammopathy of uncertain significance (MGUS) so serum LC aberration cannot be assumed 
to signify AL amyloidosis [56]. Hence, the definitive diagnosis of transthyretin amyloid 
continues to rest on the combination of finding transthyretin amyloid on endomyocardial 
biopsy and wild-type TTR gene sequencing [57, 58]. The correct diagnosis is crucial as 
management differs markedly from AL cardiac amyloid i.e. the mainstay of management is 
supportive care and symptomatic management in ATTRwt amyloid as opposed to potentially 
chemotherapy or stem cell transplantation in AL amyloidosis. In two prospective studies the 
median survival time from diagnosis was 43 and 46.7 months, with 78% of the deaths in the 
latter being secondary to cardiac causes [47, 59, 60]. A recent study of 121 patients with 
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ATTRwt identified uric acid, Brain Natriuretic Peptide (BNP), left ventricular ejection fraction 
(LVEF), and relative wall thickness as predictors of shorter survival [60]. 
 
Hereditary Transthyretin Amyloidosis 
Hereditary TTR amyloidosis mostly affects the peripheral and autonomic nervous system 
and/or the heart, termed Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid 
Cardiomyopathy (FAC) respectively [61, 62]. Depending upon the mutation, the: penetrance, 
presence, age of onset, severity and extent of cardiac and neuropathic involvement differs.  
Additionally, there are varying degrees of amyloid deposition in the viscera, vitreous, gut, 
and occasionally the central nervous system.  Typically, the neuropathy is a length 
dependent ascending, sensorimotor, axonal polyneuropathy; autonomic involvement is 
usually present, manifesting as: orthostatic hypotension, dysfunctional sweating, a change 
in bowel habit, erectile dysfunction, urinary incontinence and orthostatic syncope [63].  
Untreated FAP is a progressive disease resulting in death within 7-15 years; although renal 
amyloid deposits do occur, only 34.6% develop chronic kidney disease (CKD) and 10% 
progress to ESRF [64, 65]. Notable variants are as follows: 
 
Met30 TTR variant 
This is the commonest transthyretin mutation globally, arising from the substitution of 
methionine for valine at position 30 (ATTRV30M) and is characterised by a progressively 
debilitating and painful sensorimotor neuropathy and autonomic involvement with cardiac 
involvement being rare. Onset is usually by 30-40 years in the Portuguese cohort, but about 
20 years later in the Swedish one and death occurs a median of 10 years post symptom 
onset [66-68]. 
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T60A TTR Variant 
This is the commonest cause of FAP in the UK and Ireland, usually presenting after the 
age of 50 with autonomic symptoms, but cardiac amyloid is virtually always present at 
diagnosis [69]. It is believed to originate from northwest Ireland, specifically Donegal [70]. 
 
V122I Variant 
3-4% of African-Americans have the V122I transthyretin variant, which is associated with a 
predominantly cardiac phenotype without a neuropathic component, usually presenting 
after the age of 60 and clinically indistinguishable from ATTRwt [71, 72] . It does not 
actually contribute to excess mortality but does contribute to excess morbidity, in that there 
is a higher incidence (10%) of New York Heart Association Classification III and IV [73]. 
The mutation is thought to have originated from the Caribbean [58].  
 
Transplantation in Hereditary TTR Amyloidosis 
As >90% of circulating TTR protein is liver derived, ‘surgical gene therapy’ with orthotopic 
liver transplantation has been undertaken in more than 2000 FAP patients since 1990 [74, 
75]. Liver transplantation when performed early has been shown to prolong life, particularly 
in patients with the TTR Met30 variant, which makes up 83% of transplant cases, but long-
term outcomes reveal that neuropathy and organ involvement are not typically reversed [76, 
77]. BMI, early disease onset (age <50yrs), disease duration pre- transplantation and TTR 
V30M versus non-V30M TTR mutations are independent and significant factors affecting 
survival [63]. Post-transplantation, patients with V30M mutations have a 5year survival rate 
of 100% as opposed to 59% for patients with non-V30M ATTR [75]. This may reflect the 
occurrence of amyloid cardiomyopathy post-operatively, thought to be due to the deposition 
of wt transthyretin on a template of pre-existing cardiac amyloid derived from variant proteins 
[78]. In fact, renal, neuropathic and or GI deposits have also been found to contain both wt 
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and variant TTR amyloid in mutant TTR carriers, and in patients, post liver transplantation, 
the ratio of wt to mutant TTR increases implying that ‘pathological’ wtTTR continues to 
deposit in affected tissues post- transplant in a time-dependent manner and leads to a 
deterioration in quality of life ~4 years post liver transplantation [79]. The clear need for other 
therapies has resulted in the development of novel anti-amyloid therapies, both with a view 
to stabilising soluble TTR in the blood i.e. tafamadis and diflunisal which have already been 
proven effective in FAP and are used by several hundred patients, and by inhibiting its 
production through silencing RNA and anti-sense oligonucleotide approaches [80].  Several 
strategies have already progressed to clinical trial [81].    
Hereditary non- ATTR Systemic Amyloidosis 
There are several forms of hereditary systemic amyloidosis, which are associated with 
genetically variant proteins, mostly comprising single amino acid substitutions. They 
are inherited in an autosomal dominant manner with variable penetrance accounting for 
a frequent absence of a family history, suggesting a contributory role of other factors [82].  
 
Hereditary Gelsolin Amyloidosis (AGel) 
Hereditary gelsolin amyloidosis otherwise known as familial amyloidosis of the Finnish, is 
an autosomal dominant disorder secondary to at least 2 known mutations:  guanine’s 
replacement by adenosine on chromosome 9 at q33.2, GSN c.640G > A, and GSN 
C.640G>T [83]. The former was first described and believed to be most common in the 
Finnish population where it is one of the most common hereditary disorders. It has now been 
identified in North America, Asia and Mexico, whilst GSN C.640G>T has been found in 
Denmark, former Czechoslovakia, France and Brazil [84]. 
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Gelsolin itself is a calcium-activated, actin-modulating protein [85]. AGel amyloid fibres are 
believed to accumulate in various tissues with a triad of clinical sequelae: progressive 
corneal lattice dystrophy, a cranial bifacial neuropathy (amongst other neurology) and signs 
of cutix laxa [86]. Other less common features include potentially fatal generalised amyloid 
angiopathy, renal amyloidosis (nephrotic syndrome), conduction defects, valvulopathies, 
depression and progressive cranial neuropathy leading to bulbar palsy and oropharyngeal 
tissue laxity [87-91]. The age of onset can be as early as 13 years in homozygous disorders 
and around the age of 30 in heterozygous disorders.  Although penetrance is 100%, disease 
manifestations and severity vary between patients, with the diagnosis being verified using 
molecular genetic analysis [84]. In a recent study, 20% of 272 deaths were attributed to 
AGel, although the exact mechanism was not found and interestingly cancer as a cause of 
death was less frequent than in the general population and renal complications were more 
frequently fatal, especially in females [92]. There is no specific curative treatment at present 
but symptomatic treatments to improve quality of life include: good ophthalmological care 
and lubrication, corneal transplantation, surgical intervention to correct facial laxity, and 
renal transplantation [86, 93]. 
 
Fibrinogen A α-chain (FibA) Amyloidosis 
Renal amyloid composed of fibrinogen A α-chain is the most common form of hereditary 
renal amyloidosis worldwide and was first identified in 1993 in a Peruvian family [94].  
Fibrinogen is a liver-derived plasma glycoprotein that plays an essential role in the 
coagulation pathway. It consists of 2 identical sets of 3 polypeptide chains termed α, β, and 
γ, joined by disulfide bridging. Each polypeptide is encoded by a distinct gene and known 
as Fibrinogen alpha (FGA), beta (FGB) and gamma (FGG). The gene for the fibrinogen A 
α-chain which has 610 amino acid residues is localised on chromosome 4 and has 6 exons. 
Mutations in any of the 3 genes encoding for fibrinogen polypeptides can cause 
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dysfibrinogenemias, and mutations in the A α-chain gene can lead to hereditary systemic 
amyloidosis [95]. The diagnoses FibA amyloidosis, including the different variants, using 
proteomics is further discussed in Chapter 4 of this thesis. 
 
Patients with AFib amyloidosis typically present with nephrotic syndrome and hypertension, 
usually in the 5th decade of life [96]. CKD usually develops within 1-5 (median 4.6) years 
from the time of diagnosis. Patients with ESRD have an estimated survival time of 
approximately 9 years and survival from the time of presentation is typically 15 years. Renal 
transplantation has been undertaken but graft survival, on average, is 6.7 years and failure 
occurs due to recurrent disease [94]. In comparison, combined liver and kidney 
transplantation, in which the circulating amyloidogenic variant has been removed, is a 
curative operation and removes the risk of allograft failure due to recurrence of amyloid. 
However, despite careful patient selection there was not an inconsiderable amount of 
morbidity and mortality associated with a combined liver-kidney transplant with a procedure 
related mortality of 33% [94].  
 
Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) 
ALECT2 is believed to be hereditary although the exact mutation has not yet been identified 
[11]. It is a familial disorder and one which has been found to occur most frequently in certain 
population groups, including Hispanic, Punjabi, Arab, Israelis, Native Americans and 
Sudanese [97, 98]. It is the third most common cause of hereditary renal amyloidosis and 
second commonest cause of hepatic amyloidosis. The median age of diagnosis in the 
largest case series was 70.4 years and a progressive decline in renal function was noted 
with an eGFR deterioration of 0.5 ml/min/1.73 m2 per month [99]. Heavy proteinuria was not 
a feature unless there was a co-existing glomerulopathy and most patients had proteinuria 
<200mg/day [99]. From the 3 largest studies, proteinuria was absent in up to 67% of cases 
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[98-100]. ALECT2 deposits are very Congophilic and widespread, save for the medulla, with 
deposits being noted in the renal cortex, glomeruli and arteries.- unlike APOA IV which has 
a medullary preponderance [99]. 26 of the 40 patients in this case series underwent gene 
sequencing and all 26% were homozygous for the G nucleotide in a non-synonymous SNP 
at position 172 (SNP rs31517). However, this polymorphism is common in those with a 
Mexican heritage and so does not necessarily imply causality, however the authors 
concluded that there was another, as yet unknown, mutation which, combined or having 
aggregated with the aforementioned polymorphism, led to the ALECT2 phenotype [101]. 
Serum LECT2 concentrations were not shown to be elevated, suggesting that systemic 
overexpression of the LECT2 protein is not the aetiology. There is no specific treatment for 
ALECT2, although it is important to accurately diagnose this type of amyloid to avoid 
mismanagement of ALECT2 as though it were AL amyloidosis [101]. Patients have 
undergone renal transplants with a good short-term outcome thus far [102].  
 
Localised Amyloidosis 
Localised amyloidosis refers to amyloid deposition confined to a single organ or tissue which 
will not evolve into systemic amyloidosis and so it is particularly important to ensure that it 
is not an early manifestation of the relatively more common systemic AL. These local 
deposits are believed to be associated with LCs, as identified by immunohistochemistry, 
arising from a focal B cell dyscrasia [103]. Case reports and the largest retrospective cohort 
study to date (606 patients) has found that most of the sites affected are mucosal in nature 
and include (in order of frequency of occurrence): bladder, laryngeal or tonsillar, cutaneous, 
pulmonary nodular, gastrointestinal, oral, tracheobronchial, lymph node, conjunctival, bone, 
eyelid, orbital, breast, ureteric, urethral, soft tissue, prostate, cerebral and aortic valve in one 
(<1%). Assessment also included gene sequencing if, for example laryngeal amyloid was 
suspected as this is associated with APOA 1 mutations and TTR gene sequencing where 
40 
samples stained for transthyretin, to exclude ATTR amyloidoisis (1% of bladder biopsies) 
[104]. Although follow up studies have not revealed evolution into systemic amyloidosis over 
20 years, it is important to follow up such patients to ensure that the initial diagnosis is correct 
as 1% of patients have actually been found to have systemic disease and required 
chemotherapy [104]. Additionally, follow up is important as patients require assessment of 
local symptoms and sometimes treatment i.e. 51% of patients needed an intervention and 
21% of them needed more than one. Treatment in these cases was for pressure effect and 
pain and comprised of surgical resection and/or radiotherapy. Diagnosis usually takes 7 
months from the time of medical presentation with a median age of presentation of 59.5 
years and no gender bias; life expectancy is not affected by this diagnosis [104]. 
 
                                    Symptoms, Signs and Assessment 
 
The insidious and diverse nature of symptoms arising from amyloidosis which may well 
overlap with any number of disease processes, can make diagnosing amyloidosis difficult 
at times- and yet there are some patients who present without any of the overt signs of 
amyloidosis. The sequelae of amyloidosis, regardless of type, arise from the infiltration of 
that organ by amyloid fibrils. The textbook patient would be one who presents with bilateral 
peri-orbital bruising, macroglossia, carpal tunnel syndrome or another neuropathy, 
dyspnoea and swollen lower limbs- however this constellation of symptoms is not usually 
seen. Additionally, phenotype can vary widely not only between the differing forms of 
hereditary amyloid but also within the same genetic disorders i.e. age of onset and severity 
can vary between family members, with females being affected later and less severely. The 
number and combination of different tissues affected differs between different subtypes and 
also amyloid can occur as a localised disease, restricted to one particular tissue [67]. There 
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is no evidence that amyloid deposition occurs in the brain [105]. The table below summarises 
the different symptoms and signs arising from involvement of various tissues and the usual 
mode of assessment and diagnosis. The statements in bold refer to diagnostic features in 
systemic AL as proposed by the 10th International Symposium in Amyloid and Amyloidosis, 
importantly a histological diagnosis is essential in every case [106].  
 
Table 1.3 Organ specific symptoms and signs associated with amyloid deposition 
Tissue Involved Symptoms & Signs* Diagnosis & Assessment 
Cardiac Dyspnoea 
Peripheral and pulmonary oedema  
Pleural and pericardial effusions 
Atrial and/or ventricular arrhythmias 
Hypotension 
Syncope 
Sudden death 
6-minute walk test 
Biomarkers: Nt-proBNP 
                    cTnT 
ECG +/- Holter monitoring 
DPD scan 
Echo: mean wall thickness > 
12 mm, no other cardiac 
cause 
CMR 
Endomyocardial biopsy 
Coagulation 
cascade 
Periorbital purpurae 
Bruising  
Testing for Factor X and IX 
deficiencies [107] 
Eyes Vitreous amyloid deposits (localised and in 
some variant TTRs)  
Extraocular muscle involvement (ptosis, 
ocular motility disturbances) 
Lacrimal gland (keratoconjunctivitis sicca) 
Orbital fat- palpable mass lesions 
Biopsy 
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Corneal lesions/ Lattice corneal dystrophy- 
visual disturbances, painful erosions 
Conjunctiva- painless yellow, pink rubbery 
lesion, haemorrhage 
Lung Dyspnoea 
Haemoptysis 
Direct biopsy verification with 
symptoms 
Interstitial radiographic 
pattern in systemic AL 
Hepatic Right upper quadrant fullness 
Bruising 
Peripheral oedema (low albumin) 
Jaundice 
Can progress to liver failure 
Elasticity 
Clotting, transaminases 
Radionuclide imaging/CT: 
Total liver span > 15 cm in the 
absence of heart failure or 
alkaline phosphatase > 1.5 
times institutional upper limit 
of normal 
Biopsy 
GI tract Motility disturbances secondary to 
autonomic nervous system involvement 
Malabsorption 
Altered bowel habit 
GI haemorrhage 
Biopsy of affected site 
Palmer fascia Carpal tunnel syndrome EMG 
Skin Bruising 
Lichen amyloid- pruritis 
Macular amyloid 
Nodular localised cutaneous amyloidosis 
Biopsy 
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Connective tissue Pseudohypertrophy of skeletal muscle, 
arthropathy, carpal tunnel syndrome, 
lymph node (s) 
Biopsy: myopathy 
Tongue Macroglossia: dysphagia, dysphonia 
obstructive Sleep Apnoea 
 
Nervous System Peripheral neuropathy (17-35% of AL 
amyloidosis patients and majority of TTR 
cases)- length dependent 
thermanesthesia, autonomic symptoms 
e.g. orthostatic hypotension, impotence, 
urinary retention and GI dysfunction and 
burning neuropathic pain. In advanced 
cases this can progress to a motor 
neuropathy [108-110] 
 
Gelsolin [111] 
Apolipoprotein A1 [112] 
Clinical examination 
findings: 
Peripheral: clinical; 
symmetric lower extremity 
sensorimotor peripheral 
neuropathy 
Autonomic: gastric-emptying 
disorder, 
pseudo-obstruction, voiding 
dysfunction not related to 
direct organ infiltration 
Renal Uraemic symptoms 
Froth in urine 
Serum creatinine/eGFR 
24-hr urine protein > 0.5 
g/day, predominantly 
albumin 
 
*not all or none may be present depending on severity and site of lesion 
Statements in bold refer to diagnostic criteria as per Gertz et al. for AL amyloidosis [106] 
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Investigations 
Investigations are more extensively described in the materials and methods’ section. This is 
an explanation for the rationale behind the investigations performed.  
 
Investigation for an Underlying Plasma Cell Disorder 
The diagnosis of AL amyloid requires both evidence of amyloid deposition on biopsy and 
also the demonstration of an underlying PCD. An increase in serum FLC levels precedes 
the development of AL amyloidosis by many years [113]. An evaluation for suspected 
amyloidosis should therefore include serum and urine immunofixation electrophoresis to 
detect monoclonal proteins and a FLC assay to determine the ratio of λ:κ light chains. 
Circulating FLCs are now quantified by a nephelometric assay (Freelite, The Binding Site, 
Birmingham, UK) which is reported to be >10 times more sensitive than immunofixation 
electrophoresis; this quantification is part of the revised Mayo Clinic staging system, which 
is widely used for risk stratifying patients to certain/any therapy, in clinical trials and also for 
monitoring response to treatment [114-117].  Evidence for an underlying PCD was detected 
in 99.8% of patients seen at the NAC [118]. A bone marrow biopsy is still required in AL 
amyloidosis, to assess the plasma cell burden and to exclude multiple myeloma, in 
conjunction with a skeletal survey. The presence of a PCD without biopsy, would not serve 
as definitive evidence of amyloidosis alone, as previously mentioned.  
 
Cardiac Investigations 
Biomarkers 
In AL amyloidosis, most causes of death are cardiac related and cardiac involvement 
determines prognosis and management to a large extent i.e. a patient with significant 
cardiac amyloid would not be suitable for autologous stem cell transplantation (ASCT) and 
the prognosis in amyloid subtypes that do not affect the heart is much better as compared 
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to those patients with cardiac amyloid. Hence, a risk stratification system known as the Mayo 
Clinic (after where it was first devised) criteria using cardiac biomarkers and the difference 
between the involved and the uninvolved FLC (dFLC) is used for management, prognostic 
and research standardisation purposes [119]. The two cardiac biomarkers in use are serum 
cardiac troponin T (TnT) and Brain Natriuretic Peptide (BNP). TnT is a sensitive and specific 
marker for myocyte injury and is found to be abnormal in >90% of cardiac AL patients [120]. 
ProBNP is made by myocytes in response to increased wall stress. This 108-amino acid 
propeptide is produced predominantly in the left ventricle, and when released, is cleaved 
into two fragments: the active BNP (amino acids 77 to 108) and a leader sequence known 
as NT-proBNP (amino acids 1 to 76) [121]. The latter has been shown to be a sensitive 
indicator of cardiac abnormalities. The diagnostic and prognostic significance of both TnT 
and NT-proBNP has been more widely investigated in AL amyloidosis as opposed to other 
subtypes, such as wtTTR, and elevated levels are associated with increased mortality i.e. 
an NT-proBNP level >152 pmol/L as opposed to <152pmol/L is associated with a mortality 
rate of 72% vs. 7.6% per 100-person years (Table 1.4) [122].  
 
Table 1.4 Risk stratification in AL amyloidosis  
Mayo Stage cTnT (mcg/L) NT-proBNP (ng/L) dFLC mg/dL 5-year Survival (%) 
[119] 
I <0.035 <332 <18 59 
II <0.035 
Or ≥0.035 
≥332 
<332 
<18 42 
III ≥0.035 ≥332 <18 20 
IV ≥0.035 ≥332 ≥18 14 
Abbreviations: cTnT: cardiac Troponin T, dFLC: difference between the involved and 
uninvolved free light chains, NT-proBNP: N-terminal pro-Brain Natriuretic Peptide 
 
46 
One third of patients with AL amyloidosis present with cardiac failure associated with marked 
elevation of both NT-proBNP and TnT concentration and these are the patients who were 
investigated further in Chapter 6 [123]. BNP/NT-proBNP may also have a local effect with 
BNP granules being found in high concentrations in myocytes adjacent to amyloid deposits. 
NT-proBNP’s concentration in AL amyloidosis may fall dramatically within weeks following 
successful chemotherapy, as reflected by a fall in LCs and this is associated with improved 
outcomes [124].  An early transient increase in BNP/NT-proBNP may occur after treatment 
frequently used in the management of AL amyloidosis, thalidomide and lenalidomide, but 
the significance and cause of this are unclear [125]. 
 
Electrocardiogram (ECG) 
ECG patterns can aid differentiation between AL and TTR amyloidosis and also between 
cardiac amyloid and hypertrophic cardiomyopathy. The most common finding is low voltage 
QRS complexes, defined by all limb leads being <5mm in height and this is usually 
associated with extreme right- or left axis deviation and more commonly seen in AL (46-
60%) rather than wtTTR (25-40%) amyloidosis [53, 126]. Poor R wave progression in the 
chest leads, is present in up to 50% of patients with cardiac AL amyloidosis and a 
pseudoinfarct pattern is seen equally frequently in AL and TTR (47-69%) amyloid [53, 126]. 
Left (more common in wtTTR, rare in AL) and right bundle branch block can also occur. The 
most commonly seen conduction defects are: first-degree atrioventricular block (21%), 
nonspecific intraventricular conduction delay (16%), second- or third-degree atrioventricular 
block (3%), atrial fibrillation/flutter (20%), and ventricular tachycardia (5%) [127]. These 
findings are reflected in the cohort of patients studied in Chapter 6. ECG findings, specifically 
the combination of R wave voltage of I, avR and QRS was of diagnostic value in 
differentiating cardiac amyloid from non-obstructive hypertrophic cardiomyopathy [128].  
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Holter ECG monitoring identifies asymptomatic arrhythmias in >75% of cardiac AL patients 
(mainly supraventricular tachyarrhythmias and some nonsustained ventricular tachycardia). 
Congestive cardiac failure, echocardiographic and holter abnormalities have been found to 
adversely affect survival [129]. 
 
Echocardiography & Cardiac MRI 
Echocardiography has traditionally been used in the assessment of cardiac amyloidosis and 
is more recently being used in conjunction with cardiovascular magnetic resonance (CMR), 
although the latter is restricted to specialist centres with specific operators and is 
contraindicated in certain subsets of patients e.g. those with severe renal failure and most 
patients with implanted pacemakers and ICDs [130]. Echocardiography remains better at 
identifying diastolic dysfunction, which is one of the earliest signs of cardiac amyloid and 
often precedes symptoms although findings are operator dependent and less precise than 
in CMR imaging [58]. The granular/ speckled appearance characteristically described is 
indicative of increased myocardial and valvular echogenicity secondary to amyloid 
infiltration, although sensitivity for cardiac amyloidosis depends upon machine settings [58].  
 
Cardiac MRI is more useful than conventional echocardiography in assessing systolic 
function, delineating cardiac amyloid from other causes of hypertrophic conditions e.g. 
hypertensive, hypertrophic and uraemic cardiomyopathy and storage disorders and 
producing a more precise 3-dimensional image. CMR also provides diagnostic and 
prognostic information through the kinetics of global, delayed subendocardial gadolinium 
enhancement and late transmural gadolinium enhancement. The gadolinium is distributed 
into the extracellular space, which is greatly expanded secondary to amyloid fibril infiltration, 
in fact more so than any other cardiomyopathy and these findings have been found to 
correlate with cardiac biopsies [131]. TI, a CMR parameter used to measure the intrinsic 
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myocardial signal in mapping studies, has been used to quantify this expansion and serial 
measures are used to track changes. Equilibrium contrast CMR (EQ-CMR) is a relatively 
new technique where the equilibrium reached between the amounts of gadolinium in the 
myocardial interstitium and that in the plasma, allows a numerical estimation of the 
myocardial interstitial volume. EQ-CMR may detect amyloid infiltration earlier than 
conventional MRI and can potentially provide a direct measure of the amyloid burden with 
scope for use in early diagnosis and disease monitoring [132]. Recently transmural late 
gadolinium enhancement (LGE) has been found to be an independent risk factor for death, 
as imaged using the technique of phase-sensitive inversion recovery. This is a LGE image 
reconstruction technique which has been shown to be more sensitive and specific in 
identifying cardiac involvement and potentially improving risk stratification [133]. This 
technique obviates the need for determining the optimal ‘null point’ – the point at which a 
black and unenhanced myocardium (a normal myocardium) is reached, which is vulnerable 
to operator error i.e. the abnormal rather than the normal myocardium may be nulled 
resulting in false negative LGE patterns [134]. However, arrhythmias especially atrial 
fibrillation and ectopic beats degrade CMR image quality and early cardiac amyloid 
particularly may only show atypical and patchy LGE, making diagnosis difficult [135].  
 
Typical findings in cardiac amyloid, in both echocardiography and CMR include: 
• Biatrial dilatation  
• Biventricular, valvular, and interatrial and ventricular septal thickening, especially in 
wtTTR [136].  
• Concentric ventricular thickening with right ventricular involvement, poor 
biventricular long-axis function with normal/near-normal ejection fraction [137] 
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• Much greater restriction of basal strain compared to apical movement as opposed to 
hypertrophic cardiomyopathy. The mean LV basal strain is an independent predictor 
of both cardiac and overall deaths [125] 
• An intracardiac thrombus in 33% of cases of AL cardiac amyloid [138, 139] 
 
Renal Biomarkers 
 
As with other organ biomarkers, these have mainly been studied in the commonest 
amyloidosis, AL amyloidosis, where renal involvement occurs in 70% of patients [31]. 
Accurate risk stratification using biomarkers is of great importance in ensuring that the risks 
of therapy do not outweigh the benefits and precipitate/ hasten renal failure. 
 
Currently used biomarkers are creatinine, modified eGFR and proteinuria. Palladini et al. 
have recently devised the only widely known renal risk stratification system which found that 
proteinuria and eGFR independently predict renal survival. Patients with either (Stage II) or 
both (Stage III) proteinuria >5g/24hrs and eGFR ≥50 mL/min per 1.73 m2 were found to have 
a 3-year dialysis requirement of 7-30% and 60-85% respectively. If neither of these risk 
factors was present, the 3-year progression risk to dialysis was 0-4% [116]. The Mayo group 
also found that a >75% reduction in proteinuria at 1 year was associated with longer patient 
survival and an even greater advantage found once proteinuria had reduced by >95% [140]. 
 
There are a number of new biomarkers being identified and investigated, in the hope that a 
more sensitive and specific marker of renal disease, as compared to creatinine, may be 
found. One such potential biomarker, Retinol Binding Protein, is investigated further in 
Chapter 5. 
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      Imaging 
 
Serum Amyloid P Component Scintigraphy 
This was first developed by Hawkins et al. in 1990 and is based on the knowledge that SAP 
is a component of all amyloid deposits and thus when labelled with 123Iodine (123I-SAP) it 
enables the identification and quantification of visceral amyloid deposits in vivo, in a non-
invasive, safe, specific and proportionate manner [141, 142]. Although a histological 
diagnosis remains gold standard, sequential SAP scintigraphy allows disease monitoring 
over repeated time intervals and an assessment of response to treatment [143]. The 123I-
SAP images do not provide a diagnosis of the amyloid subtype but the pattern of involvement 
seen may make a particular diagnosis more likely i.e. significant bony uptake is characteristic 
of AL amyloid [144]. 
 
The radiotracer used is rapidly catabolised and excreted from the body with the dose of 
radiation being similar to a lumbar spinal radiograph; it does not accumulate in healthy 
subjects or those without amyloid [145]. SAP scintigraphy is used in routine clinical practice 
at the NAC and the ‘amyloid load’ is interpreted in a semi-quantitative manner as being mild, 
moderate or heavy for each organ in comparison to the surrounding blood pool. This result 
has implications for prognosis and also guides management strategies [42, 146, 147]. 
 
Although SAP scintigraphy allows imaging of most solid organs and bone, it does not image 
the skin, nerves, hollow viscus and, importantly, the heart. Additionally, the radiotracer is 
expensive and not easily available, however it remains, globally, the most efficient modality 
for assessing amyloid extent and distribution [144].  This investigation was utilised in the 
studies detailed in Chapters 3, 5 and 6. 
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Bisphosphonate Bone Tracers 
The incidental uptake of 99m-technetium-3,3,-diphosphono-1,2- propanodicarboxylic acid 
(99mTc-DPD) was first noted in the 1970s and 80s whist being used for bone scanning and 
this phenomenon was later attributed to cardiac amyloid. The exact mechanism of uptake 
remains unclear but its use as a sensitive, inexpensive and simple technique in imaging 
cardiac deposits in ATTR variant and ATTRwt amyloid is now increasingly realised following 
Perugini et al’s findings of 100% sensitivity and specificity of 99mTc-DPD in imaging [148]. 
Indeed, cardiac amyloid can be identified even if patients are asymptomatic and other 
imaging modalities do not yet reflect this disease process. These scans are graded using 
the Perugini Grade 1-3 scoring system: Score 0 - absent cardiac uptake and normal bone 
uptake. Score 1 - mild cardiac uptake, inferior to bone uptake. Score 2 - moderate cardiac 
uptake and normal bone uptake. Score 3 - Strong cardiac uptake with attenuated bone 
uptake.  
 
Notably, tracer uptake occurs in a third of patients with cardiac AL amyloid, although less 
avidly than in TTR amyloid patients and 99mTc-DPD-SPECT-CT can help to distinguish the 
two types [149]. In fact, it has been proposed that a high DPD grade, in the absence of 
haematological markers for an underlying PCD and echo/ CMR imaging suggestive of 
cardiac amyloid can reliably diagnose TTR amyloid over AL amyloid, without the need for 
an invasive cardiac biopsy [118]. 
 
Biopsy 
 
 A biopsy is essential to diagnose amyloidosis and usually, in systemic amyloid, a biopsy of 
the clinically involved organ is not necessary where a less invasive, cheaper and quicker 
biopsy, typically is an abdominal subcutaneous fat aspiration, can be taken. Where AL 
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amyloidosis is suspected, a bone marrow biopsy is taken and this, in conjunction, with a fat 
biopsy will identify amyloid in 85% of affected patients [150]. If both biopsies do not show 
amyloid and the index of suspicion remains high, then a biopsy of the affected organ e.g. 
heart, liver, tongue, skin could be undertaken and an evaluation made, perhaps using the 
other assessment tools listed such as SAP scintigraphy, as to whether the amyloid is 
systemic or localised.  
 
 The presence of extracellular amorphous eosinophilic deposits on brightfield light 
microscopy after staining with haematoxylin and eosin may alert the pathologist to the 
possibility of amyloid [31]. Further demonstration of amyloid deposits demonstrating green 
birefringence when viewed under cross-polarised light, after staining of tissue with Congo 
red dye, is the definitive diagnostic test and has been in use since first described by Puchtler 
et al. in 1962 [3, 4].  Under electron microscopy, amyloid deposits appear as randomly 
arranged but rigid non-branching fibrils of around 10 nm in diameter and of indeterminate 
length [5]. 
 
Amyloidosis, therefore, is a histological diagnosis either diagnosed following purposeful 
biopsy of the affected organ or discovered incidentally; amyloid deposits must be followed 
in all cases by tests to determine the amyloid fibril protein.  In clinical practice, this has 
traditionally been achieved with immunohistochemistry and/or immunofluorescence, 
although more recently, proteomic analysis of micro dissected amyloid deposits has been 
used to determine the amyloid fibril protein with great accuracy, as described in Chapter 4. 
[31]. Sometimes a characteristic distribution of deposits on light microscopy alone can 
provide useful pointers, for example fibrinogen Aα amyloidosis typically displays isolated 
heavy glomerular involvement, but generally immune-typing is required to distinguish 
between the different amyloid subtypes [151]. For example, a diagnosis of AL amyloidosis 
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should be suspected when there is LC restriction in the glomeruli, interstitium and/or vessels 
following staining of renal tissue with antibodies against κ and λ immunoglobulin LCs.  There 
are a number of other proteins which can deposit as amyloid in the kidneys such as 
apolipoprotein A-I (apoAI), apolipoprotein A-II, fibrinogen Aα chain, gelsolin, lysozyme and 
LECT2 with differing management strategies and therefore identification is essential. DNA 
sequencing, in addition to immuno-typing is invaluable in diagnosing and excluding the 
known hereditary forms of amyloidosis. 
 
The importance of biopsies and their evaluation is essential is discussed further in this 
thesis: in avoiding a misdiagnosis (Chapter 3), in procuring tissue for proteomics (Chapter 
4), in correlating with biomarker evaluation (Chapter 5) and identifying Light Chain 
Deposition Disease (Chapter 7). 
 
Mass Spectrometry and Bioinformatics 
Proteomic analysis using mass spectrometry after laser microdissection, is playing an 
increasing role in diagnosing the amyloid subtype where results from histological and/or 
genetic tests prove ambiguous [152]. For example, absence of staining in immune-typing 
may sometimes occur where epitopes are hidden in the protein folds or epitopes are not 
present in the truncated fibrillary forms of the protein deposits and indeterminate results 
occur when more than one antibody is stained, perhaps due to plasma protein contamination 
leading to non-specific background staining [153].   Importantly, proteomic analysis can only 
be undertaken following histological confirmation of Congo red deposits, as it is this material 
that is laser micro dissected for mass spectrometry, hence conventional histological 
identification of amyloid must be performed. This technique has mainly been spearheaded 
in the United States but is being increasingly used in the National Amyloidosis Centre, UK 
and its establishment is further described in Chapter 4 [154]. 
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Several mass spectrometry methods are now routinely used for protein identification with 
standard mass spectrometers readily available in research facilities. Proteomics is 
dependent on the determination of the mass of ionised protein or peptide i.e. the mass-to-
charge ratio (m/z), by the mass spectrometer. The proteolytic digestion of protein, e.g. by 
trypsin (which cleaves the C-terminal of arginine and lysine, except before proline), 
generates peptides that are ‘charged’ by the mass spectrometer and the unique mass of 
each ionised sequence in highly purified samples can lead to the identification of the 
peptides present- a process known as Peptide Mass Fingerprinting. For reasons of greater 
sensitivity, the method of ionisation in most cases is matrix-assisted laser desorption 
ionisation with the mass analyser being an ion trap device, a subtype of the Quadrupole 
analyser, which traps selected ions hence allowing greater sensitivity. The other widely used 
analyser is ‘time-of-flight’ [155]. Tandem mass spectrometry, MS/MS or tandem MS, is used 
to further fragment selected peptide ions and the resulting daughter ions are detected in a 
second mass analyser. The identification is undertaken by ‘search engines’ which have 
specific spectral matching algorithms and are reliant upon matching the generated spectra 
to theoretical spectra generated from a sequence database [156]. Hence, only sequences 
within the selected database have a chance of being “identified”. De novo MS/MS peptide 
sequencing without the reference to a sequence database can be performed manually by 
correlating the mass difference between MS/MS peaks, but this is a tedious and 
understandably unpopular method which would be too time consuming in high throughput 
diagnostics [157].  Many algorithms have been developed for automated de novo 
sequencing over the past decade. 
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                                                               Treatment 
 
This is dependent upon the type, severity and distribution of amyloid as well as the clinical 
status of the patient. Treatments are aimed at reducing the rate of amyloid production 
whether it be through chemotherapy in AL amyloidosis or the use of anti-inflammatories in 
AA amyloidosis. Once production decreases, one can occasionally observe regression of 
existing amyloid deposits- as visualised on imaging and also as evidenced by functional 
testing i.e. exercise and blood tests [158]. Where such treatment is prohibited by the clinical 
status of the patient i.e. due to significant co-morbidities, or where either the window of 
treatment or no suitable generalised treatment is available, then organ specific supportive 
measures are taken. Importantly these measures may differ to those employed for the 
management of other conditions e.g.  although the general management principles of heart 
failure are followed including fluid and salt restriction as well as diuretic use, notable 
differences include the possible avoidance of non-dihydropyridine calcium channel blockers 
(significant negative inotropy and high degree heart block), digoxin (binds avidly to fibrils 
and half-life is increased significantly), angiotensin-converting enzyme inhibition and nitrates 
(may contribute to hypotension) and high dose beta blockade (interferes with demand for a 
raised heart rate due to a low and fixed stroke volume) [159-162].  
 
AL amyloidosis 
Current treatment is centred on suppressing the clonal B cells that give rise to the instigating 
PCD, and hence reducing the supply of the AL amyloid fibril precursor protein. This may 
facilitate gradual regression of amyloid deposits and preservation or improvement in vital 
organ function. There is convincing evidence that more complete clonal responses are 
associated with both longer treatment free survival and a greater chance of improvement in 
organ function. In low risk patients, autologous stem cell transplantation is widely regarded 
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as the treatment of choice [163]. The prognosis of untreated AL patients remains 12-15 
months, and just a few months for patients with significant cardiac involvement, highlighting 
the need for novel, more effective regimes [9].  
 
The agents currently used, including the newer immunomodulatory drugs, as well as the 
more traditional regimes, are summarised in table 1.5. Current regimes have been modified 
from multiple myeloma protocols and treatment choice is dependent upon the type and 
severity of organ involvement for example cardiac involvement, peripheral neuropathy, or 
significant hypotension may preclude particular agents.  
 
Immunomodulatory Drugs 
 
Thalidomide is most commonly combined with cyclophosphamide and dexamethasone, 
33% of patients have been reported to have achieved a complete or very good partial 
response, after a median of 7 months, but 29% of patients died and 50% of treated patients 
had to be hospitalised for treatment toxicities mainly: fluid retention, lethargy, infection, 
hypotension and neuropathy [164, 165].  
 
Lenalidomide has a haematological response rate ranging from 41% to 47% which includes 
relapsed and thalidomide refractory cases. Doses higher than 15mg are poorly tolerated 
with side-effects including cytopaenias, fatigue and fluid retention [166, 167].  In a 
retrospective analysis from the Boston group, 66% of patients exposed to lenalidomide 
developed renal dysfunction, which was reversible in 44% of cases [168]. However, it was 
reasonably well tolerated in patients with ESRF. There has also been an observed increase 
in NT-proBNP and other cardiac biomarkers with the use of immunomodulatory agents and 
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this has been correlated with mortality [169]. Time to haematological response is longer than 
that observed with bortezomib, but complete responses have been seen [170].  
 
Pomalidomide 
This thalidomide analogue was reported by Dispenzieri et al, to induce a 48% 
haematological response rate with 3% complete responses in 33 heavily pre-treated 
patients. One-year progression-free survival and overall survival rates were 59 and 76%.  
12 of the 33 patients had renal involvement and 2 of these patients demonstrated organ 
improvement [171]. 
 
Proteosome Inhibitors 
Bortezomib induces a rapid decrease in serum free LC concentration in patients with 
myeloma and purified plasma cells from amyloid patients are twice as vulnerable to 
bortezomib inhibition as those from myeloma patients [172, 173]. The amyloidogenic plasma 
cell clone synthesises LCs with a propensity to misfold thus overloading the proteosome and 
increasing sensitivity to Bortezomib and higher doses of Bortezomib are associated with 
better haematological responses although side effects also increase. Bortezomib is being 
increasingly used in those with severe cardiac involvement whose outlook is extremely poor. 
Venner et al. reported a haematological response of 81.4% using biweekly bortezomib, 
cyclophosphamide and dexamethasone, superseding that achieved by other combinations 
including 71% with bortezomib/ dexamethasone, 67% with bortezomib/ 
melphalan/dexamethasone, and 69% with bortezomib alone [174-176]. Other novel 
proteasome inhibitors currently undergoing trials include ixazomib and carfilzomib [173, 177, 
178]. 
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Family 
Primary Agent plus 
Adjunctive Treatment 
 
Main Side-Effects 
 
Comments 
 
Immunomodulatory  
Thalidomide (with 
cyclophosphamide and 
dexamethasone 
Fluid retention ,fatigue and postural 
hypotension, peripheral neuropathy, 
thromboembolism, increase in cardiac 
biomarkers, skin rash, teratogen  
 
Immunomodulatory 
(2nd generation) 
 
Lenalidomide (with 
dexamethasone) 
Fatigue, constipation/diarrhoea, 
myelosuppression, thromboembolism, 
skin rashes, increase in cardiac 
biomarkers, renal dysfunction 
Useful in disease refractory to alkylators 
and bortezomib. Response is not 
achieved rapidly. Addition of 
cyclophosphamide or melphalan has 
improved CR rate but 2/3 patients develop 
side effects. 
Immunomodulatory 
(3rd generation) 
Pomalidomide (with 
dexamethasone) 
Fluid retention, fatigue and postural 
hypotension, peripheral neuropathy, 
thromboembolism, myelosuppression, 
Useful where myeloma is 
relapsed/refractory to lenalidomide and 
thalidomide including cardiac patients 
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Table 1.5 Current chemotherapy regimens for AL amyloidosis 
 
Abbreviations: AL, immunoglobulin light chain amyloidosis; CR, complete response; GI, gastrointestinal; IV MDex, intravenous 
melphalan-dexamethasone 
increase in cardiac biomarkers, skin rash, 
teratogen 
Alkylator Melphalan- 
Dexamethasone 
Haematological toxicity, fatigue, 
peripheral oedema, GI side effects 
Good choice for intermediate risk and frail 
patients without significant cardiac 
involvement. IV MDex too toxic for routine 
use but used if poor GI absorption. 
Alkylator and 
Purine Analogue 
Bendamustine (and 
dexamethasone) 
Cytopaenias Useful for relapsed/refractory disease  
Proteosome-
Inhibitor 
Bortezomib (and 
cyclophosphamide  
with dexamethasone) 
Peripheral neuropathy, hypotension, GI 
disturbance, peripheral oedema 
Advised upfront in those with a poor 
prognosis where a rapid response is 
required 
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CPHPC and Anti-Human SAP Antibodies 
SAP, a constituent of all amyloid deposits, can comprise up to 14% of the dry mass of 
amyloid. Its binding serves to both stabilise the amyloid fibrils and protect them from 
proteolysis and degradation by phagocytic cells [179]. 
 
(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid 
(CPHPC) is a competitive inhibitor of SAP binding to amyloid fibrils. It consists of 2 D-proline 
residues joined by a six-carbon aliphatic linker. The palindromic structure of this drug cross-
links pairs of SAP molecules in the plasma which triggers their complete clearance by the 
liver, gradually depleting SAP from the amyloid deposits [124, 180]. It also rapidly depletes 
SAP from the CSF. Gillmore et al. undertook a prospective study in 31 patients with 
advanced systemic amyloidosis of AL, AFib, ATTR, Gelsolin, ApoA1, AA and Aβ2M types 
[181]. The patients received CPHPC by twice daily subcutaneous injection, and six subjects 
continued to receive CPHPC for another year. This treatment produced a sustained and 
profound depletion of circulating SAP in all cases, and in the two patients in whom 
amyloidotic material became available for analysis, there was also substantial SAP depletion 
from the amyloid deposits. In four of the five dialysis independent patients with AFib 
amyloidosis, proteinuria decreased whereas proteinuria increased and renal survival was 
shorter in five of six matched untreated historical controls. Amongst 13 patients with 
advanced AL amyloidosis, organ function improved in two cases and was stable in seven. 
In two AL cases with refractory clones and a third with a modest clonal response, organ 
function deteriorated. The only adverse events attributable to CPHPC were transient minor 
local stinging at the injection site for two patients. There were 5 ‘expected’ deaths associated 
with advanced amyloid cardiomyopathy [181]. CPHPC is now being used on compassionate 
grounds for a select few patients. 
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The removal of large amounts of visceral amyloid deposits, containing human SAP, in mice 
was demonstrated following the administration of anti-human-SAP antibodies. This triggered 
a potent, complement-dependent, macrophage-derived giant cell reaction and no significant 
adverse effects occurred [23]. Richards et al. have recently reported on the 16-patient 
clinical trial of CPHPC, to deplete the circulating SAP, prior to the administration of a fully 
humanised monoclonal IgG1 anti-SAP antibody to activate macrophage destruction of the 
SAP-containing amyloid deposits in tissues. There were clinically no adverse effects to 
patients and there was evidence on SAP scintigraphy of reduction in hepatic and renal 
amyloid loads in patients [7]. However, prognosis in AL amyloidosis especially, is to a large 
degree determined by the presence and severity of cardiac amyloid and we do not yet know 
whether anti-SAP antibodies target the heart at higher doses. Further clinical trials are yet 
to take place.  
 
Device Therapy 
The prognosis of systemic AL amyloidosis is substantially influenced by the presence and 
severity of cardiac involvement [125]. Greater than two thirds of deaths occurring in patients 
with AL amyloidosis are secondary to cardiac causes, notably congestive cardiac failure and 
sudden cardiac death [129].  Despite progress in chemotherapy, sudden cardiac death 
(SCD) occurs within 8 months in the majority of patients with marked elevations in both TnT 
and Nt-proBNP and only 29% survive a year [122, 123, 182, 183] . Cardiac death is thought 
secondary to worsening amyloid infiltration and subsequent chamber hypertrophy and 
valvular thickening. The severity of cardiac involvement can be evaluated through serum 
biomarker concentration, echocardiography and CMR [28, 131, 162, 182]. Whilst ventricular 
tachyarrhythmias and pulseless electrical activity (PEA) have been observed as terminal 
events, little is known about the electrical activity preceding terminal cardiac 
decompensation [129, 184, 185]. There has long been interest in, but few systematic studies 
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of, interventions including anti-arrhythmic drug therapy, implantation of permanent 
pacemakers (PPM) or cardiac defibrillators (ICD) that might improve survival in cardiac AL 
amyloidosis [186]. Unfortunately, the very poor prognosis of patients affected by advanced 
cardiac AL amyloidosis, with a survival from the time of diagnosis reported to be between 
5.8 to 7 months, has largely resulted in their exclusion from prospective clinical studies [123, 
182].  Furthermore, since consensus guidelines do not support ICD placement for primary 
prevention of SCD in patients with a life expectancy of less than 1 year; these devices have 
rarely been implanted in patients with cardiac AL amyloidosis. It is also not entirely clear as 
to what the exact mode of death is and if it would therefore warrant ICD placement. Studies 
are conflicting: in one small cohort of patients with advanced symptomatic cardiac AL 
amyloidosis, ICD insertion did not appear effective in preventing SCD which was attributed 
to causes ‘not amenable to ICD therapy’. In contrast, two recent retrospective analyses of 
patients with cardiac amyloidosis identified ventricular tachyarrhythmias in a significant 
proportion of cases, some of which did respond to ICD therapy [187, 188]. In one study, 
patients receiving ICD therapy survived for an additional 6 weeks to 19 months, however a 
larger and more recent retrospective study failed to show any survival benefit [189].  It may 
be that such patients would benefit from higher than normal defibrillator thresholds, due to 
the massive interstitial expansion of cardiac tissue and that this may be a more effective 
intervention [189]. Furthermore, although complex ventricular arrhythmias are reportedly 
common, only couplets have been shown to be an independent predictor of survival and 
correlate with sudden death [129].  Biventricular pacing appears to have a limited role, 
theoretically this may be the ideal pacing option to avoid decompensation of the stiffened 
ventricle as a result of induced dyssynchrony from right ventricular pacing.  I have 
investigated arrhythmias, including the terminal arrhythmias occurring in the worst affected 
cardiac amyloid patients, through Loop Recorder Insertion. This study is detailed further in 
Chapter 6.  
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Systemic AA Amyloidosis 
 
Current treatment has the objective of reducing the production of SAA to healthy normal 
levels, with the median level in healthy blood donors being 3 mg/L, through control of the 
respective underlying inflammatory disease. Sustained suppression of SAA production has 
been shown to result in amyloid regression [42].  Lachmann et al reported an improvement 
in renal functions in patients with a median SAA concentration of 6 mg/L and deterioration 
in patients with a median SAA concentration of 28 mg/L [40]. Proteinuria may diminish 
substantially, albeit gradually over months and years in patients with AA amyloidosis when 
the underlying inflammatory disease remains quiescent [40]. Essentially, management is 
aimed at treating the source of inflammation and hence suppressing SAA levels and so, to 
a degree, treatment is specific to the underlying disorder e.g. surgery for solid tumours, 
colchicine for Familial Mediterranean Fever and chemotherapy for widespread and/or 
haematological malignancies. Additionally, more universal therapeutic strategies may be 
required on occasion to manage acute insults e.g. kidneys extensively infiltrated by amyloid 
are exquisitely vulnerable to hypoperfusion, hypertension, nephrotoxic drug usage, surgery 
etc. all of which should be avoided if possible. An overview of novel treatments and their 
corresponding targets in SAA amyloidosis is shown in Fig. 1.1 below. 
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. Figure 1.1       Pathogenesis and novel treatment options available in SAA amyloidosis 
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Colchicine  
Familial Mediterranean Fever (FMF), first identified in 1949, is an autosomal recessive 
inherited condition ethnically restricted to populations, such as Armenians, Turks, Middle-
Eastern and Sephardic Jews, arising from the Mediterranean basin and Middle-East. The 
single amino-acid mutations arise in the Mediterranean Fever gene on chromosome 
16p13:3, which codes for the marenostrin/ pyrin protein and can be identified through 
genetic analysis, with 30% of those with the clinical syndrome having one mutated allele 
only [190-192]. It is the most common autoinflammatory disease worldwide, believed to arise 
from pyrin’s role in the NLRP3 inflammasome complex leading to increased interleukin-1 β 
production, resulting in inflammatory attacks [193]. These first occur in childhood and consist 
of 24 to 72 hour episodes of recurrent fever, severe abdominal pain, arthralgias or 
monoarthritis, pleurisy, or an erysipeloid rash on one ankle or foot and are characterised by 
a large tissue influx of polymorphonuclear leucocytes, neutrophilia and a subsequent rapid 
acute phase response [194]. Subclinical inflammation may exist between attacks. 
The alkaloid, colchicine is in widespread use as a life-time long treatment of FMF since 1972 
and routine usage has resulted in a 95% reduction in the frequency and severity of attacks 
and the stabilisation of proteinuria in those patients with established amyloid nephropathy 
[195-197]. It can be used both acutely and for long term complications including AA 
amyloidosis. 60% of untreated FMF patients developed nephrotic syndrome secondary to 
AA amyloidosis resulting in a high mortality rate. There is no significant effect on survival if 
amyloidosis is absent [198].  
 
Colchicine, interferes with the process of microtubule self-assembly by forming tubulin-
colchicine complexes, reduces TNF-α production and interferes with neutrophils binding to 
the adhesion molecules on the vascular endothelium [199, 200]. At higher doses, colchicine 
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interferes with L-selectin so impeding leucocyte movement along the vascular endothelium, 
suppresses phospholipase A2 activation, lysosomal enzyme release and phagocytosis at 
the transcriptional level [201-203]. The typical colchicine dose is 1.5 to 2mg a day and can 
be divided if adverse effects occur e.g. diarrhoea and/or abdominal pain [204, 205]. 
Predisposed patients e.g. those with renal and/or hepatic failure may also suffer from 
myopathy, leukopenia and neuropathy in predisposed patients (renal and/or hepatic failure) 
[206]. 5-10% of patients have primary or acquired colchicine resistance [207, 208] . Of note 
most ‘resistant’ patients are actually non-compliant. Resistance is believed to arise due to 
the inadequate activity of the p-glycoprotein pump in granulocytes or due to competitive 
inhibition of colchicine metabolism via the CYP 450 system. Parenteral colchicine has had 
some success in patients resistant or intolerant to oral colchicine, perhaps by overcoming 
the lymphocyte absorption failure in some non-responders [209]. However, the risk of 
colchicine poisoning is much higher with parenteral usage and can, rarely, result in multi-
organ failure. Other more recent options, where colchicine is ineffective or not tolerated, 
include anti-TNF-α preparations, interferon-α and thalidomide. 
 
Eprodisate 
Glycosaminoglycans, such as heparin sulphate, can promote fibril assembly by acting as 
chaperones during early stages of protein refolding and amyloid formation. Eprodisate 
(Kiacta, Neurochem) is a negatively charged, sulfonated molecule that is structurally similar 
to heparin sulphate and works by the competitive inhibition of the interaction between SAA 
and glycosaminoglycans. It has been found to inhibit the development of AA amyloid in 
experimental mouse models. A multicentre randomised double-blind placebo-controlled trial 
in 180 patients with AA amyloidosis-associated nephropathy has been completed [210]. As 
eprodisate is renally cleared, the dosage of daily drug prescribed was dependent upon 
creatinine clearance. Study medication was continued for 24 months unless the patient 
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progressed to ESRD, had a significant adverse event, withdrew from the study or required 
rescue medication such as cytotoxic agents, colchicine or anti-TNF agents. Rheumatoid 
arthritis (49% of the patients) and FMF (19%) were the most common underlying 
inflammatory diseases. Treatment with eprodisate was associated with a 42% reduction in 
the risk of worsening renal disease (as measured by creatinine clearance) or death (0.37-
0.93 P=0.02).  More specifically, compared to placebo, eprodisate significantly reduced the: 
risk of doubling the serum creatinine, risk of a 50% reduction in creatinine clearance and 
slope of decline in creatinine clearance. In particular, the decline in creatinine clearance was 
4.7ml per minute per 1.73m2 per year greater in the placebo group than in the eprosidate 
group, a relative difference of 30% [210]. Perhaps surprisingly, there was no significant 
difference in terms of overall changes in proteinuria. Despite these encouraging results there 
was concern that some of the apparent drug benefit reflected a poor outcome in the 
subgroup of placebo patients who had nephrotic range proteinuria at baseline and the US 
and European regulatory bodies requested a confirmatory second Phase III trial which is 
ongoing [211]. 
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Table 1.6: Current treatment strategies for AA amyloidosis  
 
Treatment Description Studies in SAA Amyloidosis Notes 
Etanercept Recombinant human TNFR 
(p75)-Fc fusion protein: 
comprising two receptors linked 
by an IgG1 Fc fragment 
TRAPS-reduced symptoms and inflammatory 
markers [212] 
RA- improved eGFR, albumin and acute 
phase reactants as compared to 
cyclophosphamide [213] 
Poor long term adherence 
Does not completely normalise 
symptoms or acute-phase 
reactants [212] 
Etanercept-resistance 
Decreased responsiveness with 
time [214] 
Anakinra IL-1 receptor antagonist FMF- decrease in acute phase reactants 
[215] [216] 
Useful in FMF with spondylitis  
Requires a daily injection 
Used safely in haemodialysis and 
transplant patient [217] 
Rilonacept IL-1 decoy receptor: extracellular 
domain of humanized IL-1 type I 
receptor and the IL-1 receptor 
accessory protein fused with the 
Fc portion of IgG1 
FMF- Reduced frequency of attacks by 76% 
as compared to placebo, in colchicine 
intolerant patients over 3 months. 
Improvement in quality of life but duration of 
attacks not decreased [218] 
CAPS- Clinical improvement and SAA 
normalisation [219] 
Once-weekly administration 
 Binds both IL-1α and IL-1β with 
high affinity, and so it has been 
suggested that rilonacept might 
have better inhibitory effect in vivo 
compared to other IL-1 blockers. 
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No serious adverse events. 
Increased incidence of arthralgia, 
injection site reactions and URTI 
[219] 
Canakinumab Humanised IgG1k monoclonal 
antibody against IL-1β 
RA-Improved function, QoL and arthralgia 
over and above ongoing methotrexate [220] 
CAPS-improvement in symptoms, eGFR, 
proteinuria, QoL and SAA levels [221] [222] 
Gouty arthritis- Improved QoL, symptoms 
and fewer flares [223] 
MWS- improved symptoms and SAA levels 
[224] 
Systemic-onset juvenile idiopathic arthritis 
FDA and EMEA approved for 
CAPS, familial cold auto-
inflammatory syndrome and 
Muckle-Wells syndrome.   
Once monthly administration 
No significant/ life-threatening 
adverse effects although 
increased incidence of infections 
[222] 
 
Tociluzimab Humanised anti-IL-6 receptor 
antibody 
Stronger than TNF inhibitors 
Decrease in SAA and proteinuria level [225] 
 
Complex formation of IL-6 with 
STAT-3 NF-kappaBp65 and p300 
is essential for the synergistic 
induction of the SAA gene and so 
for SAA transcription [25–26]. 
Inhibition of IL-6 activity by 
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Toclizumab in RA, completely 
suppresses STAT-3 activity and 
the subsequent expression of 
SAA mRNA 
Eprodisate Low molecular weight, negatively 
charged, sulfonated molecule: 
Disrupts the heparan sulfate-β-
peptide fibril aggregate by 
competitively binding to the 
glycosaminoglycan-binding sites, 
thus inhibiting fibril polymerisation 
[226] 
Eprodisate reduces deterioration of renal 
function in patients with AA compared to 
placebo, independently from SAA 
concentration [210] 
The confirmatory Phase III trial has finished 
recruiting in over 20 centers worldwide 
(clinicaltrials.gov identifier: NCT01215747). 
Principally renally excreted so 
dose adjustment required in renal 
impairment. 
Good bioavailability when 
administered orally and is not 
protein-bound. 
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Transthyretin (ATTR) Amyloidosis 
 
Diflunisal 
Diflunisal is a non-steroidal anti-inflammatory drug which stabilises tetrameric TTR in vitro 
by binding via the thyroid hormone receptor sites [227, 228]. Berk and colleagues have 
recently completed an international, multi-centre, placebo-controlled study of 130 patients 
with FAP, with neurological outcome as the primary endpoint [229]. The exclusion criteria 
included patients >75 year old, a history of gastrointestinal bleeding, eGFR <30 ml/min and 
NYHA Class IV heart failure. Sixty-three  patients with a median age of 59.7 years of whom 
54.6% had TTR Met30  completed the study, having taken either 250mg diflunisal or placebo 
daily over a 2 year period and the authors reported a significant reduction  in the rate of 
progression of neurological impairment and an improved quality of life in the diflunisal 
treated group with 29.7% of the diflunisal and 9.4% of the placebo group displaying a stable 
neurological score as assessed by the Neuropathy Impairment Score plus 7 nerve tests 
(NIS+7) at 2 years. Drug related adverse events including gastrointestinal bleeding and renal 
dysfunction did not differ between the two groups [229]. 
 
Tafamadis 
Tafamadis, 2-(3,5-dichloro-phenyl)-benzox-azole-6-carboxylic acid), is an orally 
administered drug that also stabilises the TTR tetramer through its affinity for the T4-binding 
site, which does not carry the risks associated with nonsteroidal anti-inflammatory drug use 
[230].  It is protein bound, metabolically stable and ≥94% is excreted unchanged from the 
digestive tract.  Coelho et al., undertook a randomised Phase II/III double-blinded trial that 
assigned either 20mg oral tafamadis or placebo to 128 FAP patients (mean age 39 years) 
with the V30M TTR mutation and early neuropathy for a period of 18 months [231].   Plasma 
72 
TTR stabilisation was seen in 98% of tafamadis treated patients and none of the placebo 
arm. The study did not show a significant change in the predefined primary end point but 
suggested a slowed deterioration in small fibre neuropathy in the tafamadis arm at 18 
months with 45.3% of the evaluable diflunisal and 29.5% of the placebo group displaying a 
stable neurological score by Neuropathy Impairment Score of the Lower Limb (NIS-LL) at 
18 months.  The most common side-effects included urinary tract infections and diarrhoea. 
There has been no evidence that Tafamadis affects thyroid function tests however routine 
monitoring is advised. Of note Coelho’s study excluded patients with an eGFR <30 ml/min 
and there currently remains no evidence of efficacy in cardiac ATTR amyloidosis. This study 
has split the drug regulatory authorities with European Medicine Agency granting approval 
for its use in FAP for TTR Met 30 in patients with early disease who can still walk 
independently.  It has not yet been approved by the US Food and Drug Administration.  
Ongoing questions relating to whether either of these agents will be beneficial in cardiac 
amyloidosis are being addressed at present.  
 
Oligonucleotide Based Therapies 
The discovery of RNA interference (RNAi) by Fire and Mello, for which they were awarded 
the Nobel Prize in Physiology in 2006, demonstrated how the transfer of genetic information 
from DNA to protein can be blocked [232]. Oligonucleotide based therapies, including small 
interfering RNAs (siRNAs) and antisense RNAs have the ability to cause changes at the 
translational level without becoming integrated into the human genome [233].   
 
SiRNAs are non-coding, double-stranded molecules which are components of the 
endogenous RNAi pathway, which serves to control gene expression.  They vary in length 
from 18-30 base pairs and are chemically modified for drug delivery to increase stability and 
limit immunogenicity [234, 235]. Lipid nanoparticles have been used to deliver siRNAs to 
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hepatocytes parenterally; these have resulted in a robust and durable reduction in genetic 
expression across a variety of species. Antisense oligonucleotides (ASOs) are 13-25 
nucleotide single-stranded DNA molecules that hybridise to a specific mRNA sequence and 
prevent transcription [236, 237]. They can act through an RNase H mediated mechanism, 
with RNase H being a ubiquitous enzyme that hydrolyses the RNA strand of the RNA/DNA 
duplex and hence reduces target RNA expression thus inhibiting protein expression to 
virtually any region of the mRNA. The mechanisms through which both types of 
oligonucleotide work, is illustrated in Fig.1.2. 
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Fig 1.2 The mechanism by which small interfering RNAs (siRNAs) block and 
antisense oligonucleotides disrupt TTR formation
 
 
 
Hepatocyte schematic demonstrating the mechanism by which small interfering RNAs 
(siRNAs) block the transcription process and antisense oligonucleotides interfere with the 
translation process, ultimately preventing transthyretin (TTR) formation. (1) The siRNAs bind 
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to the RNA-inducing silencing complex (RISC) in an adenosine triphosphate (ATP)–
dependent manner. (2) This multisubunit protein complex migrates toward messenger RNA 
(mRNA). At some point, the siRNA unwinds and the antisense strand remains bound to the 
RISC and blocks transcription by the direct degradation of the target mRNA sequence 
through the use of both endo- and exonucleases [227, 238]. (3) The mRNA migrates into 
the cytoplasm where (4) hybridisation with the antisense oligonucleotide prevents protein 
translocation (5). 
 
Oligonucleotide therapies for ATTR have shown great promise in pre-clinical models, and 
both siRNAs and antisense oligonucleotides are being investigated in clinical studies 
(ClinicalTrial.gov NCT01960348 and NCT01737398). Coelho et al., undertook a single-
dose, randomised, placebo controlled phase I trial using ALN-TTR01 and ALN-TTR02 (first 
and second generation lipid nanoparticles), these contained an identical siRNA that bound 
to an mRNA segment common to both wt and mutant TTR. There was a rapid, dose-
dependent and durable reduction of transthyretin levels in the 32 patients with TTR 
amyloidosis [239]. Alnylam is developing an RNAi therapeutic which has been chemically 
modified by conjugation to an N-acetylgalactosamine moiety thereby refining hepatocyte 
targeting and allowing subcutaneous administration, and which is currently in Phase II trial 
for cardiac ATTR amyloidosis [234]. 
 
ASOs have already been tested clinically in the treatment of viral diseases, cancer and 
metabolic diseases [240-242].  ISIS-TTRRX is a second-generation chimeric antisense 
inhibitor of its molecular target TTR. It binds selectively and with high-affinity to the non-
translated portion of the human TTR mRNA and results in its degradation, preventing 
production of both wild type and variant TTR protein. ISIS-TTRRX twice weekly sc injections 
have been well tolerated in both TTR transgenic mouse models and monkeys with a 
76 
reduction in hepatic TTR mRNA and plasma wt TTR protein levels by approximately 80% 
and is currently under evaluation in a phase I clinical trial in normal healthy volunteers [243]. 
It will initially be developed for patients with FAP and a randomised, double-blind, placebo-
controlled study to assess the long-term safety and efficacy of ISIS-TTRRx in patients with 
FAP was initiated in 2013. The mechanism by which ASOs mediate their effect could be 
beneficial in other types of amyloidosis. Kluve-Beckerman et al. used ASOs to suppress 
SAA production in mice and demonstrated that SAA levels in ASO-treated mice were 63% 
lower than those in controls resulting in reduced AA amyloid deposition [64, 244]. 
 
Renal Transplantation 
There is some hesitancy surrounding renal transplants in amyloidosis patients, mainly due 
to fears of recurrent disease and early allograft loss as well as the effect of 
immunosuppressive regimens on the underlying disease i.e. PCDs in AL amyloidosis and 
infection/ neoplasm in AA amyloidosis.  
 
The rate of renal allograft decline mirrors that of the native kidneys, in that decline is slower 
in Lys and AApoA1 where median allograft survival is 13.1 years, as compared to AL, AA 
and AFib where native decline is typically more rapid and median allograft survival is 8.3 
years [245].  
 
From 25 AL patients, there were no graft failures secondary to recurrent amyloid despite 
amyloid recurrence in 28% of allografts a median of 5.9 years post-transplant and 64% of 
patients not actually having achieved a complete response to chemotherapy [245]. Amyloid 
recurrence in AL amyloidosis was not seen where there was complete precursor protein 
suppression [245]. However, graft survival was significantly worse in those who had not 
achieved any form of response: 5.3 years vs 8.9 years in those who had responded to 
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chemotherapy [245]. The median estimated graft survival in AA amyloidosis was 10.3 to 
19.3 years, without any significant difference to graft survival in chronic glomerulonephritis 
[246]. 14 to 20% of patients have recurrent amyloid diagnosed between 5.3 to 9.8 years 
post-transplant and these patients had significantly higher SAA levels as compared to 
patients who did not have amyloid recurrence [245, 247]. 5% of grafts failed due to recurrent 
amyloid [245]. Graft survival noncensored for death was 14.5 years in patients with a median 
SAA value of <10 mg/L, and 7.8 years in those with a median SAA of >10 mg/L [245]. The 
most common cause of death post- transplant for any amyloid subtype is infection [245, 247, 
248].  
 
Transplantation in AFib patients has a 70% chance of recurrence if there are only isolated 
renal transplants and no recurrence in cases of combined liver and kidney transplantation; 
however, these isolated renal allografts lasted 7.3 years as opposed to 6.4 years in those 
with a liver and kidney transplant. Fourteen patients with ApoA1 had a renal transplant and 
median graft survival was 13.1 years, so significantly better than all other subtypes and also 
conferring a survival advantage to transplanted patients [245, 249, 250].  
 
Hence renal transplantation should be considered in patients with amyloidosis, with graft 
recurrence being less when the precursor protein is sufficiently suppressed i.e. at least a 
partial response in AL and SAA<10mg/L consistently in AA should be pursued. Although 
graft recurrence is less in AFibA in those patients where combined liver and kidney 
transplantation was undertaken, one has to balance this against the high perioperative 
mortality [251, 252]. 
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    Aims and Scope of the Thesis 
 
The over-riding theme and aim of this thesis was to investigate, evaluate and improve upon 
the diagnostic processes employed in ascertaining both the presence of amyloid and the 
exact subtype. The secondary aim was to identify and evaluate treatment options in a cohort 
of patients with the worst prognosis in AL amyloidosis and also to evaluate the treatment 
options and related prognostic implications in a related disorder, that is Light Chain 
Deposition Disease. 
 
The introduction is a general overview of amyloid and its subtypes as well as our current 
knowledge base of this field.  The materials and methods section then details the current 
techniques employed in every study and also the methodology involved in the newer 
techniques used for this research, in particular, the use of: mass spectrometry and 
proteomics, urinary retinol binding protein assays and implantable loop recorders.  
 
The specific aims and their derivation for each study are briefly given below and expanded 
upon in the beginning of each results’ chapter: 
 
Misdiagnosing Renal Amyloidosis as Minimal Change Disease 
Aim:  To evaluate current histological practices employed in diagnosing renal amyloidosis 
and the potential pitfalls that may lead to misdiagnosis.  
 
Current UK histological practices employed in diagnosing amyloidosis have not been 
previously evaluated. This study investigates the reasons why renal amyloid was 
misdiagnosed as minimal change disease, a disorder which presents similarly to renal 
amyloid. In particular it investigates whether or not Congo red staining and/ or electron 
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microscopy was undertaken. In cases where correct histological staining took place, I 
discuss why a misdiagnosis occurred and the impact misdiagnosis has had on patient 
morbidity and mortality. This retrospective study serves to evaluate current histological 
practices and the pitfalls present that necessitate advancement in diagnosing amyloidosis. 
 
Mass Spectrometry in the Diagnosis of Renal Amyloidosis and its Subtypes 
Aim: to investigate whether a method could be established, namely proteomics, by which 
amyloidogenic variants, specifically Fibrinogen A α-chain, could be identified in a sensitive 
and specific manner. 
 
Although mass spectrometry has increasingly ventured into the clinical domain in the US, it 
had not yet been established in the UK National Amyloidosis Centre. I highlight the 
deficiencies in current techniques, including the labour intensive IHC process and the failure 
of IHC to identify the correct subtype in 20-25% of cases, due to the absence of staining, 
secondary to: epitopes being hidden in protein folds or not present in the truncated fibrillary 
forms of protein deposits, indeterminate staining perhaps due to background contamination, 
the loss of epitope detectability in the tertiary structure due to protein cross-linking after 
formalin fixation or the absence of good quality antibodies [67, 152, 253]. I, alongside 
colleagues at the NAC, sought to establish proteomics as a diagnostic technique at the NAC 
and I specifically evaluated its success in identifying Fibrinogen A α-chain variants. I detail 
how laser capture and mass spectrometry is undertaken and the use of search engines, 
specifically the modification of the existing Uniprot database by appending a variant 
database which allows the identification of different pathological variants, including from 
background contaminants. The use of mass spectrometry in conjunction with IHC in 
amyloidosis, has increased the diagnostic success rate from 76% to 94% [152]. 
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The Usefulness of Urinary Retinol Binding Protein Measurements in Amyloidosis 
Aim: To investigate whether urinary retinol binding protein could potentially serve as a novel 
sensitive and specific biomarker for renal injury across the amyloid subtypes and, 
furthermore, provide prognostic information.  
 
The current biomarkers, similar to research-based and clinically applied nephrology in 
general, used in assessing renal amyloidosis are creatinine, including the derived eGFR and 
proteinuria. However, creatinine is thought to be a ‘late’ and non-specific marker of disease 
progression and there has been a search for a more sensitive and specific biomarker [254].  
Urinary Retinol Binding Protein is an important and sensitive biomarker for the loss of 
function of the human proximal renal tubule and, at the time of my study, had only been 
investigated comprehensively by one other group and that only in AL amyloidosis and 
without histological correlation [255]. I undertook a prospective cohort study with 81 patients 
across different amyloid subtypes and correlated urinary RBP findings with: amyloid 
precursor proteins e.g. light chains, Serum Amyloid A, histological findings, proteinuria, 
tubular phosphate reabsorption, glycosuria and amyloid burden. This study also investigated 
whether urinary RBP had a role in prognostication across a range of amyloid subtypes. 
 
Implanted Cardiac Rhythm Recorders in Advanced Cardiac AL Amyloidosis 
Aims: To characterise the nature of and disease-related risk factors for, cardiac arrhythmias 
in patients with severe cardiac AL amyloidosis, by offering the insertion of an implantable 
loop recorder (ILR) to a series of consecutive patients with newly diagnosed Mayo stage III 
cardiac AL amyloidosis  
 
To reveal possible new therapeutic strategies in this cohort of patients, who are known to 
have the worst prognosis in AL amyloidosis 
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Approximately a third of patients diagnosed with systemic AL amyloidosis present with 
cardiac failure and marked elevation of NT-proBNP and TnT [123]. Despite major recent 
advances in chemotherapeutic strategies for treating AL amyloidosis, these patients 
frequently die of SCD within 12 months of diagnosis and there has been no improvement in 
early deaths [123, 256]. Over the past 30 years, the question of whether anti- arrhythmic or 
chemotherapeutic drug therapy, or the implantation of PPMs or ICDs might improve survival 
in cardiac AL amyloidosis remains definitively unanswered although ventricular arrhythmias 
and PEA have been observed [129, 184-186].Unfortunately, due to the exceptionally poor 
prognosis of patients with advanced cardiac AL amyloidosis, they are rarely included in 
prospective studies and would not ordinarily be candidates for ICD, in accordance with 
consensus guidelines [257]. By implanting loop recorders in a cohort of 20 patients with the 
worst affected cardiac amyloid, I sought to determine, for the first time, the nature of 
arrhythmias after the diagnosis of amyloid, those immediately before the terminal rhythm 
and the terminal rhythm itself. This study also sought to assess the effect of treatment 
strategies, such as the effects of certain chemotherapeutic agents and/ or rate limiting 
medication and the use of cardiac devices. 
 
Outcome of Light Chain Deposition Disease with Chemotherapy 
Aim: To report on the clinical presentation, histologic features, molecular basis and outcome 
among 53 patients with LCDD who were prospectively followed at the UK National 
Amyloidosis Centre, highlighting the importance of aggressively treating the underlying 
monoclonal proliferative disease 
 
LCDD is a multi-system disorder and, similar to AL amyloidosis, arises from the deposition 
of monotypic immunoglobulin LCs in various organs [258]. The diagnosis, treatment and 
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prognosis in relation to haematological response and treatment in LCDD have never before 
been comprehensively evaluated in a large cohort of patients and there are no international 
guidelines on how to treat LCDD. I undertook a retrospective analysis of 53 patients with 
LCDD, analysing the presentation, renal histology and treatment of these patients including 
ASCT and renal transplantation. The use of the haematological response criteria applied to 
AL amyloidosis permitted a grading of the haematological response and a comparison with 
AL amyloidosis, allowing an evaluation of the effects of the pathological light chains alone 
as compared to the light chains within the amyloid structure. This strategy also led to an 
assessment of the relationship between the haematological response achieved and the 
patient’s prognosis.  
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Chapter 2: Material and Methods 
 
Declaration 
The concepts underlying all the studies resulted from discussions between myself and my 
supervisor, Dr Julian Gillmore. I subsequently designed the studies, identified and recruited 
patients, collected data and performed all of the statistical analyses using Excel, Graphpad 
Prism (Version 4) and/or SPSS v20 (IBM SPSS). Individual statistical methods are 
discussed separately in each results’ chapter. Historical patient information was obtained 
from the NAC database. I obtained data on deaths and follow up reports from the relevant 
patients’ General Practitioners, local hospital teams and the Office for National Statistics. I 
performed Congo red staining, laser dissection and prepared specimens for mass 
spectrometry in the Fibrinogen Aα study and ran results through the search engines and 
analysed the data obtained. Training was provided by Janet Gilbertson and Dr Nigel Rendell 
from the NAC laboratories and laser microdissection training specifically was provided by 
Thomas Adejumo at the MRC Clinical Sciences Institute, UCL with interpretation training 
undertaken at a Wellcome Trust Proteomics and Bioinformatics’ Course.  
 
For the Implantable Loop Recorder (ILR) Study, I was trained by Ms Lindsay Ford at 
Medtronic’s, and I subsequently taught patients on how to use the ILR device including 
setting up and downloading data remotely. I identified suitable patients, examined, recruited 
them and informed their local teams of the study and their participation. I co-ordinated patient 
admission to the cardiology unit and informed the on-call cardiology team and technicians 
of the patients’ admission for an ILR device. I then prepared the pre-operative notes and 
was available post-operatively to educate patients on how to use the device. Patients 
contacted me at the time of each download on a weekly basis or whenever they experienced 
worrisome symptoms. I examined these downloads immediately to rule out any life-
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threatening arrhythmias and then reviewed the rhythm strips with a consultant cardiologist: 
Dr Dominic Rogers, Dr Fakhar Khan or Dr Carol Whelan on a weekly basis. For any patients 
who died, and as per prior consent, I obtained downloads from mortuary staff. Having 
collated the data, I performed the statistical analysis. Measurement for biochemical and 
haematological data were performed by the Royal Free Hospital laboratory services. 
Informed consent from all patients was obtained and documented.  
 
With regards to the Light Chain Deposition Disease Study and the Retinol Binding Protein 
Study, amyloid distribution was assessed by myself, Janet Gilbertson and an expert 
consultant at the NAC. Historical histological data, as reviewed by referring hospitals, Janet 
Gilbertson and the NAC consultants, was used in the Minimal Change Disease Study. All 
immunostaining was performed by Janet Gilbertson, Nicola Botcher and Karen Boniface at 
the NAC laboratories. Gene sequencing was performed by Dorota Rowczenio and Hadija 
Trojer. SAP scintigraphy was undertaken by David Hutt and Stephanie McKnight. I attended 
a Wellcome Institute course on proteomics and was trained in data analysis post 
spectrometry by Drs. Graham Taylor and Nigel Randall at the NAC.  
 
Patients 
Patients for all studies were referred to and investigated at the National Amyloidosis Centre. 
Assessment including examination, history, clinic letters, investigations and serology. These 
were incorporated into the centre’s database, which has >20 years’ information. Where 
earlier or later data was required, I obtained this from General Practitioners, local hospital 
teams and the Office for National Statistics. All patients were treated in accordance with the 
Declaration of Helsinki and provided informed consent for all studies included in this thesis 
and publication of data.  Separate consent was obtained for interventional procedures, 
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namely the insertion of the Implantable Loop Recorder Device Approval was obtained from 
the Royal Free Hospital Research Ethics Committee.   
 
Functional Assessment 
 
The 6- Minute Walk Test (6MWT) 
The 6-minute walk test was used as a standardised measure of functional assessment of 
cardiothoracic capacity [259]. The same protocol was adhered to by two trained clinical 
technicians [260]. In brief, the distance walked on the same flat, hard surfaced corridor in a 
period of 6 minutes was noted for each patient with each patient setting their own walking 
pace and being allowed to vary their speed and rest as required. All patients rested at least 
10 minutes prior to the test, wore comfortable walking shoes and used their usual walking 
aids. The turnaround point was marked by closed double doors. Patients who had suffered 
a myocardial infarction within the past month or had unstable angina were excluded (none 
of the patients included in this thesis). Relative contraindications included a resting heart 
rate of  >120 beats per minute, a systolic blood pressure of more than 180 mm Hg, and a 
diastolic blood pressure of more than 100 mm Hg. Reasons for immediately stopping the 
6MWT include the following: (1) chest pain, (2) intolerable dyspnoea, (3) leg cramps, (4) 
staggering, (5) diaphoresis, and (6) pale or ashen appearance.  
 
A comprehensive protocol and discussion was obtained from 
https://www.thoracic.org/statements/resources/pfet/sixminute.pdf. 
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Eastern Co-operative Group (ECOG) Performance Status 
Functional evaluation of patients’ performance grades was evaluated in the clinic by using 
the Eastern Co-operative Group (ECOG) performance status. This is a standardised and 
numbered scale used to assess a patient’s functional capacity, in terms of their self-care, 
ambulation and level of daily activity (table 2.1). It is widely used by researchers to define 
their study participants and has been derived from as assessment tool used in oncology to 
determine a patient’s tolerability to treatment dosage or in fact to treatment all together [261].  
 
Table 2.1 Eastern Co-operative Group (ECOG) Performance Grades 
 
Grade Description 
0 
 
No restriction in undertaking pre-disease activities. Fully active. 
1 
Physically strenuous activity not possible but ambulatory and able 
to undertake light activity e.g. housework 
2 
 
Active for >50% of waking hours, independent for all self care only 
but no additional activities 
3 
Limited to certain aspects of self care and sedentary or prone for 
>50% of waking hours 
4 
Complete disability, dependent for all self care and confined to bed 
or chair.  
 
* Adapted from: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity and Response Criteria Of The Eastern Cooperative 
Oncology Group. Am J Clin Oncol 5:649-655, 1982. 
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New York Heart Association Classification 
This was used to grade the severity of functional limitations imposed by the presence of 
heart disease, as scored by the same experienced technician. 
 
Table 2.2 New York Heart Association class and description 
 
 
NYHA 
Class 
 
Limitations to 
Physical Activity 
Effect of physical activity 
I None No undue fatigue, dyspnoea or palpitations 
II Slight Fatigue, palpitations, dyspnoea or angina pectoris 
III Marked Symptoms with subnormal physical activity 
IV Severe 
Symptoms of CHF even at rest and discomfort with 
any level of physical activity 
 
Adapted from: National Heart Foundation of Australia and the Cardiac Society of Australia and New 
Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, 
detection and management of chronic heart failure in Australia. Updated October 2011). 
 
Transthoracic Echocardiography  
 
Echocardiography was performed in all patients with two-dimensional and M-mode settings 
using a GE Vivid E9 system, by 3 echocardiographers who were experienced in imaging 
patients with cardiac amyloidosis specifically, with > 40 years’ experience between them. 
Views most commonly used were parasternal long axis and apical long axis. Tissue Doppler 
was performed immediately above the mitral valve annulus at the septal and left ventricular 
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septal wall. Left ventricular wall thickness, left ventricular diastolic function, left ventricular 
systolic function and atrial diameter were assessed using defined criteria from the British 
Society of Echocardiography (http://www.bsecho.org). Left atrial area was measured using 
criteria defined by the American Society of Echocardiography (http://www.asecho.org). 
 
The parameters looked at in particular and utilised in this thesis, included: 
The thickness of the IVSd (the interventricular septum at end diastole), where <1.1 cm is 
deemed ‘normal,’ is believed to be thickened in amyloidosis secondary to fibril infiltration 
and classically precedes a decrease in LVEF, which tends to be a late finding [162]. Current 
guidelines use an increase in IVSd thickness with a positive biopsy for amyloid, usually from 
an extra-cardiac site, to make a diagnosis of cardiac involvement [106]. 
 
The ratio of peak early diastolic mitral inflow velocity (E) to peak early diastolic mitral annular 
velocity (e’) i.e. the E/e’ ratio, is an independent predictor of survival, which represents the 
diastolic function. A higher E/E′ index indicates greater LV end-diastolic pressure [262]. 
 
The global longitudinal strain, assessed using automated speckle-tracing echocardiography, 
has been found to be more effective than the conventional measurement of ejection fraction 
in detecting subtle changes in LV function and better at predicting cardiac events and all-
cause mortality [263, 264]. This is the change in length per unit length, a sensitive measure 
for detecting early systolic dysfunction and reflects the longitudinal contraction of the 
myocardium. 
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Histology  
 
Congo- red Staining  
 
All unprepared tissue samples were formalin-fixed and paraffin-embedded. Serial sections 
were stained with haematoxylin and eosin and six to ten µm-thick renal sections were cut 
(rather than the usual 2 µm). In brief, sections were dewaxed, for 5 minutes, through each 
bath of xylene, hydrated through graded alcohol, immersed briefly in Mayer’s haematoxylin, 
rinsed or ‘blued’ under running tap water, immersed for 20 minutes in filtered alkaline 
alcoholic NaCl solution, drained briefly, stained with alkalinised Congo red as per the method 
developed by Puchtler et al., dehydrated with increasing concentrations of alcohol, cleared 
with xylene and then mounted with resinous mounting medium [265]. All such samples along 
with previously stained slides were viewed under brightfield and under cross-polarised light 
by two independent observers at the National Amyloidosis Centre to determine the presence 
and location of amyloid deposits. Positive controls were obtained from a known Congo red 
positive block validated by laser microdissection and mass-spectrometry based proteomic 
analysis which was always processed in parallel. 
 
Immunohistochemistry 
 
Following Congo red staining and confirmation of Congo red deposits, the amyloid subtype 
was determined by immunohistochemical staining. Formalin fixed sections were 
deparaffinated in xylitol, 3 × 10 minutes and dehydrated in a descendent alcohol series 
(100%, 90%, 80%, and 70%, 10 minutes each). After 30 minutes of treatment with 100% 
formic acid, the endogenous peroxidise activity was inhibited by incubation in aqueous 0.3% 
hydrogen peroxide (H2O2) in methanol, for 30 minutes. The sections were rinsed in 
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phosphate-buffered saline (PBS) containing 0.05% Tween (Calbiochem) to decrease non-
specific background staining and enhance reagent spread. Further non-specific tissue 
binding was abolished by incubating for 30 minutes in normal, non-immune serum from the 
species providing the secondary antibody (Vector Part of the ImmPRESS Kit). Sections were 
incubated overnight with primary antisera at 4oC and rinsed with PBS containing 0.05% 
Tween (Calbiochem) and labelled with secondary antibodies. Sections were washed in PBS 
and enzyme-antibody bound complexes were visualised using a metal-enhanced 3,3′-
Diaminobenzidine tetrahydrochloride (DAB) (Fisher Scientific solution). A panel of anti-
human monospecific antibodies reactive with: SAA (Eurodiagnostica, Huntington UK) AL κ, 
λ, TTR and lysozyme (DAKO Ltd, Denmark House Ely UK), Apolipoprotein AI (Genzyme 
Diagnostics) and fibrinogen Aα chain (Calbiochem) were used where appropriate. For TTR 
staining, pre-treatment was performed for enhanced antigen retrieval using by incubating 
for 10 minutes with 1% sodium periodate, slides were then washed and further incubated 
for 10 minutes with 0.1% sodium metabisulphate, washed again and incubated for 5 hours 
at room temperature with 6M Guanadine dissolved in 0.9% NaCl. Immunohistochemically 
stained sections were counterstained in haematoxylin, ‘blued’ under running tap water and 
stained with Congo red.  
 
Laser Microdissection and Mass Spectrometry 
TPrior to liquid chromatography/tandem MS (LC/MS/MS) analysis, paraffin wax was 
removed from the fresh frozen paraffin embedded specimens. Laser capture 
microdissection was then undertaken using Photoactivated Localisation Microscopy (PALM) 
(Carl Zeiss, Oberkochen, Germany) (Fig. 2.1) to cut and extract Congo red positive deposits 
(2.2), which show up as bright red under fluorescent light (Fig. 2.3).  Typically, at least 6-7 
glomeruli were extracted. The microdissected tissue was catapulted into the adhesive 
inverted microfuge tube cap placed directly above the sample. The force for catapulting was 
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produced by a defocused laser pulse that propelled the sample to an awaiting capture 
device. This contact-free microdissection allows for greater purity of the sample obtained.   
 
Fig 2.1  PALM microscope used to undertake microdissection. This is a super 
resolution technique that dramatically improves the spatial resolution of the optical 
microscope (19) 
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Fig 2.2 Congo red stained glomerular deposits of amyloid, as viewed under the 
PALM microscope 
 
Fig.2.3 Congo red deposits as examined under a PALM microscope, using the 
tetramethyrhodamine isothiocynate filter, with amyloid deposits appearing red 
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Sample Preparation for Mass Spectrometry 
 TEZ (Tris, EDTA and Zwittergent) buffer, composed of the pH buffer Tris 0.1M, the cation 
chelator disodium EDTA 10 mM and Zwittergent (Z3-16) 0.02% w/v was made up and 0.35 
ul was added to each tissue sample.   These were then vortexed to enable thorough mixing 
and left at room temperature for 20 mins. Samples were centrifuged for 5 minutes at 5000 
rpm to allow the liquid to settle to the bottom of the eppendorfs. They were then heated for 
90 mins at 99°C (Techne Dri-Blok) mixing every 20 to 25 minutes, cooled at room 
temperature for 5 minutes then centrifuged at 5 minutes for 5000 rpm to recover as much 
condensate as possible from the tube lids. The eppendorfs were then sonicated. 245 µl of 
TEZ was added to 5µl of stored frozen trypsin and 1.5 µl of working trypsin was aliquoted 
into each sample, this was vortexed and centrifuged at 5000 rpm for 1 minute. Samples 
were digested overnight at 37°C. 5 µl of dithiothreitol (DTT) was placed in each eppendorf 
to reduce the trypsin generated digests, vortexed and then heated at 99°C for 5 mins and 
then centrifuged again. This was then frozen at -80 °C for 5 minutes and placed in a vacuum 
to freeze dry for up to 24 hours. Each freeze dried sample was re-constituted with 20 µL of 
1% MeCN/aq and 0.1 % TFA (20 µL/sample) was added to each freeze dried sample and 
this was sonicated for 5-10 minutes, then spun at 3000 rpm for 5 minutes. 18 µL of this 
solution was then transferred to the mass spectrometry vials [266, 267].    
 
Protein Identification via Mass Spectrometry 
The trypsin generated digests were reduced with 0.1% dithiothreitol and separated by 
nanoflow liquid chromatography–electrospray tandem mass spectrometry using a Thermo 
Scientific™ Orbitrap Velos Pro™ Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo 
Fisher Scientific, Inc.) coupled to an Eksigent nanoLC-2D HPLC system (Eksigent, Dublin, 
CA, USA). The MS/MS raw data files were submitted to a workflow tool and the Mascot 
search algorithm was used. The results were assigned peptide and protein probability 
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scores. All searches were conducted with variable modifications and restricted to full trypsin-
generated peptides allowing for two missed cleavages. Peptide mass search tolerances 
were set to 10 p.p.m. and fragment mass tolerance to ±1.00 Da. The human SwissProt 
database was utilised. The MS data show peptides and spectra that match a particular 
protein based on the amino-acid sequence available in the database. Some of the peptides 
(and spectra) from different proteins can be common and be shared depending upon the 
homology of their amino-acid sequence. On the other hand, unique peptides and spectra 
are distinctive to the particular protein. The ‘Spectra' value indicates the total number of 
mass spectra collected on the mass spectrometer and matched to the protein using the 
proteomics software. A higher number of mass spectra is indicative of greater abundance 
and will typically yield greater amino-acid sequence coverage. A higher mass spectra value 
also indicates a higher confidence in the protein identification. Amyloid was confirmed by 
presence of the ‘amyloid signature’ defined as the presence of two or more of the following 
proteins: apolipoprotein E, apolipoprotein A-IV and SAP. Following the initial search results, 
four known amyloidogenic variant fibrinogen A α-chain peptide sequences, including the 
commonest E526V (pGlu545Val) variant, were added to the Uniprot database of the 
complete human proteome. Samples containing fibrinogen A α-chain were interrogated via 
the new database. 
 
Serological Tests 
Measurement of Retinol Binding Protein  
Analysis of urinary RBP was undertaken using a very sensitive immuno-nephelometric 
technique involving the use of latex enhanced antibodies (the Binding Site Group Limited, 
Birmingham), according to the manufacturer’s protocol and employing an ELISA technique 
[268]. A Siemens BN II nephelometer Analyser II was used. This method is dependent on 
the measurement of light scattered by particles in solution, the particles in this case being 
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insoluble RBP-antibody immune complexes and the scattered light being directly 
proportional to the antigen concentration. Prior to RBP analysis, calibration curves were 
initially prepared using a series of diluted standards of known RBP concentration. Samples 
of unknown RBP concentration were then assayed and concentration levels determined 
using the calibration curve. Latex-enhanced antibodies were used to enhance the light-
scattering ability of the antibody-RBP complexes and hence avoid the complication of 
undetection secondary to immune complexes that are too small. This assay was undertaken 
by Dr Jahn Persaud at the Royal Free Biochemistry laboratory. 
 
Serum Free Immunoglobulin Light Chain Assay  
Both κ and λ serum FLCs were measured using a latex-enhanced immunoassay (The 
Binding Site, Birmingham, UK) on a Behring BNII autoanalyser which uses sheep anti-
human polyclonal antibodies that are directed against epitopes which are only revealed 
when ĸ or λ light chains are free, as opposed to when they are part of an intact 
immunoglobulin molecule (Dade Behring, Marburg, Germany). The sensitivity of the assay 
is <5 mg/L. The reference range was established after having tested sera from 100 healthy 
blood donors, where the mean concentrations of polyclonal free κ and free λ light chains 
were 11.38 mg/L (95% CI, 7.41-16.77 mg/L) and 17.36 mg/L (% CI, 8.91-29.87 mg/l) 
respectively. The normal κ: λ ratio is 0.26 to 1.65 [114, 115]. Because FLCs undergo 
glomerular filtration, the ratio, rather than the absolute level, is the relevant measurement in 
individuals with renal impairment. A κ: λ ratio of <0.26 strongly suggests the presence of a 
population of plasma cells that are producing clonal λ free light chains, whereas a ratio >1.65 
suggests production of clonal κ FLCs [269]. 
 
In AL amyloidosis, as in LCDD, the production of pathogenic LCs arising from a plasma cell 
clone is directly responsible for the disease process and halting this production is of 
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paramount importance. Hence, the involved free LCs, usually κ in AL amyloidosis and λ in 
LCDD should be measured regularly and the dFLC is calculated. Worsening CKD, in 
individuals without a proliferative disorder, results in an increase in both FLC isotypes; 
however, levels of ĸ LCs selectively increase as they are produced in greater abundance 
relative to λ light chains and in CKD the difference between the clearance of the smaller 
monomeric κ LC as opposed to the larger dimeric λ LC is reduced. This has led to the 
adoption of a revised ratio of 0.37-3.17 in individuals with CKD [270, 271]. Pallidini et al., 
have devised a grading response system, adapted from that used in myeloma, for AL 
amyloidosis and demonstrated the correlation of dFLC with survival [272]. This correlation 
is seen as early as 3 months post treatment. The dFLC was compared across a series of 
time points for each individual patient, to monitor disease progression including response to 
treatment, as standardised by Pallidini et al. (Table 2.3).   
 
Table 2.3: Haematologic response criteria for disease caused by light chains 
Response Criteria 
Complete Response The normalisation of ĸ and λ ratio 
No detectable monoclonal protein by serum and urine immunofixation 
electrophoresis 
Very Good Partial 
Response 
Decrease in dFLC to <40 mg/l 
Partial Response >50% decrease in dFLC 
No Response ≤50% decrease in dFLC 
 
Adapted from Palladini et al. 2012 [117] 
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Gene Sequencing (as per the method described by Dr Rowczenio) 
Following patient consent, an EDTA tube of whole blood was taken. Gene sequencing was 
performed on the first visit if a hereditary amyloid subtype was strongly suspected or the 
sample was stored, should hereditary amyloid be queried at a later date if investigations for 
the more common subtypes prove futile.  Genomic DNA was isolated by a rapid method 
[273]. The blood was added to NH4CL and spun, the sample was then re-suspended in 0.9% 
NaCl and re-spun. It was then suspended again in 0.05M NaOH, incubated, cooled and 
neutralised with 1M Tris pH8. PCR was undertaken to amplify the fragments, with Ready-
To-Go tubes (Amersham Pharmacia Biotech) with the use of solutions and cycling 
conditions that have been previously described [274]. These were used to amplify the coding 
regions for: transthyretin (exons 2,3 and 4), apolipoprotein AI (exons 3 and 4) and fibrinogen 
A α-chain (exon 5) and lysozyme (exon 2). The PCR products were purified with a QIAquick 
PCR purification kit (Qiagen) according to the manufacturer’s protocol and automated 
sequencing of the products was performed using the Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) following the procedures recommended by the 
manufacturer. Gene sequences were analysed on the ABI 3130xl Genetic Analyser using 
Sequencing Analysis Software version 5.4. The primers used for the PCR process are 
shown in table 2.4. 
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Table 2.4 Primers used in the PCR process for genotyping hereditary amyloidosis 
 
Gene 
 (exon) 
Forward primer sequence Reverse primer sequence 
Transthyretin 
(2) 
5’-TTTCGCTCCAGATTTCTAATAC-3’ 
5’-
CAGATGATGTGAGCCTCTCTC-3’ 
Transthyretin 
(3) 
5’-GGTGGGGGTGTATTACTTTGC-3’ 
5’-TAGGACATTTCTGTGGTACAC-
3’ 
Transthyretin 
(4) 
5’-GGTGGTCAGTCATGTGTGTC-3’ 
5’-
TGGAAGGGACAATAAGGGAAT-3’ 
Apolipoprotein 
(3) 
5’-
GGCAGAGGCAGCAGGTTTCTCAC-
3’ 
5’-
CCAGACTGGCCGAGTCCTCACC
TA-3’ 
Apolipoprotein 
(4) 
5’-CACTGCACCTCCGCGGACA-3’ 
5’- 
CTTCCCGGTGCTCAGAATAAAC
GTT-3’ 
Fibrinogen 
 (5) 
5’-AGCTCTGTATCTGGTAGTACT-3’ 5’- ATCGGCTTCACTTCCGGC-3’ 
Lysozyme 
 (2) 
5’-GTTATATTGTTCGTTGGTGT-3’ 
5’- 
CATTTGTATTGAGTCTCAATTC-3’ 
 
SAP Scintigraphy 
SAP scintigraphy was undertaken in all patients at their baseline assessment and only 
repeated at clinic follow-up visits at 6 or 12 months, if clinically indicated. Contra-indications 
included pregnancy and relative contraindications included claustrophobia.  Highly purified 
SAP was radiolabelled with the medium-energy, short half-life pure gamma emitter 123I and 
each subject undergoing SAP scintigraphy received approximately 200µg of SAP with 
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190MBq of 123I by bolus intravenous injection. This is equivalent to 3.8 mSV of radiation and 
comparable to the dose received for an IV pyelogram. If amyloid is absent then labelled SAP 
is not retained and is rapidly excreted post catabolism, whereas is individuals with amyloid, 
the tracer is localised to the affected sites in proportion to the amyloid amount present.  
Thyroid uptake was blocked by administrating 60mg of potassium iodide immediately prior 
to the study and then 5 further doses over the next three days. Anterior and posterior imaging 
was performed at either 6 or 24 hours after injection using an Infinia Hawkeye gamma 
camera (General Electric). The images were reviewed at the time of acquisition by a panel 
of physicians with experience of over 29 000 scans. The diagnostic sensitivity in patients 
with AA amyloidosis is 100% and ~90% in AL amyloidosis. 
 
The scoring of the amyloid load, as standardised by Professor Hawkins at the NAC, was as 
follows: 
 
Table 2.5: Amyloid load scoring 
Total Amyloid Load Description 
None No abnormal tracer localisation. Normal blood pool signal 
Small Tracer uptake into one or more organs with blood pool clearly visible at 
normal intensity 
Moderate Tracer uptake into organs with blood pool only just visible 
Large Tracer uptake into organs with loss of blood pool signal following 
adjustment of grey scale to encompass target organ 
 
Regression of the amyloid burden was defined as a reduction in tracer uptake in affected 
organs or an increase in the blood-pool background signal, whereas an increase in tracer 
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uptake in affected organs, an abnormal tracer uptake in a previously unaffected organ, or a 
decrease in the blood-pool background signal suggested progression of the amyloid load. 
 
Implantable Loop Recorder (ILR) Insertion and Data Capture for Cardiac Study 
ILRs (Reveal DX or Reveal XT, Medtronic, Minnesota, USA) were inserted subcutaneously 
under local anaesthetic, using standard implantation techniques, by a cardiologist.  
Appropriate sensing was confirmed in all cases.  Devices were programmed to allow storage 
of three manual activations (each lasting up to 7.5 minutes); settings for automatic 
recordings of arrhythmias were as follows: bradycardia - <30 beats per minute (bpm); 
pauses - >3 seconds; VT - >176 bpm; and fast VT - >231 bpm.  Up to 30 episodes of each 
of those 4 arrhythmia types (bradycardia, pause/asystole, VT, fast VT) were stored per 
download, with each episode recorded for 60 seconds.  Prior to discharge, patients and their 
next of kin were taught how to activate their device and instructed to perform an activation 
immediately after any symptomatic episode (palpitations, pre-syncope or syncope) by 
myself.  They were taught how to download recordings using the Carelink remote monitoring 
system (Medtronic, USA) and received instruction on how to download recordings at weekly 
intervals in order to capture arrhythmias recorded automatically by the ILR, as well as after 
any manual activation of the device. Patients contacted me at the time of download and 
recordings were then reviewed immediately to exclude a malignant arrhythmia. All 
recordings, including episodes of bradycardia, tachycardia, pauses and atrial arrhythmia, 
were then interpreted by a cardiologist, either on a routine weekly basis or as soon as 
possibly if intervention was deemed likely.  
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Results & Discussion Section 
 
Chapter 3: Misdiagnosing Renal Amyloidosis as Minimal Change Disease 
This chapter is based on the publication 
 
Misdiagnosing renal amyloidosis as minimal change disease. Sayed RH, Gilbertson 
JA, Hutt DF, Lachmann HJ, Hawkins PN, Bass P, Gillmore JD. Nephrol Dial Transplant. 
2014 Nov; 29(11):2120-6. 
 
My contribution was undertaking the study and data analysis and subsequently writing the 
publication. 
 
Aims The aim of this study was to look at current histological practices employed in 
diagnosing renal amyloidosis and the potential pitfalls that may lead to misdiagnosis. 
 
 
Introduction 
Renal amyloidosis and Minimal Change Disease (MCD) typically present with heavy 
proteinuria and the nephrotic syndrome (NS).  Despite their similar clinical presentations, 
therapeutic interventions aimed at inducing clinical remission differ substantially between 
these conditions.  Similarly, outcomes differ markedly between patients with these two renal 
lesions; amyloidosis is usually a multi-system, progressive disease with a poor renal and 
overall prognosis, whereas MCD is typically a non-scarring, renal-isolated disease which 
remits following commencement of immunosuppressive therapy and has a good renal and 
overall prognosis.   
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MCD accounts for approximately 90% of cases of NS in children who are <10 years old, 
50% of cases among children between 10 and 18 years, and 10-15% of adults presenting 
with NS [275]. Histologically, it is characterised by a lack of any detectable abnormality on 
light microscopy (LM), other than possible slight mesangial prominence.  On electron 
microscopy (EM) there is epithelial cell foot process effacement.  Immunohistochemical 
staining in MCD may sometimes demonstrate low intensity staining for C3 and IgM  but is 
often negative [276]. Since MCD accounts for 90% of cases of NS in young children and is 
typically steroid-responsive, the usual practice in those presenting with NS from this age 
group is to initiate treatment with corticosteroids without recourse to a diagnostic kidney 
biopsy [277]. In contrast, adults who present with NS usually undergo a diagnostic kidney 
biopsy before commencement of disease-modifying therapy.  Only ~75% of adults with MCD 
are steroid responsive and there may be a delay of 3-4 months before the response is 
achieved; total steroid exposure, with tapering, is usually around 6 months [276, 277].  The 
Kidney Disease Improving Global Outcomes guidelines recommend Calcineurin Inhibitors 
(CNIs) and cyclophosphamide in those intolerant of high-dose corticosteroids or those who 
are steroid unresponsive [277]. Renal amyloidosis is rare in children but accounts for 2-5% 
of cases of NS in young adults, and 11-13% in middle and old age [278].   
 
Here, we highlight a cohort of patients diagnosed with MCD on renal biopsy following a 
proteinuric clinical presentation, in whom a subsequent diagnosis of renal amyloidosis was 
established.  We investigate the validity of the initial diagnosis of MCD and attempt to 
establish whether ‘standardised’ operating procedures in the histology laboratory might 
enable a greater detection rate of renal amyloid deposition.  
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Methods Specific to this Study (please see ‘Materials and Methods’ Section’ for more 
extensive descriptions) 
 
Study Design and Patients 
A retrospective analysis of 2116 patients referred to the UK National Amyloidosis Centre 
(NAC) with amyloid on renal biopsy between January 2001 and July 2013 was conducted.  
Those patients in whom an initial diagnosis of MCD had been made were identified through 
a search of patient referral letters and corroborated in all such cases, by original biopsy 
reports.  This constitutes the study population.  Patient demographics at the time of renal 
amyloid diagnosis, disease-modifying therapeutic interventions, time between the diagnosis 
of MCD and the diagnosis of renal amyloid, as well as clinical outcomes were evaluated in 
the study population.   
 
Histology  
Kidney biopsy samples (unstained formalin fixed, paraffin embedded blocks and stained 
slides) and histology reports detailing a diagnosis of MCD (from the study population) were 
obtained.  Six µm thick renal sections were cut and stained with alkalinised Congo red by 
the method developed by Puchtler, Sweat and Levine in 1962 (Fig. 3.1a) [265].  In each 
case that amyloid was present, identification of the fibril protein type was sought using a 
standard panel of antibodies (Fig. 3.1b).  All such samples along with previously stained 
slides were viewed under cross polarised light by two independent observers at the NAC to 
determine the presence of renal amyloid deposits that initially had been missed (Fig. 3.1c).  
Wherever possible, EM reports were obtained and/or EM pictures were reviewed or EM was 
retrospectively undertaken on the relevant biopsy samples in order to identify the presence 
or absence of fibrils within the kidney tissue (Fig. 3.1d).   
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Fig 3.1 Renal histology showing amorphous material within the glomeruli staining with Congo 
Red at ×100 magnification (a), and a single glomerulus with Congo red deposits at ×400 
magnification (b), apple green birefringence under cross-polarized light after staining with 
Congo red in the same glomerulus at ×400 magnification (c) and EM showing randomly 
orientated fibrils (d). 
 
Radiolabelled 123I-SAP scintigraphy  
SAP scintigraphy was performed during the initial evaluation at the NAC, a median 21 days 
after histological confirmation of renal amyloidosis.  Individual organ involvement by amyloid 
and whole-body amyloid burden were recorded in each case, as previously described 
(Table 2.5).  
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Results 
Twenty-seven patients were identified in whom the initial renal histology was reported as 
MCD prior to subsequent identification of renal amyloid.  Patient characteristics at the time 
of review at the National Amyloidosis Centre, shortly after the diagnosis of amyloidosis, are 
detailed in table 3.1.  Thirteen patients were female and median age at time of diagnosis of 
MCD was 62 years (range 32 to 73 years).  The median time lapse between the diagnosis 
of MCD and that of renal amyloidosis was 241 days and the range was from 20 to 3632 
days.  The amyloid type was AL in 25 cases and AA in 2 cases.  
 
By the time of review at the NAC, median proteinuria was 6.9 g/24 hours (range 0.3-12.2 g) 
and median eGFR was 64 ml/min (range 6 to 191 ml/min).  Extra-renal amyloid deposits 
were identified by SAP scintigraphy (Fig. 2) and/or echocardiography in 21/27 (78%) cases 
at the initial NAC evaluation and 9 (33%) patients had a moderate or large total body amyloid 
burden by SAP scintigraphic criteria at this time (Table 1, Fig 3.2 and 3.3) [279].  Ten of 25 
(40%) patients with AL amyloidosis had significant cardiac infiltration and both patients with 
AA amyloidosis had liver involvement, poor prognostic features in the respective amyloid 
types [125, 146]. 
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Table 3.1: Patient characteristics at the time of initial review at the NAC 
 
Patient Gender 
M/F 
Age 
yrs 
Amyloid 
Subtype 
Presenting 
eGFR 
ml/min/1.73m2 
Presenting 
Proteinuria 
g/24 hr 
Presenting 
Amyloid Load on 
SAP Scan 
Extra-Renal Organ 
Involvement at time of 
Diagnosis of Amyloid 
Renal 
Replacement 
Required? 
1 F 38 AL 96 5.99 Large Liver, spleen, heart No 
2 M 73 AL 12 10.7 Small Spleen Yes 
3 M 70 AL 91 4 Small Spleen, heart No 
4 F 63 AL 29 7.31 Small Spleen Yes 
5 F 66 AL 172 10.67 Equivocal  No 
6 M 63 AA 16 8.07 Moderate Liver, spleen Yes 
7 M 61 AL 185 5.4 Moderate Liver, spleen, heart No 
8 F 61 AL 116 6.72 Large Liver, heart No 
9 F 53 AL 122 7.5 Equivocal  No 
10 F 50 AL 20 4.12 None Heart No 
11 F 64 AL 56 3.4 Small Spleen, heart No 
12 M 72 AL 6 5.83 Small Spleen Yes 
13 M 62 AL 45 6.9 Large Liver, spleen Yes 
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14 F 66 AL 64 11.57 Small Spleen No 
15 M 61 AL 11 0.29 Moderate Spleen, liver Yes 
16 F 41 AL 131 5.1 Small Liver, spleen, heart No 
17 M 51 AL 128 5.5 Small  No 
18 M 80 AL 90 3.54 Small Spleen, heart No 
19 M 70 AL 57 9.1 Small  No 
20 M 32 AA 191 8.8 Moderate Liver, spleen No 
21 M 67 AL 51 9.17 Small  No 
22 F 41 AL 67 11.6 Small Heart No 
23 M 69 AL 47 7.8 Small Spleen No 
24 F 53 AL 21 6.3 Small Heart Yes 
25 M 46 AL 107 9.89 None  No 
26 F 68 AL 93 4.25 Moderate Spleen No 
27 F 40 AL 43 12.23 Moderate Spleen No 
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Fig 3.2 Extra-renal amyloid infiltration of organs at the time of presentation to the 
NAC 
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Fig. 3.3: (a) Anterior and posterior whole body SAP scans showing a large total body 
amyloid load, with tracer uptake in the liver and spleen in a case of systemic AL 
amyloidosis. The kidneys are obscured by the large burden of amyloid in those 
organs. (b) Anterior and posterior whole body SAP scans showing amyloid in the 
spleen and kidneys of a patient with systemic AA amyloidosis 
 
 
 
 
With median follow up in the whole cohort of 3.3 years, 18/27 (67%) patients died, and 7/27 
(26%) patients required dialysis (including 2 who were dialysis dependent at the time of 
diagnosis of renal amyloidosis).  Median estimated time to dialysis, from the time of the initial 
MCD diagnosis was 8.6 years and from diagnosis of renal amyloidosis was 8.3 years (Fig 
3.4a).  Median patient survival by Kaplan Meier analysis was 5.2 years (range 0.8 to 8.4) 
from diagnosis of MCD and 4.7 years (range 0.3 to 6.4) from diagnosis of renal amyloid (Fig 
3.4b). 
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Fig 3.4: Kaplan–Meier survival analyses. (a) Renal survival from the time of 
diagnosis of renal amyloid. (b) Patient survival from the time of diagnosis of renal 
amyloid. 
 
 
 
 
All subsequent analyses were carried out on 26 of the 27 patients since neither the initial 
biopsy nor the report for one patient could be retrieved.  Seventeen of the 26 (65%) patients 
were diagnosed with MCD without Congo red staining of kidney biopsies having been 
performed (Fig 3.5a).  All 17 biopsies did however contain amyloid deposits that were 
evident when sections were stained with Congo red by the method of Puchtler et al and 
viewed under cross polarised light at the NAC [265].  Interestingly, 1 of these 17 biopsies 
had been stained with Sirius Red at the local hospital, and was reported as equivocal for 
amyloid despite a ‘final diagnostic’ report indicating MCD (Fig. 3.5a).   
 
The remaining 9 biopsies, had been stained with Congo red locally but thought not to show 
amyloid.  We were able to retrieve 5 of these biopsy samples; four were found to show 
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amyloid on Congo red staining at the NAC but 1 did not show green birefringence after 
Congo red staining although there was evidence of renal amyloid on the basis of EM, 
corroborated by SAP scintigraphy. 
 
The diagnosis of MCD was made without EM in 17 of 26 patients in this series.  In the 
remainder, EM was performed but was reported not to show fibrils thus supporting a 
diagnosis of MCD.  Interestingly, 9/26 (35%) patients had neither Congo red staining nor 
EM performed prior to being diagnosed with MCD (Fig 3.5b).  EM was retrospectively 
undertaken on 10 of 17 biopsy specimens that did not have EM performed initially.  This 
revealed the presence of fibrils, typical of amyloid, in every case; all ten of these biopsy 
specimens were also found to contain amyloid by Congo red staining at NAC review.  
 
Fig. 3.5: Histological staining patterns. (a) Proportion of patients whose initial renal 
biopsy was stained with Congo red and those in whom the result was equivocal. 
 
 
CR applied
CR equivocal
CR not applied
Fig. 3.5a
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3.5b: Proportion of patients whose biopsies were reviewed under EM 
 
 
 
 
 
Sixteen patients underwent a second, and one a third renal biopsy before the diagnosis of 
amyloidosis was made.  Fourteen of these 16 (88%) patients did in fact have demonstrable 
amyloid on their first renal biopsy when this was re-stained and/or reviewed at the NAC.  
 
Discussion 
I report here 27 patients with renal disease in whom an initial diagnosis of minimal change 
disease was revised to renal amyloidosis following reassessment of their kidney biopsies. 
This cohort highlights several distinct and important reasons for delays in establishing a 
diagnosis of renal amyloidosis.  Seventeen of 26 available renal biopsies reported to have 
shown MCD had not been stained with Congo red, although each one was subsequently 
confirmed to contain amyloid deposits when sections were stained with Congo red and 
viewed under cross polarised light.  Furthermore, EM images, available in 10/17 of these 
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biopsy specimens, showed the presence of characteristic fibrils.  These data highlight the 
need for every renal biopsy specimen to be stained with Congo red and viewed under cross 
polarised light.  A diagnosis of MCD cannot be made without the exclusion of amyloid using 
this ‘gold standard’ diagnostic test.  EM should also be undertaken on renal biopsy 
specimens wherever possible, particularly for suspected MCD, with the presence of fibrils 
alerting the pathologist to the possibility of amyloid or alternative fibrillar pathology.  It is 
noteworthy that in one of these 17 cases, Sirius Red staining was used.  Although Sirius 
Red has been reported to result in ‘stronger’ staining that might be ‘more noticeable’ than 
Congo red, it is not associated with green birefringence under cross-polarised light and is 
thus inadequate for the exclusion of amyloid [280].  It remains uncertain whether these 
specimens were viewed under cross- polarised light or simply under brightfield light, but on 
review at the UK NAC, amyloid deposits were identified in each of 5 available tissue 
specimens; 4/5 on viewing the Congo red stained tissue under cross-polarised light, the 
remaining case showing characteristic fibrils on EM despite the absence of amyloid on 
Congo red.  The diagnosis of renal amyloid in this last case was corroborated by abnormal 
renal uptake by SAP scintigraphy.  These five cases highlight another likely important reason 
for failure to diagnose renal amyloid.  Renal amyloid cannot be excluded by the absence of 
obvious extracellular eosinophilic material when viewed under brightfield light alone, even 
after Congo red staining of the specimen.  It must be viewed in all cases under cross-
polarised light.   
 
There was a median time lapse of 241 days between the diagnoses of MCD and renal 
amyloidosis amongst these patients.  The renal and overall outcomes in this group were 
poor with an eventual need for renal replacement therapy in 26% and median survival from 
diagnosis of amyloid of 4.7 years.  AL amyloidosis is a progressive disease which in the 
absence of therapy is almost universally fatal, but chemotherapy directed towards the 
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underlying clonal plasma cell disease is increasingly successful.  Prior to being diagnosed 
with renal amyloid, patients received steroids, often in combination with cyclophosphamide, 
calcineurin inhibitors or azathioprine in order to bring about resolution of their nephrotic 
range proteinuria. In each case, the reason for reviewing the initial kidney biopsy or 
undertaking a repeat kidney biopsy was a failure to respond to therapy.  Taken together, 
these data support the need for the review of biopsy specimens in a Specialist Centre 
whenever the suspicion of renal amyloidosis remains high.  Examples might include a 
patient with a PCD diagnosed with MCD who fails to respond to steroid therapy, or a patient 
with a PCD diagnosed with MCD who has significant cardiac or hepatic disease.  Another 
situation in which review of histology by a Specialist centre is warranted, is when EM pictures 
show fibrils but the precise diagnosis remains unclear.   
 
The case that failed to show the presence of amyloid, despite viewing of the Congo red 
stained tissue specimen under cross-polarised light, highlights some important issues.  This 
patient presented with 9.1 g per 24 hours of glomerular proteinuria.  EM confirmed the 
presence of randomly arranged, non-branching fibrils despite the absence of green 
birefringence on viewing of the Congo red stained tissue under cross- polarised light.  One 
might postulate that the absence of amyloid on Congo red stain was due to ‘sampling error’ 
since this can be a patchy disease and the site of biopsy on this occasion may have been 
‘amyloid poor.’  Alternatively, it may be that a certain number of fibrils are required before 
Congo red dye can intercalate sufficiently to demonstrate green birefringence under 
polarising filters and that this patient presented with proteinuria in the context of a ‘pre-
amyloid’ state, as suggested by Hetzel [281].  Although amyloid fibrillogenesis by proteins 
must, by definition, involve a phase of pre-fibrillar aggregate formation, there is little 
evidence to support the idea of clinical disease before amyloid has supervened.  It is thus 
more likely that sampling error is responsible for the failure to identify renal amyloid on the 
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very rare occasions that it may be missed despite correct staining of tissue specimens 
viewed under the correct conditions.  
  
Treatment of amyloidosis with appropriate chemotherapeutic or biological agents in a timely 
fashion can halt ongoing amyloid deposition and prevent progression to ESRD and the 
requirement for renal replacement therapy [40, 282]. Furthermore, early diagnosis may 
mean a reduction in the likelihood of infectious and thrombotic complications associated with 
a prolonged nephrotic state [282].  Finally, correctly diagnosing renal amyloidosis will 
prevent inappropriate, ineffectual and potentially harmful use of drugs such as steroids, 
cyclophosphamide and/or CNIs.  It is thus paramount that all kidney biopsy specimens are 
routinely stained with Congo red and viewed under cross-polarised light.  In addition, renal 
tissue should be obtained for EM wherever possible, at the very least so that the pathologist 
can revert to analysis of EM pictures when the clinical picture demands it.  Whenever the 
clinical suspicion of renal amyloidosis remains high, tissue blocks should be forwarded to 
Specialist Amyloidosis Centres.   
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Results and Discussion 
Chapter 4: Mass Spectrometry in the Diagnosis of Renal Amyloidosis and its 
Subtypes 
 
Aim 
The pitfalls of current established diagnostic techniques, specifically immunohistochemistry 
(IHC), have been highlighted in the ‘Introduction’ session. This study was undertaken to 
investigate whether a method could be established, namely proteomics, by which 
amyloidogenic variants, specifically Fibrinogen A α-chain, could be identified in a sensitive 
and specific manner.  
 
Introduction 
Amyloidosis is a disorder arising from the extracellular deposition of insoluble proteins, in a 
β-pleated form [13]. Examination under light microscopy reveals the presence of amorphous 
deposits that further stain red following the application of Congo red dye and, 
characteristically, demonstrate apple-green birefringence under cross-polarised light [265]. 
Electron microscopy further reveals the presence of rigid, non-branching fibrils 7.5 to 10nm 
in diameter and as explained more extensively in the introduction, this deposition eventually 
leads to both the structural and functional deformation of organs, with the exact pattern and 
severity of disease depending upon the subtype of amyloid fibril protein involved [22]; with 
AL amyloidosis and reactive or secondary AA amyloidosis being the commonest forms 
[283]. The current techniques employed to diagnose the amyloid subtype are not without 
significant pitfalls. IHC is not diagnostic in up to 50% and 10% of cases of AL and AFib 
amyloidosis respectively [94, 284]; this may be due to high background staining secondary 
to serum contamination and loss of epitope detectability in the tertiary structure, due to 
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protein cross-linking after formalin fixation [67] [253]. Mass spectrometry may prove to be a 
more sensitive and specific method by which to diagnose the particular amyloid subtypes 
[266] [267]. Furthermore, IHC requires the application of different antibodies on separate 
slides which is a labour-intensive process. 
 
Renal amyloid deposition in AFib has a very typical appearance on light microscopy: 
typically there is extensive deposition of amyloid which is confined to the glomeruli and 
causes their enlargement and almost complete obliteration [151]. The tubulointerstitial space 
and vessels are, by comparison, almost completely spared. Immunohistochemical staining 
with antibodies is very specific for the fibrinogen Aα chain and a previous study of 71 patients 
by Gillmore et al., found the sensitivity to be 93%, with the remaining cases being identified 
through direct DNA sequencing, typical renal morphology and a family history and/or a 
disease course typical for AFib amyloidosis. In this group, SAP scintigraphy revealed tracer 
uptake in 89% of patients and splenic uptake in 21% [151]. Thus far, gene sequencing has 
led to the recognition of a range of fibrinogen A α-chain variants that give rise to this condition 
and there is evidence that the presenting age, severity of disease and prognosis varies 
between the different genotypes. There are currently 15 known amyloidogenic fibrinogen A 
α-chain variants arising from both single nucleotide substitutions and frameshift mutations:  
-Glu526Lys, Pro552His, Gly519Arg, Glu526Val, Gly555Phe, Thr538Lys, Arg554Leu, 
Arg554Leu, Glu540Val, Val522Alafs*27, Pro552His, Glu524Glufs*25   Phe521Serfs*27, 
Glu540Val). The first described and most common amyloidogenic variant is E526V, which 
arises from a single point mutation resulting in the substitution of valine for glutamic acid at 
position 526 of the mature protein [94].   
 
As mentioned in the introduction, patients with AFib amyloidosis show a progressive 
worsening of function, typically presenting with nephrotic syndrome and hypertension in the 
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5th decade of life. CKD usually develops within 1-5 (median 4.6) years from the time of 
diagnosis and when progression to ESRD has occurred, there is an estimated survival time 
of approximately 9 years and survival from the time of presentation is typically 15 years [94]. 
Hence, the diagnosis of this rapidly progressive renal disorder is of the utmost importance 
in planning renal replacement therapy, including renal transplantation and considering the 
potentially curative procedure of hepato-renal transplantation [274]. It is also becoming 
increasingly evident that the identification of the particular variant is important in predicting 
disease trajectory, which may vary between different subtypes. 
 
Methods Specific to this Study 
Specimen Preparation and Microdissection 
We undertook laser dissection and mass spectroscopy on 165 renal biopsies, received from 
centres that had referred patients to the NAC for diagnostic and treatment advice purposes. 
10 µm thick sections of formalin-fixed paraffin embedded tissues were stained with Congo-
Red dye. Samples that stained with the dye were first identified under bright field light and 
then viewed under cross-polarised light to demonstrate the previously discussed tinctorial 
properties that are unique to amyloid fibrils. Immunohistochemical stains were performed 
with the aid of a DAKO Autostainer (Dako North America Inc., Carpinteria, CA, USA) using 
the Dual Link Envision+ or ADVANCE (Dako) detection systems.  Antibodies were directed 
against the following antigens, with the corresponding clones for the monoclonal antibodies 
specified: CD3 (Novocastra, Newcastle, UK; clone PS1; dilution 1:50), CD20 (Dako; clone 
L26; dilution 1:60), CD68 (Dako, clone KP-1; dilution 1:3000), CD138 (Dako; clone M115; 
dilution 1:50), Kappa Free Light Chains (Dako, polyclonal, dilution 1:6000 ), Lambda Free 
Light Chains (Dako; polyclonal; dilution 1:2000 ), Lambda Light Chain (Auto ProEnzyme 
pretreatment; Dako; polyclonal; dilution 1:3000), Prealbumin (Transthyretin) (Dako; 
polyclonal; dilution 1:5000 ), Serum Amyloid A (SAA; Dako; clone MC-1;  dilution 1:1000), 
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and Serum Amyloid P component (SAP; Biocare; polyclonal, dilution 1:20) and Fibrinogen 
(FB) 1:400 camb bioscience. 
  
Laser section microdissection and protein identification via mass spectrometry was 
undertaken as described previously in the Material and Methods’ section.  
 
PCR and Direct Sequencing of the FGA gene 
 
Genomic DNA was extracted from whole blood treated with EDTA as previously described 
[273].  A 707-base pair fragment of exon 5 of the fibrinogen α-chain gene (FGA) was 
amplified by polymerase-chain-reaction assay (PCR) and analysed by automated 
sequencing.  PCR was carried out with Ready-To-Go tubes (Amersham Pharmacia Biotech) 
with the use of solutions and cycling conditions that have been previously described [285]. 
The PCR products were purified with a QIAquick PCR purification kit (Qiagen) according to 
the manufacturer’s protocol and sequenced with the Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) following the procedures recommended by the 
manufacturer.  Sequence of the FGA gene was analysed on the ABI 3130xl Genetic 
Analyser using Sequencing Analysis Software version 5.4. 
 
Results 
From these 165 biopsies, 58 patients were identified by microscopy, to have isolated 
glomerular amyloid. Light microscopy, staining with antibodies and gene sequencing 
revealed that 32 of these patients had AFib and the remaining 26 ‘controls’ had other amyloid 
subtypes. Mass spectrometry was undertaken on all biopsies and revealed that the ‘amyloid 
signature’ was present in all cases (Table 4.1) i.e. ≥2 of apolipoprotein E, serum amyloid P 
component and apolipoprotein A-IV. 
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Table 4.1 Amyloid signature proteins 
 N ApoE SAP ApoA-IV 
AFib  32 32 (100%) 32 (100%) 14 (44%) 
Control 26 26 (100%) 25 (96%) 14 (54%) 
 
Results revealed multiple potential amyloid fibril proteins in most samples (table 4.2).  
Hence, it was important to identify the actual variant peptide of fibrinogen A α-chain in order 
to confirm the diagnosis of AFib amyloidosis. 
 
Table 4.2  Amyloid fibril proteins identified 
 N FibAα variant 
present 
N 
AFib 32 32 (100%)           
E526V(pGlu545Val)            
E524K(pGlu543Lys)       
P552H(pPro571His)         
R554L(pArg554Leu) 
29
1 
1
1 
Controls 26 0 (0%)  
 N FibAα Other amyloid fibril proteins 
AFib 32 32 (100%) 23 (72%) 
Controls 26 11 (42%) 26 (100%) 
 
An example of how variant peptides were identified when the sequences for known 
fibrinogen variants were added to the Uniprot database, is given below (Fig. 4.1): 
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4.1a.                                                                                                        
        
 
 
 
 
 
 
   4.1b 
                 
              
                
Fig 4.1. The most common mutation (p.Glu545Val or position 545 of the mature protein), This 
involves a single base substitution that alters the codon at position 526 of the mature protein from 
that for glutamic acid (GAG) to valine (GTG), as demonstrated by the circled area (Fig 4.1a). Primary 
search with results using the standard Uniprot database, 4.1b. Secondary search with results using 
the Uniprot database with the variant database appended, reveal the single mutation at position 545. 
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Results following findings post-searches using the Uniprot database with the additional 
database of known fibrinogen variants appended, are summarised in Table 4.3. 
  
Table 4.3 Gene sequencing was used to compare the presence or absence of a variant 
in each case. 
 N FibAα variant present N 
AFib 32 32 (100%) 
             E526V(pGlu545Val) 
             E524K(pGlu543Lys) 
             P552H(pPro571His) 
             R554L(pArg554Leu) 
 
29 
1 
1 
1 
Controls 26 0 (0%)  
 
Discussion 
This study demonstrates that proteomics can be used to successfully identify AFib 
amyloidosis on the basis of the presence of the variant peptide. The current techniques 
employed i.e. IHC and then gene sequencing are not without their own difficulties. Problems 
encountered include non-binding of antibodies to epitopes that may be ‘hidden’ such that 
the amyloid subtype cannot be identified [286]. Also a constellation of antibody tests is 
undertaken on each sample and this process can be avoided if mass spectrometry is used. 
The step of gene sequencing can also be omitted once a sufficiently large database of 
fibrinogen variants is acquired.  However proteomics, at present, has its own limitations and 
although used as an adjunct in particularly difficult cases, it is not currently being used in 
isolation for identification of amyloid subtypes and particular genetic variants. Problems 
encountered include: the easy introduction of background contaminants for example, if one 
did not have a fibrinogen database for variants, one would see fibrinogen in any number of 
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samples that have been contaminated with blood, not an uncommon occurrence. Wild-type 
fibrinogen A α-chain is not amyloidogenic so that identification of a variant peptide confirms 
AFib amyloidosis, as compared to ATTR in which the wild-type protein does form amyloid. 
The formalin fixation process can chemically alter proteins so reducing the efficacy of 
protease cleavage and/or altering the mass of resulting peptides. The timely processing of 
a large number of samples is also hindered by the need for a rate-limiting overnight trypsin 
digestion step. The variables discussed must be considered in the bioinformatics analysis 
to ensure accurate protein identification. Moreover, current quantitative analysis methods 
are based on the spectrum count, which ignores differences in protein length and may lead 
to misdiagnosis i.e. larger proteins generate more peptides. 
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RESULTS AND DISCUSSION 
 
Chapter 5: The Usefulness of Urinary Retinol Binding Protein Measurements 
in Amyloidosis  
 
Aim 
To investigate whether urinary retinol binding protein could potentially serve as a novel 
sensitive and specific biomarker for renal injury across the amyloid subtypes and, 
furthermore, provide prognostic information.  
 
Introduction 
AL amyloid, as previously mentioned, is the most prevalent of the amyloid subtypes and the 
kidney can be affected in 50-80% of cases. Not all subtypes affect the kidneys, whereas 
some subtypes exclusively deposit in the kidneys alone, with notable hereditary forms 
including Fibrinogen Aα, Gelsolin, ApoAI, ApoAII and ‘acquired’ types including AL 
amyloidosis arising from amyloidogenic light chains and AA amyloidosis, the latter arising 
from a chronic inflammatory source [95, 287, 288]. Proximal tubular involvement varies upon 
the subtype involved with renal impairment progressing less rapidly when tubulointerstitial 
rather than glomerular deposition predominates with heavier proteinuria being associated 
with glomerular lesions [31, 289]. Another extraglomerular manifestation of renal 
amyloidosis is Fanconi’s syndrome, reflecting injury to the proximal tubular cells (PTCs) by 
filtered light chains in the case of AL amyloidosis [290, 291]. There are 2 possible 
mechanisms by which light chains are believed to promote tubular toxicity. One is through 
their inherent toxicity towards PTCs, including tubulointerstitial inflammation and fibrosis, 
noted in vitro and in vivo and the other is through crystallisation in the proximal tubular 
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cytoplasm [292-296].  It is thought that injury to the PTCs by filtered LCs reduces the 
capacity of the tubules to reabsorb glucose, uric acid, bicarbonate and amino acids from the 
glomerular filtrate. This alteration in reabsorptive function produces Fanconi’s syndrome, the 
most readily identifiable signs of which are glucosuria and metabolic acidosis [291, 292]. 
More recently, work by Luciani et al, postulates that light chains accumulate in PTC 
lysosomes and alter their function leading to defective acidification so that the apical 
transport capacity of PTCs is lost [294].  
 
A ‘biomarker’, derived from the term ‘biological marker,’ has been defined by the National 
Institutes of Health Biomarkers Definitions Working Group as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention [297].”  The 
attributes of an ideal biomarker have previously been summarised and are widely accepted 
as including: being non-invasive, identifying the risk of developing an illness (antecedent 
role) including identifying subclinical disease (subclinical role), being sensitive and specific 
in diagnosing disease (diagnostic role), being robust, correlating rapidly and reliably with the 
degree of organ/process injury (staging and risk-stratification role), providing prognostic 
information (prognostic role), being site specific, being applicable across different 
populations, identifying possible mechanisms of injury e.g. prerenal, intrarenal, postrenal, 
being highly stable over time, different temperatures and pH and not interfering with drugs 
and being reproducible [298-301].  
 
There are a number of new biomarkers being identified and investigated, potentially to 
replace or aid the diagnostic and prognostic information obtained through an invasive 
biopsy. Currently, the only widely established and accepted renal biomarkers, not just in 
amyloidosis but in general nephrology, are serum creatinine (including the derived eGFR) 
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and urinary protein loss. Specifically, in AL amyloidosis, proteinuria >5 g/24h and eGFR <50 
mL/min predicted progression to dialysis best, as previously described [116]. Urinary RBP 
is being investigated as an important and sensitive biomarker for the loss of function of the 
human proximal renal tubule. It may also have a possible association with the extent of 
interstitial kidney fibrosis [296]. Damage to the proximal tubule leads to ‘tubular’ proteinuria 
as smaller proteins including RBP (21 kDa) are readily filtered by the glomerulus and appear 
in the urine when they fail to be re-absorbed in the proximal tubule. In the ‘healthy’ state the 
fractional tubular reabsorption of RBP is 99.97% and the presence of urinary RBP is 
therefore a sensitive marker of tubular dysfunction [296].   Marked tubular proteinuria with 
very high urinary RBP levels is found in hereditary forms of Fanconi’s syndrome, which 
include Dent’s disease, Cystinosis and Lowe syndrome. Lower levels are sensitive 
indicators of the carrier status of these hereditary disorders and also of toxic tubular damage 
[255, 295, 296].  Most recently, Li et al., retrospectively studied 119 AL amyloidosis patients 
and found that RBP had a significant positive correlation with blood urea nitrogen, serum 
creatinine, urinary κ light chains and urine protein and a significant negative correlation with 
creatinine clearance, eGFR and serum albumin [255]. However, they did not look at other 
forms of amyloidosis and it would be interesting to note whether there is any correlation with 
forms of amyloidosis other than AL. 
 
We sought to determine whether renal amyloidosis was associated with tubular proteinuria 
and in particular, whether non-AL renal amyloidosis was associated with evidence of 
proximal tubular dysfunction, in order to determine the relative contribution to tubular 
dysfunction from amyloid deposits as opposed to light chains. Further study will also help to 
determine whether urinary RBP has a role in predicting renal outcome among patients with 
a range of amyloid types.  
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Material and Methods Specific to this Study 
81 patients with known or suspected renal amyloid had fasting samples taken for renal 
profile, bone profile, serum glucose, glucosuria, urinary electrolytes and creatinine, 24 hour 
urine collection for proteinuria and spot urine RBP measurements performed between 6th 
November 2014 and 19th December 2014. In this study, the urinary RBP/creatinine ratio 
(RCR) was used as opposed to just the just the urinary RBP to account for differences in 
concentration of the urine. Patients were included in the study as they appeared on a routine 
clinic list between those dates i.e. there was no pre-selection.  All patients were managed in 
accordance with the Declaration of Helsinki, and informed patient consent and institutional 
review board approval from the Royal Free Hospital Ethics committee were obtained for this 
study. 
 
Analysis of Samples 
Urine samples immediately underwent urinalysis and aliquots were then stored at -80 
degrees Celsius without preservative and within an hour of collection, to reduce the risk of 
microbial contamination. They were analysed for urinary RBP and creatinine within a week 
of the study sample collection being completed and samples were thawed to room 
temperature only at the time of analysis. The analysis of urinary RBP was undertaken using 
a very sensitive immuno-nephelometric technique involving the use of latex enhanced 
antibodies (the Binding Site Group Limited, Birmingham), according to the manufacturer’s 
protocol and employing an ELISA technique [268].  The reference range for urinary 
RBP/creatinine ratio (RCR) using this method is 3.9-32 ug/mmol for children aged 10-16 
years and there is no adult reference range for this RBP method, although previous studies 
have found the upper limit of normal to be 17ug/mmol [302]. The Siemens BNII 
Nephelometer was used. Urine samples were centrifuged prior to assaying and controls 
were run with every batch of samples. All samples and calibrators were analysed in duplicate 
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and the mean absorbance results were plotted against calibrator concentration. Any 
samples with an absorbance greater than the top calibrator were re-assayed using a greater 
dilution. The measured values were normalised to the urinary creatinine concentration. The 
within batch coefficient of variation was <2% and the between batch coefficient of variation 
was < 5%, across the assay range.  Urinary creatinine was measured using the Jaffé 
method.  
 
Stick urinalysis was performed using Multistix (Bayer Diagnostics), according to the 
manufacturer's instructions and using an automated reader by the same person throughout 
the study. The degree of glucosuria was classified as negative, trace or more than trace 
(>100mg/dL).  
 
The glomerular filtration rate was estimated using the Cockcroft‐Gault equation (eGFR) 
[303]. Renal improvement or deterioration was defined as a 25% decrease or increase in 
serum creatinine or an increase or decrease in modified eGFR respectively, as per Gertz et 
al. [106].  The mean eGFR at initiation of renal replacement therapy (RRT) in 2013 was 8.5 
ml/min/1.73 m2 [304] and this was taken as the figure where patients started RRT.  Patients 
who did not fulfil the criteria for renal progression or deterioration were deemed to have 
stable kidney function.  
 
SAA levels were assayed with the use of latex-enhanced immunonephelometry (BN II 
analyser, Dade Behring) using the World Health Organisation's International Reference 
Standard. 
 
The renal tubular maximum reabsorption rate of phosphate to the glomerular filtration rate 
(TmP/GFR) was calculated [305], with values being derived from a fasting serum phosphate 
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and creatinine and a spot urinary phosphate. The normal range was taken as per the study 
by Minospla et al [306], with male or females >55 years old having a TmP/GFR of 0.80-1.35.  
 
Amyloid Load 
Quantitation of visceral amyloid deposition was by whole-body 123I-labeled SAP 
scintigraphy, as previously described [144]. Resulting images were assessed by two 
independent specialists and graded as a small, moderate or large load. 
 
Renal Biopsy Specimens  
Specimens for light microscopy were fixed in 10% formaldehyde (formalin) and embedded 
in paraffin, sectioned, and stained with haematoxylin-eosin, periodic acid–Schiff, Masson 
trichrome, and Jones silver methenamine. Specimens were initially assessed at the referring 
hospital and then sent to the National Amyloidosis Centre where they were further reviewed, 
alongside unprepared tissue samples. Tubular atrophy (TA) was graded in accordance to 
the percentage of atrophy seen in the total biopsy by 2 independent observers as per the 
MEST criteria in the Oxford Classification, with 0-25% being mild (T0), 26-50% (T1) being 
moderate and above 50% (T2) being severe [307]. In 7 samples, the amount of renal 
material was insufficient to accurately assess this and 2 biopsies were of extra-renal tissue 
i.e. liver and fat.  
 
All unprepared tissue samples were fixed in formalin and embedded in paraffin. Serial 
sections were stained with haematoxylin and eosin and six µm-thick renal sections were cut 
and stained with alkalinised Congo Red by the method developed by Puchtler et al. [265]. 
All such samples along with previously stained slides were viewed under cross-polarised 
light by two independent observers at the NAC to determine the presence of renal amyloid 
deposits. Immunohistochemistry was performed with commercially available monoclonal 
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antibodies directed against AA amyloid, polyclonal antibodies against amyloid P-
component, fibrinogen, lysozyme, transthyretin, λ-light chain, κ-light chain as well as non-
commercially available polyclonal antibodies directed against Apo A1, as described 
previously [284].  
 
DNA Sequence Analysis 
Genomic DNA was extracted from whole blood treated with EDTA as previously described 
and the following genes were sequenced; LECT2, Fibrinogen Aα chain, APOA1, APOA2, 
lysozyme [308]. 
 
Statistics 
Data were analysed using IBM SPSS Statistics version 19 (IBM, Somers, NY) and data are 
presented either as mean +/- SD or SE or median (range) for continuous variables. Ordinal 
variables are presented as frequency and percentage. Pearson two-variable correlation 
analysis was used between RCR and eGFR, proteinuria, TmP/GFR and serum albumin. 
Spearman’s rho “r” rank correlation co-efficient was used to analyse the correlation between 
RCR and amyloid load, glucosuria, TA and LC levels. A p value of <0.05 was taken as being 
statistically significant. Mean survival and SE was calculated by using Kaplan-Meier and 
follow-up and SE was calculated using reverse Kaplan-Meier. The Mann-Whitney U test was 
used in finding a difference in RCR values between different pathognomonic LCs in AL 
amyloidosis. 
 
Results 
81 patients were included in the study, 79 of those patients had a renal amyloid subtype, 1 
had light chain deposition disease (LCDD) and the other had MCD (table 5.1). The average 
age at inclusion of study was 65.9 years and the median follow up period by reverse Kaplan-
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Meier was 1.65 years (standard error 0.014). Mean survival by Kaplan-Meier was 1.61 years 
and standard error 0.04, with 7 patients having died during follow up. 51 (62.96%) of the 
patients were male. 
 
Further analyses were performed on the 79 patients with amyloidosis. Pearson two-variable 
correlation analysis between RCR and other laboratory characteristics showed that RCR 
had a significant and moderate negative correlation with eGFR only (r=-0.43 and p<0.001) 
and no significant correlation with serum albumin and proteinuria. In fact, there was no 
significant correlation between proteinuria and RCR in any of the various amyloid subtypes 
(RBP correlation for proteinuria. AA, r=0.506 and p=0.136; AL, r=0.144, p=0.272; Fib Aα, 
r=0.748. p=0.087; LECT2, r=0.027, p=0.983). Spearman’s rank correlation co-efficient was 
used to analyse the correlation between RCR and amyloid load (as seen on the SAP scan), 
glucosuria, TA and a change in eGFR at the end of the study. There was a significant 
negative correlation seen between RCR and glucosuria and a significant and moderate 
positive correlation between RCR and the degree of TA. There was no correlation between 
RCR and change in eGFR (p=-0.033 and p=0.785). 
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Table 5.1 Laboratory and imaging characteristics at baseline 
Diagnosis No. 
of 
Pts 
Median 
eGFR 
(ml/min) 
Median 
proteinuria 
(g/24hr) 
Median 
RCR 
(range) 
Amyloid 
Load*  
N/S/M/H 
(%) 
TmP/GFR 
Below 
NR (%) 
Glycosuriaᶧ 
N/T/>T 
(%) 
AL 60 39 2.78 66.65 
 (7.1-38675) 
23/47/22/
8 
22 87/5/8 
AA 10 26 3.31 2689  
(8-9577) 
0/40/60/0 20 60/30/10 
Fib Aα 6 23.5 23.5 696.9  
(44.8-10540) 
0/100/0/0 0 67/0/33 
LECT2 3 53.33 0 35 
 (3.6-1018) 
0/67/33/0 33 3/0/0 
LCDD 1 44 0.83 74.7  N/A 0 100/0/0 
MCD 1 >90 1.2 206 N/A 0 100/0/0 
 
*Amyloid Load: N= None, S=Small, M=Moderate and H=Heavy 
ᶧGlucosuria: N=None detected, T=Trace detected, >T=greater than trace detected 
Amyloid load: None, Small, Moderate, Heavy (N/S/M/H); LCDD: Light Chain Deposition Disease; 
MCD: Minimal Change Disease; NR Normal Range 
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Table 5.2 Correlation between RCR, serum eGFR, proteinuria, amyloid load, 
glucosuria, serum albumin, TmPGFR and tubular atrophy at baseline- for all patients 
with amyloid 
 eGFR Proteinuria Load 
on 
SAP 
Glucosuria Serum 
Albumin 
TmPGFR Tubular 
Atrophy 
Correlation 
Co-efficient 
-0.43 -0.19 0.06 0.65 -0.05 -0.301 0.450 
Significance 
(2- tailed) 
0.000064 0.093 0.6 5.93x10-11 0.659 0.007 <0.01 
 
The parallel box plots below demonstrate the comparative lie of data across the different 
amyloid subtypes, asterisked data denote outliers 1.5x greater than that demonstrated by 
the ‘range’ of data. 
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Fig 5. A comparative box plot showing median and interquartile ranges across the 
amyloid subtypes with circled and asterisked data denoting outliers.  
 
In order to better appreciate the lie of distribution, an AL outlier with an RCR value of 38 
675 ug/mmol has not been shown. 
 
Analysing just the AL group, the mean RCR level for patients with an amyloidogenic Kappa 
(n=10) LC pathology was 4921.1 (s.d. =12148.96) and for amyloidogenic Lambda (N=50) 
LC pathology was 1425.4, however this was not a significant difference (U=190.000, 
p=0.23). However, RCR values did significantly correlate positively with Lambda LC levels 
(r=0.434, p= 0.002) and had borderline significance for Kappa LCs (r=0.624, p=0.054), the 
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p value being influenced by the relatively small number of patients with pathogenic light 
chains (n=10 for Kappa). 
 
Discussion 
The values of RCR obtained in the study ranged from 3.6 to 38 675 µg/mmol and to date 
there are no studies detailing RCR results in the amyloid population, with the most recent 
study by Li et al, using RBP values alone and only for patients with AL amyloid. A study in 
the paediatric population reveals that RCR varied between 1.99 to 376 μg/mmol for MCD 
(not dissimilar to the single MCD patient in this study, who had an RCR of 206) and focal 
segmental glomerulosclerosis (FSGS) respectively. The range in the FSGS population was 
from 6.9 to 20398 µg/mmol [308]. The highest RCR value in this study, 38 675 µg/mmol, 
was for a patient with AL amyloid, an eGFR of 18, proteinuria of 0.27g/24h, significant levels 
of glucosuria and TmP/GFR of 0.63, a Lambda light chain level of 106 and perhaps 
unsurprisingly, severe TA on renal biopsy. These features reflect the general findings of this 
study, that is: 
 
A higher RCR value was correlated with: 
• worsening eGFR 
• a greater degree of glucosuria 
• a lower TmP/GFR i.e. decreased tubular phosphate reabsorption 
• more severe TA 
• higher levels of LCs (p=0.002 for Lambda LC levels and p=0.054 for Kappa 
LC levels) 
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We found no correlation between RCR and: 
• Change in eGFR over the course of the study 
• Load on SAP scintigraphy at baseline 
• Proteinuria 
• The type of LC (for patients with AL amyloidosis) 
• And serum albumin 
Higher RCR values are thought to reflect worsening tubular dysfunction, as demonstrated 
by in vitro and in vivo studies and a feature of some tubular disorders is Fanconi’s syndrome- 
characteristics of which can include a low TmP/GFR and glucosuria- as demonstrated by 
the findings of this study. Worsening tubular function would also tend to reflect disease 
activity in the kidneys as a whole and therefore the negative correlation with eGFR is again 
unsurprising. Those with RCR values in normal range, taken as <32 ug/mmol (n=29) and 
those with a RCR ≥ 32 µg/mmol (n=50) had a significant difference in mean eGFR 
(p=<0.001) with a mean eGFR of 73.86 and 36.84 mL/min/1.73 m2 respectively.  
As seen on the parallel box plots, the median values for AA amyloid were greater than the 
other amyloid subtypes although the interquartile range was similar to FibA amyloid. This is 
perhaps surprising considering that pathogenic light chains, as in AL amyloid, are believe to 
be toxic to the renal tubules but other amyloid fibril proteins are not known to be, suggesting 
that the amyloid itself is likely to disrupt tubular function. However, we could find no previous 
studies of non-AL amyloidosis for comparison. The median SAA level was 16.5 mg/L (range 
<3.2-41.9) and it is known that amyloid regression occurs in approximately 60% of patients 
when SAA levels are <10mg/L [40].  There was no correlation in this cohort between SAA 
levels and RCR values (r=-0.004, p=0.991). Differences in the degree of TA identified on 
renal biopsy between AL and AA patients also does not account for the higher RCR values 
found (p=0.513 not assuming equal variances), realising of course the sampling error 
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present in any biopsy.  It may be that an ongoing inflammatory process per se, has a 
disruptive effect on tubular transport mechanisms as we know that tubular epithelial cells 
are targeted by inflammatory mediators which can lead to cell necrosis, as discussed in the 
review by Cantaluppi et al. [309]. The inflammatory mediators can also work indirectly to 
damage tubular function by reducing renal perfusion and lead to ischaemia-reperfusion 
injury. Lachmann et al. in their observational study on AA amyloid discuss that the molecular 
mechanisms of tissue damage in AA amyloid remain unknown and are affected by additional 
insults including drug, sepsis, hypovolaemia and hypertension- so that actually these may 
account for tubular injury rather than the presence of raised SAA levels [40, 310].   
The analysis of these results for patients with hereditary amyloid is limited by their relatively 
small number.  However, our findings indicate that further study of a larger sample of this 
population is warranted. In terms of the prognostic value of RCR, there was no correlation 
between eGFR change and baseline RCR values, although one could extend the study 
further. Additionally, this was a prospective observational study and uncontrolled for 
treatment regimens i.e. there was variation in treatment received (if any) between patients 
with the same disease, such as chemotherapy regimes/ stem cell transplantation in AL 
amyloid and anti-inflammatories in AA amyloid. Controlling for these variables which are 
known to influence renal prognosis and outcome require large studies since the degree of 
suppression of the relevant fibril precursor protein (i.e. response to treatment) varies 
substantially between individual patients and is also dependent on other factors e.g. the 
extent of cardiac amyloidosis. It may very well be that the treatments themselves were 
tubulo-toxic and therefore would affect any prognostic association that baseline RCR values 
may have with changes in eGFR. 
There was no correlation between amyloid load as seen on SAP scintigraphy and RCR 
which is perhaps unsurprising as radioactive tracer uptake and subsequent renal tissue 
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distribution will be affected by declining eGFR. Hence, the burden of renal amyloid disease 
cannot simply be delineated from SAP scintigraphy.  
The correlation between higher LC levels and RCR values in patients with AL amyloidosis 
supports previous studies demonstrating the direct tubular toxicity caused by LCs. 
This study demonstrated that RCR values at baseline can add to the information provided 
by current biomarkers but cannot replace their usage. It also suggests that RCR values at 
baseline cannot be used to prognosticate changes in eGFR although further study including 
larger patient numbers is required to confirm this due to the large number of confounding 
variables such as the presence of cardiac amyloid, infections, effect of chemotherapy or 
other treatments. It also demonstrates that amyloid patients as a whole tend to have high 
RBP values and that higher RBP values correlated significantly with lower eGFR values. 
Surprisingly, patients with Fib A and AA amyloid tended to have higher RBP values. We 
would advise further studies with a greater number of patients with hereditary amyloid and 
AA amyloid, to see if our results can be reproduced. 
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 RESULTS AND DISCUSSION 
Chapter 6: Implanted Cardiac Rhythm Recorders in Advanced Cardiac AL 
Amyloidosis 
The publication arising from this chapter is: 
A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. 
Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood 
S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD. 
Eur Heart J. 2015 May 7;36(18):1098-105 
My contribution was designing, undertaking, analysing results and writing up the 
study. 
Aim 
I sought to characterise the nature of, and disease-related risk factors for, cardiac 
arrhythmias in patients with severe cardiac AL amyloidosis by offering insertion of an 
implantable loop recorder (ILR) to a series of consecutive patients with newly diagnosed 
Mayo stage III cardiac AL amyloidosis attending the UK National Amyloidosis Centre. I 
hoped that such a study would reveal possible new therapeutic strategies in this cohort of 
patients, who are known to have the worst prognosis in AL amyloidosis. 
 
Introduction 
Deposition of AL amyloid may occur in almost any organ but involvement of the heart, 
present in more than 50% of patients at diagnosis, is associated with a poor prognosis [311]. 
The presence and severity of cardiac AL amyloidosis is assessed through serum biomarker 
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concentration, echocardiography and CMR [28, 131].  Approximately one third of patients 
diagnosed with systemic AL amyloidosis present with cardiac failure and marked elevation 
of the cardiac biomarkers NT-proBNP and TnT; despite major recent advances in 
chemotherapeutic strategies for treating AL amyloidosis, these patients frequently die of 
SCD within 12 months of diagnosis [123]. Although ventricular tachyarrhythmias and PEA 
have been observed as terminal events, little is known about the electrical activity preceding 
terminal cardiac decompensation (129, 184, 185). There has been considerable interest for 
over 30 years in whether certain interventions such as anti- arrhythmic or chemotherapeutic 
drug therapy, or the implantation of PPMs or ICDs might improve survival in cardiac AL 
amyloidosis [186].  Unfortunately, due to the exceptionally poor prognosis of those with 
advanced (Mayo stage III) cardiac AL amyloidosis, they are rarely included in prospective 
studies of novel chemotherapeutic agents [182, 312].   
 
Materials and Methods Specific to this Study 
 
Patients 
Between July 2013 and May 2014, all patients attending the UK National Amyloidosis Centre 
with untreated, biopsy proven systemic AL amyloidosis who had an echocardiogram which 
was characteristic of cardiac infiltration by amyloid in conjunction with biomarkers indicating 
Mayo Stage III disease, and symptoms of either pre-syncope or syncope, were offered 
insertion of an ILR in accordance with National Institute of Health and Clinical Excellence 
(NICE) guidance.  None of the patients had previously received a cardiac device. 
 
Baseline Clinical Assessments 
A comprehensive clinical consultation was undertaken in each case. Further evaluation 
including an ECG, transthoracic echocardiogram including tissue Doppler imaging, whole 
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body 123I-serum amyloid P component scintigraphy scan, standardised 6 min walk test, lying 
and standing blood pressure measurements, NYHA and ECOG grading. Serological 
investigations included identification and quantitation of any circulating paraprotein and 
measurement of serum free light chains. First degree heart block and interventricular 
conduction delay were defined according to standard criteria (304, 305). Diastolic 
dysfunction on echocardiography was graded as mild, moderate, or severe and left 
ventricular (LV) strain was determined by tissue Doppler imaging, as previously described 
(306, 307). 
 
Patient Treatment and Follow up 
All patients received chemotherapy as standard treatment for systemic AL amyloidosis.  All 
medications including details of each chemotherapy regimen and any changes in dosage 
were recorded at baseline and throughout the follow up period.   
 
Where relevant, time to death was recorded and every effort was made to obtain clinical 
details and ILR recordings of the terminal event.  Where these showed a rhythm compatible 
with a cardiac output in the absence of such an output, the cause of death was attributed to 
PEA.  The censor date for surviving patients was 1st October 2014.   
 
Statistical analysis 
All statistical analyses were carried out using the SPSS 16.0 statistical software package. 
Cox regression was used to determine factors at baseline associated with death. Hazard 
ratios and 95% confidence intervals were expressed per unit rise in each variable. Estimated 
median follow-up time was calculated by the reverse Kaplan–Meier method, and median 
patient survival was calculated by Kaplan–Meier analysis. 
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Results 
Patients 
Baseline characteristics of 20 consecutive patients with untreated, histologically proven 
systemic AL amyloidosis and Mayo stage III cardiac biomarkers are shown in Table 6.1.  
Median serum high sensitivity TnT was 0.13 µg/L and median NT-proBNP concentration 
was 1410 pmol/L; 13 patients had NT-proBNP >1003 pmol/L (>8500 pg/mL), known to be 
associated with a particularly poor prognosis [123].  Organ involvement by amyloid, 
assessed by amyloid consensus criteria and by SAP scan within one day of ILR placement, 
is shown in Table 6.1 [106].  At baseline, six patients were receiving beta-blocker therapy, 
one was receiving amiodarone and another took flecainide whenever he had symptomatic 
paroxysms of atrial fibrillation.  Ten patients were receiving renin-angiotensin system (RAS) 
blockade and 16 were receiving loop diuretics (median daily furosemide dose equivalent 40 
mg) of whom two were additionally receiving 50 mg daily of spironolactone.   
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Table 6.1 Baseline characteristics of patients at the time of ILR placement, including comparison between surviving and 
deceased patients 
Characteristic    
All patients 
(N = 20)  Deceased (N = 13)  Alive (N = 7)  
Hazard ratio of death 
(95% CI); P-value  
Female  N (%)  5 (25)  3 (23)  5 (71)  
1.254 (0.340–4.619); 
0.734  
Age (years)  Median (range)  60 (34–78)  55 (34–75)  60 (55–78)  
0.990 (0.937–1.045); 
0.710  
Mean arterial pressure 
(mmHg)  Mean (range)  92 (70–110)  92 (70–108)  92 (82–110)  
1.017 (0.968–1.069); 
0.500  
Systolic blood pressure 
(mmHg)  Mean (range)  119 (91–143)  121 (92–143)  116 (91–143)  
1.024 (0.989–1.061); 
0.186  
Diastolic blood pressure 
(mmHg)  Mean (range)  77 (61–95)  78 (64–95)  76 (61–79)  
1.060 (0.991–1.133); 
0.091  
 NYHA Class  I and II  N (%)  9 (45)  4 (31)  5 (71)    
NYHA Class  III and IV  N (%)  11 (55)  9 (69)  2 (29)  2.23 (0.67–7.39); 0.186  
144 
Characteristic    
All patients 
(N = 20)  Deceased (N = 13)  Alive (N = 7)  
Hazard ratio of death 
(95% CI); P-value  
Six-minute walk 
test  Distance (m)  Median (range)  279 (0–640)  67 (0–516)  322 (270–640)  
0.997 (0.993–0.999); 
0.048  
High-sensitivity troponin 
T (μg/L)  Median (range)  
0.13 (0.05–
0.37)  0.13 (0.05–0.28)  
0.13 (0.07–
0.37)  
1.089 (0.004–324.60); 
0.977  
NT-proBNP (pMol/L)  Median (range)  
1410 (296–
6600)  1712 (473–6600)  552 (296–3321)  
1.000 (0.999–1.001); 
0.081  
Amyloidogenic serum 
FLC concentration, dFLC 
(mg/L)  Median (range)  
342 (34–
6544)  463 (65–6544)  177 (34–2322)  
1.000 (0.999–1.000); 
0.158  
Updated Mayo Clinic disease stage 
 I and II  Number (%)  0  0  0    
 III  N (%)  7 (35)  3 (23)  4 (57))  1.000  
 IV  N (%)  13 (65)  10 (77)  3 (43)  
1.987 (0.545–7.240); 
0.298  
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Characteristic    
All patients 
(N = 20)  Deceased (N = 13)  Alive (N = 7)  
Hazard ratio of death 
(95% CI); P-value  
Number of organs 
involved by amyloid  Median (range)  2 (1–6)  3 (2–6)  2 (1–5)  
1.060 (0.775–1.449); 
0.713  
Anti-arrhythmic therapy  
 β-Blocker  N (%)  6 (30)  5 (38)  1 (14)  NA  
 Amiodarone  N (%)  1 (5)  1 (8)  0  NA  
Flecainide (prn basis)  N (%)  1 (5)  0  1 (14)  NA  
Renin–angiotensin 
system blockade  N (%)  10 (50)  6 (46)  4 (57)  NA  
Diuretic therapy  
 Loop diuretic  
N(mg/day 
median)  17 (40)  11 (50)  6 (35)  NA  
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Characteristic    
All patients 
(N = 20)  Deceased (N = 13)  Alive (N = 7)  
Hazard ratio of death 
(95% CI); P-value  
Mineralocorticoid 
receptor antagonists  
N(mg/day 
median)  2 (50)  2 (50)  0  NA  
Sinus rhythm  N (%)  18 (90)  11 (85)  7 (100)  NA  
Atrial fibrillation/flutter  N (%)  2 (10)  2 (15)  0  NA  
PR interval (ms)  Median (range)  200 (80–272)  180 (80–272)  202 (120–248)  
0.998 (0.984–1.011); 
0.755  
QRS duration (ms)  Median (range)  102 (86–130)  102 (86–130)  98 (90–106)  
1.042 (0.999–1.086); 
0.054  
QTc duration (ms)  Median (range)  
455 (379–
518)  458 (379–518)  449 (401–457)  
1.018 (0.999–1.038); 
0.069  
LV ejection fraction by 
biplane simpson (%)  Median (range)  42 (28–60)  38 (28–60)  52 (37–60)  
0.014 (0.000–8.699); 
0.193  
Septal wall thickness 
(cm)  Median (range)  1.5 (1.2–1.9)  1.5 (1.2–1.9)  1.5 (1.2–1.8)  
0.743 (0.047–11.647); 
0.832  
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Characteristic    
All patients 
(N = 20)  Deceased (N = 13)  Alive (N = 7)  
Hazard ratio of death 
(95% CI); P-value  
E/E′ (diastolic function)  Median (range)  
19.9 (13.5–
33.4)  22.4 (17.0–33.4)  
17.7 (13.5–
29.3)  
1.053 (1.000–1.109); 
0.050  
Global strain by tissue 
Doppler imaging (%)  Median (range)  
−10.3 (−4.3 to 
−14.0)  −7.9 (−4.3 to −12.3)  
−11.9 (−9.8 to 
−14.0)  
0.799 (0.653–0.978); 
0.029  
 
LV, left ventricle; E/E′, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E′); dFLC, difference between 
amyloidogenic and uninvolved serum free light chain; NYHA, New York Heart Association; PR, QRS, and QT, relevant intervals on 
electrocardiogram; NA, not applicable; HR, hazard ratio (expressed per unit increase in variable). 
Significant differences are shown in bold.
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Eighteen patients, including one who was known to have paroxysmal atrial fibrillation, were 
in sinus rhythm (SR), one was in atrial flutter with variable AV block and one had atrial 
fibrillation.  The PR interval was normal at baseline among 8 of 18 patients, first degree heart 
block was present in 9 of 18 cases, and one patient had Mobitz type 1 second degree AV 
block (Wenckebach phenomenon).  There was intraventricular conduction delay in 11/20 
patients although none had complete bundle branch block, defined as QRS duration >0.12 
seconds, at baseline.  Echocardiograms showed moderate and severe diastolic dysfunction 
among 12 of 20 and 8 of 20 patients, respectively. Median E/E′ and E/A wave ratios were 
19.9 and 2.38, respectively, and median deceleration time was 145 ms. Median (range) 
global LV strain was −10.3% (−4.3 to −14.0) and median (range) difference between apical 
and basal strain was −9.5% (−3.7 to −29.3). 
 
Estimated median follow-up time from ILR placement was 308 days (range 10–399). All 
patients received chemotherapy as treatment for their systemic AL amyloidosis, commenced 
a median of 16 days after insertion of the ILR. Most received cyclophosphamide, bortezomib 
(Velcade), and dexamethasone (CVD) chemotherapy and the bortezomib and 
cyclophosphamide in each case were administered once per week at doses of 0.7–1.0 
mg/m2 and 250–500 mg respectively; steroid regimens and doses varied substantially (table 
6.2). 
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Table 6.2 Drug therapy including chemotherapy regimen, cardiac events, and outcome 
Pt
  
Baseline 
rhythm  
Nature of cardiac 
rhythm change  
Anti-arrhythmic 
medication 
prior to onset 
of cardiac 
rhythm change 
(or at censora)  
Chemotherapy regimen 
(days from last dose to 
cardiac rhythm change)  
Intervention  Outcome 
(days from 
ILR to 
death/ 
censor)  
1  SR  Sinus bradycardia (HR 
25–30 bpm), significant 
pauses followed by 
CAVB  
None  CVD (2)  None (NFR)  Died, 12  
2  SR  Bradycardia (HR 30 
bpm)  
Bisoprolol 5 mg 
od  
CVD (3)  None  Died, 22  
3  SR, 1st 
degree HB  
CAVB with significant 
pauses (HR 20 bpm)  
None  Lenalidomide/dexamethasone 
(14)  
CPR, TP  Died, 57  
4  SR, 1st 
degree HB  
CAVB (HR 25)  None  CVD (4)  CPR, PPM  Died, 10  
5  Atrial 
flutter  
CAVB (HR 20 bpm)  Amiodarone 200 
mg od  
CVD (3)  None  Died, 44  
6  SR  Sinus bradycardia (HR 
35 bpm)  
Bisoprolol 3.75 mg 
od  
CVD (7)  CPR  Died, 34  
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7  SR  None detected up to 4 
days prior to death  
None  CVD (3)  None  Died, 75  
8  SR  CAVB (HR 30 bpm)  Bisoprolol 1.25 mg 
od  
CVD (4)  CPR, TP  Died, 17  
9  SR, 1st 
degree HB  
Atrial flutter 120–160 
bpm  
None  CVD (4)  Atrial 
ablation  
Alive, 399  
10
  
SR  AF at >140 bpm  None  CVD (NA)  Amiodarone  Alive, 308  
11
  
SR  None detected  Nonea  CVD (NA)  NA  Alive, 353  
12
  
SR, 1st 
degree HB  
None detected  Nonea  CVD (NA)  NA  Alive, 357  
13
  
SR, 1st 
degree HB  
Sinus bradycardia, 
significant pauses and 
CAVB  
None  None (CVD later)  PPM  Alive, 300  
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14
  
SR, 
Wenckebach
  
CAVB (30 bpm) 
followed by NSVT  
Bisoprolol 1.25 mg od  CVD (6)  None  Died, 45  
15
  
SR  None detected up to 6 
days prior to death  
None  CVD (6)  None  Died, 36  
16
  
SR, 1st 
degree HB  
None detected  Bisoprolol 1.25 mg od  Melphalan/dexametha
sone (NA)  
NA  Died, 81  
17
  
SR, 1st 
degree HB  
None detected  Bisoprolol 1.25 mg od  CVD (12)  NA  Died, 65  
18
  
SR, 1st 
degree HB 
Paroxysmal 
AF  
AF  None  CVD (NA)  Amiodarone  Alive, 186  
19
  
SR, 1st 
degree HB  
AF at 140 bpm  None  CVD (1)  Bisoprolol  Alive, 193  
20
  
AF  None detected  None  CVD (NA)  NA  Died, 49  
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SR, sinus rhythm; CVD, cyclophophosphamide, velcade, and dexamethasone; HB, heart 
block; CAVB, complete atrioventricular block; TP, temporary pacing; PPM, permanent 
pacemaker; CPR, cardiopulmonary resuscitation; AF, atrial fibrillation; NK, not known; 
ChemoRx, chemotherapy treatment; od, once daily. 
a Medication at time of censor among those without a cardiac rhythm change. 
 
Patient Deaths 
Thirteen patients died and median overall survival by Kaplan-Meier analysis was 61 days.  
Weekly ILR recordings in all 13 patients failed to identify potentially fatal dysrhythmias during 
the course of treatment other than the immediate pre-cardiac arrest rhythm, identified only 
when the ILR was obtained posthumously (Table 6.3).  Eight of 13 patients died in hospital 
and the terminal event in all 8 cases was PEA.  Median time from onset of dysrhythmia to 
PEA was 1 hour (range 0.1 to 48 hours).  Five patients died at home or in a hospice.  The 
immediate pre-cardiac arrest recordings were retrieved from 8 of 13 patients and in all cases 
the initial change in cardiac rhythm was bradycardia ≤ 35bpm (Table 6.3), including complete 
atrioventricular block (CAVB) in 6 cases. Only 1 episode of rapid VT was recorded and this 
arose during CAVB-associated extreme bradycardia and spontaneously reverted to CAVB 
after 60 seconds.  
 
The only baseline parameters associated with risk of death were global LV strain on 
echocardiogram [P = 0.029; HR 0.799 (CI 0.653–0.978) per unit improvement in strain] and 
6 min walk distance [P = 0.048; HR 0.997 (CI 0.993–0.999) per meter] (Table 6.2).
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Table 6.3.  Events leading to cardiac arrest amongst patients who died 
Patient Baseline 
Rhythm and 
AV conduction 
Pre-‘cardiac arrest’ rhythm 
change 
Hours from onset of 
pre-cardiac arrest 
rhythm to PEA  
Intervention Cardiac activity and 
place at time of 
arrest 
1 SR 
 
Sinus bradycardia (HR 25-30 
bpm) with multiple pauses 
followed by CAVB 
48 None (NFR) PEA in hospital 
2 SR 
 
Bradycardia (HR 30 bpm) 0.5 None PEA in hospital 
3 SR 
1st degree HB 
CAVB and multiple pauses (HR 
20 bpm) 
12 CPR, TP (3 hours after 
development of CAVB)  
PEA in hospital 
4 SR 
1st degree HB 
CAVB (HR 25 bpm) 1.5 CPR and inotropic 
support, PPM (8.5 
hours after 
development of CAVB) 
PEA in hospital 
5 Atrial flutter 
 
CAVB (HR 20 bpm) with 
ventricular escape rhythm 
0.5 None PEA or asystole at 
home 
6 SR Bradycardia (HR 35 bpm) 0.1 CPR PEA in hospital 
7 SR 
 
NK (SR up to 4 days prior to 
death) 
NA None ILR recording 
unavailable,  
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Died at home 
8 SR CAVB (HR 30 bpm) 3 CPR, inotropic support 
and TP (5.5 hours 
after development of 
CAVB) 
PEA in hospital 
14 SR 
(Wenckebach 
Phenomenon) 
CAVB followed by 60 seconds of 
fast VT, then CAVB (HR 30 
bpm) followed by asystole 
1 None PEA or asystole at 
home 
15 SR 
 
NK (SR up to 6 days prior to 
death)  
NA None ILR recording 
unavailable, PEA in 
hospital 
 
 
Abbreviations: SR – sinus rhythm; CAVB – complete atrioventricular block; NFR – not for cardiopulmonary resuscitation, PEA – pulseless 
electrical activity; HR – heart rate; BPM – beats per minute; TP – temporary pacing; PPM – permanent pacemaker; NA – not applicable; ILR 
– implantable loop recorder; CPR – cardiopulmonary resuscitation, VT – ventricular tachycardia; NK – not known.  Where pauses are 
mentioned, these were >3 seconds
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Arrhythmias 
A total of 272 downloads were received during the course of the study.  Interestingly, none 
of the symptom-driven manual downloads showed any rhythm change from baseline.  
Arrhythmias that were captured automatically by the ILR and medical interventions for those 
arrhythmias are shown in Table 6.2.  Six (30%) patients had atrial arrhythmias detected at 
some point during the study period, including 4 patients who were in SR at baseline but 
developed an atrial arrhythmia during the course of follow- up.  One of six such patients was 
rate controlled without a requirement for anti-arrhythmic medication, 3 cases were 
successfully rate controlled with amiodarone, one with a beta-blocker, and one patient 
underwent successful atrial flutter ablation.  One patient who was alive at censor, developed 
2:1 AV block and rapidly progressed to CAVB. He was not receiving anti-arrhythmic therapy. 
He maintained his blood pressure until he had a pacemaker implanted and he remained 
pacemaker dependent throughout six cycles of CVD chemotherapy and at censor, 300 days 
later.   
 
Timing and dosage of chemotherapy in relation to onset of change in cardiac rhythm, 
including pre-terminal bradyarrhythmias, was variable and there was no consistent pattern 
to suggest that any particular chemotherapeutic agent or dosage was pro-arrhythmogenic.  
Among a total of 9 patients who developed severe bradycardia during the study, four were 
receiving beta blocker therapy and 1 was receiving amiodarone at the time.  One of seven 
surviving patients was receiving beta blocker therapy at censor, bisoprolol 1.25 mg daily.   
 
Discussion 
This is the first study of ILR placement in a series of patients with cardiac AL amyloidosis.  
Mayo stage III cardiac AL amyloidosis is associated with a high rate of SCD, particularly in 
patients with a history of syncope, and this study confirms previous observations [30, 186].  
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However, the surprising and completely novel finding here was that every available 
recording from the terminal syncopal phase prior to death showed that the initial cardiac 
decompensation was associated with development of marked bradycardia, usually caused 
by CAVB, and that despite chemotherapy with CVD, there was only one episode of non-
sustained ventricular tachycardia observed throughout the whole follow up period.  Our 
findings are consistent with previous suggestions that the terminal event in patients with 
cardiac AL amyloidosis is typically EMD/PEA, and also supports those who have reported 
that ventricular arrhythmias are uncommon in cardiac AL amyloidosis, although the data in 
this regard are conflicting [30, 129, 185, 186, 188].  The reasons for these discrepancies 
remain unclear but might be related to the use of different heart failure or chemotherapeutic 
agents or alternatively, related to disease severity.  It is possible that ventricular 
tachyarrhythmias in cardiac amyloidosis are frequently self-limiting and tend to occur in 
patients with relatively early stage disease but that, as the disease progresses, the likelihood 
of AV block and consequent bradycardia increases.  This hypothesis would also be 
consistent with the fact that ventricular tachyarrhythmias have been reported to be amenable 
to ICD therapy and have not generally been found to be an independent risk factor for poor 
prognosis in the context of AL amyloidosis [187].   
 
We propose two hypotheses regarding the pathogenic significance of severe bradycardia in 
cardiac AL amyloidosis.  It might simply be a pre-terminal event reflecting a very sick 
amyloidotic myocardium.  Alternatively, however, the reduction of cardiac output associated 
with bradycardia might be sufficient to induce global ischaemic stunning of the heavily 
infiltrated ventricular myocardium, triggering irreversible decompensation and progression 
to PEA within a short period.  This latter explanation is reminiscent of the observation that 
acute tubular necrosis, which is usually a reversible renal lesion which complicates an 
episode of renal ischaemia, rarely recovers in the context of pre-existing renal amyloidosis 
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however minor the ischaemic insult [313].  If ischaemic stunning is indeed the mechanism, 
it is likely that there may only be a very narrow time window in which to intervene among 
patients with cardiac AL amyloidosis who develop bradycardia.  In keeping with this 
hypothesis, the only patient in the cohort who survived severe bradycardia had his PPM 
inserted before losing cardiac output, whereas three patients who received a pacemaker 
after resuscitation from PEA succumbed shortly thereafter.  These two hypotheses could be 
reliably distinguished by prophylactic pacemaker insertion into patients with Mayo stage III 
cardiac AL amyloidosis who have pre-syncope or syncope.  If interrogation of the 
pacemakers revealed that rapid correction of bradycardia by cardiac pacing did not prevent 
the terminal decline seen here, this would constitute strong evidence that bradycardias are 
a ‘symptom’ rather than a ‘cause’ of terminal amyloidotic myocardial failure.  Interestingly, a 
recent study of prophylactic pacemaker insertion among patients with familial amyloid 
polyneuropathy, who typically have cardiac and neuropathic infiltration by amyloid 
composed of variant transthyretin and are at risk of conduction disorders, showed a 
reduction in major cardiac events over a 45-month mean follow-up among those who 
received pacemakers [314].  It is noteworthy that the absence of a definite survival 
advantage conferred by ICD implantation in individuals with cardiac AL amyloidosis does 
not exclude potential benefit from permanent pacemaker insertion and is entirely in keeping 
with our findings [185, 188]; the manufacturer’s setting for the pacing capability of standard 
ICD devices is routinely 35 bpm, similar to the typical ventricular escape rate among patients 
with CAVB, and it may simply be that the reduction in cardiac output associated with this 
cardiac contraction rate in an individual with a small, stiff ventricle exhibiting restrictive 
physiology is sufficient to induce global myocardial ‘stunning’ thus triggering the irreversible 
decline highlighted above.   
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One important remaining question is whether chemotherapeutic agents that are 
administered to treat systemic AL amyloidosis may worsen prognosis among those with 
severe cardiac infiltration, either by promoting arrhythmias or affecting systolic function.  
Among this small group of severely affected individuals, nearly all of whom received 
combination chemotherapy with cyclophosphamide, bortezomib (Velcade) and 
dexamethasone (CVD), there was no indication of direct drug toxicity; arrhythmias/SCD did 
not occur within 48 hours of administration of chemotherapy in any patient in the series.  
Furthermore, one patient developed CAVB prior to receiving chemotherapy, indicating a 
substantial contribution to the conduction disturbance from the disease itself.  Similarly, 
whether beta-blocker therapy should be completely avoided in patients with cardiac AL 
amyloidosis is not known and needs to be prospectively evaluated.  Further, larger ILR 
studies in patients with cardiac AL amyloidosis, including those receiving a wide variety of 
chemotherapeutic agents as well as conventional anti-arrhythmic and cardiac failure 
medications, will be useful to definitively answer the question of drug toxicity in patients with 
severe cardiac AL amyloidosis. 
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Fig. 6.  a)  ILR recording showing severe bradycardia in a patient who proceeded to 
have a permanent pacemaker implanted but subsequently died.  b)  ILR recording 
showing severe bradycardia followed by onset of ventricular tachycardia.   
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RESULTS AND DISCUSSION 
 
Chapter 7: Outcome of Light Chain Deposition Disease with Chemotherapy 
 
This chapter is based on the publication below: 
 
Natural history and outcome of light chain deposition disease. 
Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham 
S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD. 
Blood. 2015 Dec 24;126(26):2805-10 
 
 
Aim  
To report on the clinical presentation, histologic features, molecular basis and outcome 
among 53 patients with LCDD who were prospectively followed at the UK National 
Amyloidosis Centre, highlighting the importance of aggressively treating the underlying 
monoclonal proliferative disease. 
 
Introduction 
Light chain deposition disease (LCDD) is a multi-system disorder and, similar to AL 
amyloidosis, arises from the deposition of monotypic immunoglobulin LCs in various organs 
[258]. It is the most common subtype of a group of multi-system disorders characterised by 
the deposition of monoclonal immunoglobulin light (LCDD) or heavy chains (HCDD) or both 
(LHCDD) in various organs and termed monoclonal immunoglobulin deposition disease 
(MIDD) [258, 315, 316]. LCs are overproduced by an abnormal B- cell clone and so LCDD 
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is usually described in conjunction with a PCD or other lymphoproliferative disorders, most 
commonly multiple myeloma. However, it can occur in the absence of any detectable 
haematological disorder and is then called idiopathic LCDD. Clinical manifestations of LCDD 
vary, depending upon which organs are involved [317].  Since LCs are filtered by the 
glomeruli, reabsorbed in proximal tubules by receptor-mediated endocytosis, and degraded 
in tubular cells by lysosomal enzymes, the kidney is the principal target for LC deposition, 
and renal involvement and dysfunction usually dominate the clinical disease course [258, 
317-320].  Liver, cardiac and neural deposits have also been documented however, and 
need to be considered in all newly diagnosed patients with LCDD [319, 321, 322]. 
 
LCDD typically presents with hypertension, invisible haematuria and proteinuria and, in the 
absence of therapy, the clinical course is one of inexorably progressive CKD leading to a 
requirement for RRT [315, 317, 323, 324]. Reported outcomes with renal transplantation 
have generally been poor, with most allograft failures occurring within a few years from 
recurrent LCDD; with suppression of the underlying disease, recurrence could largely be 
avoided and transplantation could provide good renal excretory function and so obviate the 
need for dialysis [325, 326]. While some studies suggest that chemotherapy may slow renal 
decline, data is generally limited and in the form of individual case reports [327-329].  
 
Patients 
We included in this study all 53 patients with biopsy-proven LCDD followed at the NAC 
between 2002 and 2015.  Patients attended the NAC for their initial evaluation and were 
followed at regular intervals (usually six monthly) for evaluation of organ function and 
haematologic parameters.  Attendance at the NAC included a comprehensive clinical 
review, serial electrocardiographic and echocardiographic evaluation, and detailed serum 
and urine biochemistry.  No patients were lost to follow-up.  
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Demographic and clinical characteristics at the point of initial presentation, as well as 
laboratory and haematologic data, were obtained from referring centres.   
 
All patients gave informed consent and were managed in accordance with the Declaration 
of Helsinki.  The study was approved by the Royal Free Hospital Ethics Committee. 
 
             Materials and Methods Specific to this Study 
 
Renal Histology, Immunohistochemistry and Electron Microscopy 
All renal biopsies were processed by standard techniques for light microscopy, 
immunofluorescence and/or immunohistochemistry, and electron microscopy as has been 
described in the ‘Material and Methods’ Section’.  They were initially reported by trained 
pathologists locally and reviewed by the renal pathologist at the Royal Free London NHS 
Foundation Trust.  At the NAC, the biopsies were additionally stained with Congo red dye 
and viewed under cross-polarised light to exclude the presence of amyloid deposits.  Light 
microscopy was used to detect the presence of nodular glomerulosclerosis and mesangial 
expansion and all biopsies were examined under electron microscopy for the presence of 
electron dense deposits along the tubular basement membrane (TBM), glomerular 
basement membrane (GBM) and capillary basement membrane, a diagnostic requirement 
in LCDD [117, 322, 325].  All biopsies in which there was sufficient remaining material (48 
of 53) were stained with antibodies to kappa and lambda immunoglobulin light chains, IgG, 
IgM and IgA [330].  
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Haematologic Investigations 
All patients underwent a bone marrow biopsy to determine the plasma cell percentage and 
morphology.  The detection and characterisation of serum and urine monoclonal 
immunoglobulins was performed using conventional immunoelectrophoresis and 
immunofixation.  All patients additionally were tested for evidence of hypercalcemia, 
anaemia and osteolytic lesions [331, 332].  Patients were defined as having a renal lesion 
associated with monoclonal gammopathy of renal significance (MGRS) where the serum 
monoclonal protein was <30g/L and bone marrow plasmacytosis was <10% in the absence 
of hypercalcaemia, anaemia or osteolytic lesions [333]. 
  
Data on serum FLCs was not available for all patients at the time of biopsy as nephelometric 
measurements of serum FLCs (Binding Site, Birmingham, UK) only became available after 
2002.  In such cases, FLCs were obtained from stored serum samples.  
 
Table 7.1.  Haematologic response criteria 
Response Criteria 
Complete Response The normalisation of ĸ and λ ratio 
No detectable monoclonal protein by serum and urine immunofixation 
electrophoresis 
Very Good Partial 
Response 
Decrease in dFLC to <40 mg/l 
Partial Response >50% decrease in dFLC 
No Response ≤50% decrease in dFLC 
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ACR is achieved with normalisation of the ĸ and λ ratio and in the absence of a detectable 
monoclonal protein by serum and urine immunofixation electrophoresis, a VGPR occurs with 
a decrease in dFLC to <40 mg/l, a PR with>50% decrease in dFLC and no response with 
≤50% decrease in dFLC [334]. 
 
During follow up, patients were asked to provide monthly or two monthly serum samples for 
the measurement of FLCs and paraproteins, to allow the monitoring of the underlying clonal 
disorder.  A haematologic response assessment was performed at 6 months from the start 
of chemotherapy.   
 
Renal Investigations 
Proteinuria was measured from a 24 hr urine collection at presentation and 6-monthly or 
annually during follow up.  Glomerular filtration rate was estimated (eGFR) on the basis of 
the MDRD formula.  Nephrotic range proteinuria (NRP) was defined as 24 hour proteinuria 
≥3 g and nephrotic syndrome was NRP accompanied by serum albumin of <2.5 g/dL and 
peripheral oedema.  Hypertension was defined by systolic BP >140 mmHg or diastolic BP 
>90 mmHg or a requirement for antihypertensive medication.   
 
Renal course was determined by change in eGFR throughout follow up.  Patients who were 
on RRT prior to receiving chemotherapy (n=19) and those whose renal course was not 
determined after 6 months (n=2) were excluded from the analysis of renal response in 
relation to haematologic response, leaving 32 evaluable patients.   
 
Extra-Renal Investigations 
All patients were rigorously and repeatedly assessed for the presence of extra-renal 
involvement by LCDD.  Investigations included a standardised 6-minute walk test to monitor 
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changes in exercise tolerance, detailed echocardiography, and serology for cardiac (Nt-
proBNP and High sensitivity Troponin T), renal (creatinine, GFR), liver (albumin, alkaline 
phosphatase, alanine aminotransferase, gamma glutamyl transferase), bone (alkaline 
phosphatase, corrected calcium, phosphate) and haematological (coagulation profile, 
protein electrophoresis and free light chain levels) dysfunction.  When cardiac involvement 
by LCDD was suspected on the basis of biomarkers and/or echocardiography, cardiac 
magnetic resonance imaging and, where possible, endomyocardial biopsies were 
performed.  
 
In a single case of suspected peripheral neuropathy due to light chain deposition, this was 
discounted following nerve biopsies.  Liver LCDD was confirmed histologically in both cases 
in which it was suspected biochemically and lung LCDD was confirmed by surgical lung 
biopsy in a patient with panacinar emphysema, as previously described [335].  
 
Statistical Methods 
Renal outcomes (native and transplant) were censored at date of last GFR measurement 
either from the local treatment centre or from the last NAC evaluation, whichever was later.  
Patient survival was censored on 30th September 2014.  Kaplan-Meier analyses were used 
to investigate both renal and patient survival and the log-rank test was used to compare 
differences in stratified survival analyses.  Univariate analysis was used to investigate the 
association of histological features with GFR and proteinuria.  Mann-Whitney U tests were 
used to compare outcomes between patients with different categories of haematological 
response.  Median follow-up time was calculated using the reverse Kaplan-Meier method. 
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Study Limitations 
The diversity of local chemotherapy regimens and the small numbers in each treatment 
group, made analysis between each regimen difficult and therefore treatment response was 
compared broadly between bortezomib- and non-bortezomib based regimens.  
 
RESULTS 
Patients 
Fifty-one of 53 patients were diagnosed with LCDD on renal histology.  Two patients were 
diagnosed on liver biopsy; in each case there was established proteinuric CKD but a renal 
biopsy had not been performed.  The mean age at presentation was 56.3 years (range 29 
to 78 years) and male/female ratio was 2.3:1.  Patient demographics and clinical 
characteristics at the time of diagnosis are shown in Table 7.2.  At diagnosis, 94% of patients 
were hypertensive and 92% had haematuria.  The mean 24 hr urinary protein loss was 4.1 g 
(range 0.1 to 15.5 g/24hr).  Ten patients received RRT before their diagnostic biopsy, 
including 1 patient who was diagnosed with LCDD on a renal transplant biopsy, performed 
to investigate deteriorating allograft function.  Details of the underlying clonal dyscrasia and 
light chain isotype are included in Table 7.2.   
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Table 7.2. Demographic, clinical and haematological characteristics at diagnosis 
Characteristic Value 
Median (range) age (years) 56.3 (29-78) 
Gender (male/female) (n) 37/16 
Race (n) 
        White 
        Black 
        Asian 
 
51 
1 
1 
Hypertension (n) 50 (94%) 
GFR 
                     CKD Stage 1 
                    CKD stage 2/3 
                    CKD stage 4/5 (including RRT) 
 
0 
23 (43%) 
30 (57%) 
Mean eGFR (ml/min)a 27 (0-79) 
RRT before diagnosis (n):  
  Dialysis 
                    Transplant 
 
9 (17%) 
1 (2%) 
Mean(range)  urinary protein loss (g/24hr)  4.1 (0.1-15.5) 
Nephrotic range proteinuria (nb) 24/45 (53%) 
Nephrotic syndrome (nb) 10/45 (22%) 
Microscopic haematuria (nc) 45/50 (90%) 
Haematological findings 
Frequency of Abnormal FLC levels 
LC isotype  
         Kappa 
         Lambda 
 
 
 
100% 
43/53 (81%) 
10/53 (19%) 
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Median (range)  Pathogenic FLC Value (mg/L) 
                       Kappa 
                       Lambda 
 
Median (range) FLC ratio ĸ:λ (mg/L) 
                        Kappa 
                        Lambda 
 
BJP by UPEP/UIFEb (n) 
Monoclonal protein in serum detected by immunofixation (n) 
No monoclonal protein in serum detected by immunofixation (n) 
 
724 (25.6-25700) 
147 (29.8-742)  
 
 
29.2 (2.9-150.8) 
0.17 (0.05-0.2) 
 
20 (44.4%) 
23 (43.4%) 
 
19 (35.8%)  
Extra-renal Involvement 
                        Cardiac 
                        Hepatic 
                        Lung 
                        Neuropathy 
5 (9.4%) 
2 (3.8%) 
2 (3.8%) 
1 (1.9%) 
0 (0%) 
Underlying Clonal Cell Disorder 
              PCD 
   ≥10% plasma cells 
   <10% plasma cells 
              CLL (n/N) 
 
52 (98%) 
 6 (11.3%) 
 46 (86.8%) 
1 (2%) 
BJP, Bence Jones Protein; CKD, chronic kidney disease; CLL, chronic lymphocytic leukaemia. LC, 
light chain MGRS, monoclonal gammopathy of renal significance; RRT, renal replacement therapy; 
UPEP/UIFE, urine protein electrophoresis/urine immunofixation electrophoresis.  a-an eGFR of 0 
was used for patients on renal replacement therapy, b - no 24-hour urine collection performed 
among 8 of those receiving dialysis at the time of renal biopsy, c -- no documentation of 
presence/absence of haematuria in 3 patients. 
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Histology 
Renal biopsy findings are detailed in Table 7.3.  
 
Table 7.3  Renal biopsy histology 
 Number of 
Patients (N=51) 
Percentage 
Patients 
Light microscopy 
 Nodular mesangial sclerosis 
 
29 
 
56.9 
             Interstitial fibrosis 31 60.8 
 Tubular atrophy 43 84.3 
 Mesangial expansion 25 49.0 
Immunofluorescence microscopy 
     Specific staining with ‘causative’ light chain* 
 Non-specific staining with κ and λ 
            Absence of staining with either κ or λ 
              Insufficient material 
 
24 
2 
20 
5 
 
47.0 
3.9 
39.2 
9.8 
Electron microscopy 
Electron dense deposits 
            GBM 
             TBM 
            Mesangial 
              Vascular 
            Subepithelial 
            Subendothelial 
 
51 
34 
20 
23 
6 
2 
15 
 
100 
66.7 
39.2 
45.1 
11.8 
3.9 
29.4 
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 On LM, nodular mesangial sclerosis (Figure 7.1A) was present in 56% of patients, 
mesangial expansion in 49%, tubular atrophy in 84%, and interstitial fibrosis in 61%.  
Amyloid deposits were excluded by Congo red staining in all biopsies.  Nearly one third of 
cases failed to stain specifically with antibodies against kappa or lambda immunoglobulin 
LCs (Figure 7.1B, 7.1C), although in every such case there was unequivocal evidence of a 
clonal proliferative disease by sFLC assay, typical LM findings, and characteristic granular 
electron-dense deposits along basement membranes by EM.  Indeed, granular electron-
dense deposits were identified by EM in all renal biopsies, as well as in the 2 respective liver 
specimens. 
 
Fig. 7.1 Histology in LCDD  
 
 
(A) Nodular glomerulosclerosis. High 
power view of a glomerulus exhibiting 
mesangial expansion by periodic acid-
Schiff–positive matrix that focally forms 
nodules with peripheral expansion 
producing lobules (periodic acid-Schiff 
stain, magnification ×400). (B) Granular 
electron dense deposits along the lamina 
rara interna of the glomerular basement 
membrane are seen on electron 
microscopy (magnification ×11 500). (C) 
Absence of specific mesangial staining 
with anti-λ antibodies, despite the 
presence of high background staining 
(magnification ×600) 
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None of the histological features were significantly associated with either baseline GFR or 
degree of proteinuria.  Furthermore, neither the presence of nodular glomerulosclerosis 
(P=0.639) nor interstitial fibrosis (P=0.475) was significantly associated with renal survival. 
 
Renal outcomes in relation to baseline investigations 
Median follow-up for the whole cohort was 6.2 years (range, 1.1-14.0 years). Among 43 
patients who were not receiving RRT at the time of diagnosis, the mean rate of GFR decline 
(prior to RRT or death) was 3.7 mL/min per year. Twenty-three patients commenced dialysis 
during follow-up; median renal survival from diagnosis by Kaplan-Meier estimate for those 
who were not already receiving RRT at baseline was 5.4 years (Figure 7.2A). Unsurprisingly, 
CKD stage at diagnosis had a significant impact on renal survival with those who had CKD 
stage 2 or 3 at diagnosis remaining dialysis independent for a median of 9.0 years compared 
with only 2.7 years among those with CKD stage 4 or 5 at diagnosis (excluding the 10 
patients already receiving RRT at the time of biopsy; P = 0.004; Figure 7.2B). There was no 
significant difference in renal survival between patients who had nephrotic range proteinuria 
(>3 g/24 hr) at diagnosis and those with subnephrotic proteinuria, although proteinuria >6 
g/24 hr was associated with reduced renal survival (P = 0.017). Renal survival was not 
influenced by the degree of bone marrow plasmacytosis. 
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Fig 7. 2 Renal and patient survival in LCDD. (A) Median renal survival from diagnosis of 
LCDD was 5.4 years. (B) Renal survival was significantly longer among those who were 
diagnosed, whereas eGFR was ≥30 mL/min per year compared with those diagnosed once 
GFR was <30 mL/min per year (P = .004). (C) Renal survival was significantly longer among 
patients who achieved a hematologic CR/VGPR with first-line chemotherapy compared with 
those who achieved a hematologic PR/NR (P = .005). (D) Renal survival from ASCT among 
11 patients with median GFR of 24 mL/min per year at the start of the procedure. (E) Patient 
survival from commencement of dialysis, censored at the time of transplantation. (F) Patient 
survival from diagnosis of LCDD; median estimated survival was 14.0 years. 
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Renal outcome in relation to haematologic response 
We compared renal outcomes among 32 evaluable patients who achieved different levels 
of clonal response (as determined by changes in their dFLC values) to chemotherapy and/ 
or ASCT, where the latter was being administered to achieve a haematologic response and 
not to consolidate an ongoing response to chemotherapy.  The chemotherapy regimens that 
were administered to these patients are shown in Table 7.4 and, as there are no existing 
guidelines as to treatment of LCDD at the time of the study, chemotherapy choice was left 
to the patients’ local centre.  
 
Table 7.4.  Chemotherapy regimens and haematologic response 
 n/32 CR VGPR PR NR 
Cyclophosphamide, Bortezomib, 
Dexamethsone (CyBorD) 
4 3  1  
Cyclophosphamide, Thalidomide, 
Dexamethsone (CTD) 
9 4 2 1 2 
Vincristine, Adriamycin, Dexamethasone 
(VAD) 
2 2    
Velcade, Dexamethasone 4 4    
Melphalan, Dexamethasone 3    3 
Lenalidomide, Prednisolone 1   1  
Melphalan autologous stem cell transplant 4 4    
Thalidomide, Dexamethasone 1    1 
Thalidomide, Prednisolone 1    1 
Rituximab, Cyclophosphamide 1   1  
Cyclophosphamide, Dexamethasone 1 1    
No treatment 1    1 
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There was a mean improvement in GFR of 6.1ml/min per year from a baseline of 26 ml/min 
among 21 patients who achieved a haematological Complete Response (CR)/Very Good 
Partial Response (VGPR), compared with a mean GFR loss of 6.5 ml/min per year from a 
baseline of 34 ml/min among both those who achieved a Partial Response (PR) (n=4) and 
those who failed to achieve a haematologic response to chemotherapy, No Response (NR) 
(n=7) (Figure 7.3, P=0.005).  Only 3 of 21 patients who achieved an initial haematologic 
CR/VGPR required RRT throughout follow up, compared to 6 of 11 patients who achieved 
an initial PR/NR (P<0.04).  Median time to haematologic relapse among responders was 
3.6 years. 
 
 
 
 
Sixteen patients in the whole cohort (median age, 50 years; range, 38-72 years) received a 
melphalan-conditioned ASCT. Median pre-treatment bone marrow plasmacytosis among 
those who underwent ASCT was 12% (range, 4-50%). Four patients were dialysis 
Fig. 7.3 
Rate of change of GFR in 
relation to hematologic 
response. The scatter graph 
and plots below demonstrate 
the rate of change in GFR 
per year and the mean ± 
standard error of the mean 
for each dataset for patients 
with varying degrees of 
clonal response. GFR 
increased among those 
achieving either a 
hematologic CR or VGPR but 
declined among those who 
achieved only a PR or NR 
with chemotherapy (Mann-
Whitney U test, P < .009). 
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dependent prior to ASCT, the aim of which was to suppress the plasma cell dyscrasia to 
decrease the likelihood of disease recurrence following subsequent renal transplantation, 
and 1 patient had a functioning renal transplant at the time of ASCT. One patient with pre-
existing severe myopathy, aged 72 years, died during ASCT from pneumonia (transplant-
related mortality, 6.7%). Median GFR prior to ASCT among 11 patients not requiring RRT 
was 24 mL/min per year (range, 11-51 mL/min per year), which had increased among the 
10 surviving patients to 38 mL/min per year (range dialysis to >90 mL/min per year) at the 
end of follow-up. Thirteen of 15 patients who survived ASCT achieved a hematologic CR 
and 2 achieved PR. After a median follow-up from ASCT of 4.4 years (range, 0.04-12.2 
years), only 2 of 14 patients required further chemotherapy for haematologic relapse, 
administered 5.2 and 5.5 years later. Only 3 of 11 patients who were not on RRT prior to 
ASCT, all of whom had CKD stage 4 at the time of ASCT, eventually required dialysis 2.4, 
2.6, and 2.8 years after the procedure; it is notable that all 3 patients had persistent 
nephrotic-range proteinuria following ASCT, whereas proteinuria fell following ASCT in all 
patients who remained dialysis independent. Renal survival after ASCT (censored at death) 
by Kaplan-Meier analysis for the cohort of 11 dialysis-independent patients is shown in 
Figure 7.2D; at censor, median renal survival had not been reached. 
 
Outcomes with RRT 
Dialysis 
Thirty-three (62%) patients from the whole cohort required dialysis during their disease 
course (including 10 from before the diagnosis of LCDD). Eight patients received peritoneal 
dialysis and 25 received haemodialysis. Median patient survival from commencement of 
dialysis, censored at transplantation, was 5.2 years (Figure 7.2E), and there was no 
difference in survival between those commencing different dialysis modalities (P = 0.336). 
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Renal Transplantation 
Seven patients from the whole cohort underwent renal transplantation, and in 3 of these 
cases, the transplant failed. Cause of renal allograft failure was biopsy-proven LCDD 
recurrence in 2 patients and rejection secondary to noncompliance with immunosuppression 
in the remaining patient. Neither patient whose LCDD recurred had received chemotherapy 
prior to renal allograft failure, which occurred after 1.6 and 1.9 years. The 4 remaining 
patients had GFRs of 45, 44, 50, and 50 mL/min per year at censor 9.7, 6.2, 5.1, and 0.8 
years after renal transplantation, respectively, without clinical, biochemical, or histologic 
evidence of LCDD in their allografts. One of these patients underwent a high-dose 
melphalan ASCT shortly after renal transplantation without loss of GFR during the 
procedure, and the other 3 patients received an ASCT prior to renal transplantation. The 
latter 3 patients remained in complete hematologic remission at censor 9.6, 8.6, and 6.8 
years after ASCT. 
 
Extra-Renal Outcomes 
There was improvement in cardiac (2 patients) and hepatic (2 patients) function among 
those with extra-renal LCDD who achieved a haematologic response.  NT-proBNP values 
fell from 909 to 6 pmol/L and from 1714 to 296 pmol/L. in association with an improvement 
in diastolic function on echocardiography in both patients with cardiac infiltration.  Alkaline 
phosphatase levels fell from 276 to 71 iu/L and from 522 to 159 iu/L in both patients with 
hepatic LCDD.  One patient with pulmonary LCDD who achieved a haematologic CR has 
had stable spirometry but has failed to improve clinically and was awaiting lung reduction 
surgery at the time of censor.   
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Patient survival 
Median estimated patient survival from diagnosis by Kaplan-Meier analysis for the whole 
cohort was 14.0 years (Figure 7.2F). Nineteen patients died during follow-up, and causes of 
death were infection (n = 6), ischaemic heart disease (n = 4), ESRD (n = 3), congestive 
cardiac failure (n = 2), cerebrovascular accident (n = 1), gastrointestinal haemorrhage (n = 
1) and multiple myeloma (n = 2). 
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Discussion 
The prolonged follow-up of this large cohort of patients with LCDD highlights systematically 
for the first time the relationship between the response of the underlying haematologic 
disease to chemotherapy and renal outcome in this disease.  The rate of native GFR loss, 
among those who did not achieve either a CR or VGPR haematologic response with 
chemotherapy, was 6.5 ml/min per year. This is markedly higher than that reported by 
Davies et al., where the average decline in GFR was 0.8 and 1.4 ml/min/yr for women and 
men >66 years old, respectively [336].  This is not surprising since these patients were 
continuing to deposit light chains in their kidneys.  On the other hand, those who achieved 
a haematologic CR or VGPR with chemotherapy, had an improvement in GFR of 6.1 ml/min 
per year throughout the time that their clonal response was sustained and only 3 of 21 such 
cases required dialysis during follow up, despite a median GFR at the start of chemotherapy 
of only 26 ml/min per year.  These data clearly indicat that one should strive to achieve a 
haematologic CR when treating patients with LCDD, even in the context of pre-existing 
stage 4 CKD.  In addition, the data demonstrates that ASCT can be successful, even when 
undertaken at a low GFR (median 24 ml/min, range 11-51 ml/min in this cohort), apparently 
with little risk of precipitating a renal decline.  Unsurprisingly however, patients treated whilst 
their GFR was >30 ml/min had a substantially better renal survival (median nearly 9 years) 
compared to patients who started treatment having already reached CKD stage 4. These 
178 
findings highlight important differences between LCDD and the more commonly diagnosed 
prototypic disease of monoclonal light chain deposition, renal AL amyloidosis.  In renal AL 
amyloidosis, which is treated with chemotherapy in a similar fashion to LCDD, it is unusual 
to see improvements in GFR once CKD stage 4 has supervened, even in the context of a 
complete haematologic response [282].  Furthermore, ASCT in renal AL amyloidosis is 
associated with a risk of transplant-related mortality and of precipitating an irreversible acute 
decline in GFR, both of which would appear to be lower in LCDD [337].  Both bortezomib-
based regimens and melphalan conditioned ASCT were associated with high rates of 
CR/VGPR in this cohort. Of note, in impaired renal function the intravenous melphalan-dose 
is usually reduced by up to 50% to reduce the likelihood of severe myelosuppression.  
 
In the absence of a haematologic response, renal transplants failed rapidly from recurrence 
of LCDD, as previously reported [325].  However, among those patients who achieved a 
haematologic VGPR or CR before or shortly after renal transplantation, there was no 
evidence of recurrent LCDD, even after prolonged follow up. These findings imply that the 
optimal current treatment would involve a bortezomib-based regime and/ or ASCT to 
suppress pathogenic free light chain levels followed by renal transplantation. Inadequate 
free light chain suppression and subsequent renal transplantation resulted in renal 
recurrence.  
 
Extra-renal light chain deposits were only identified in 4 patients (7.5%) from this cohort, 
with one patient having both cardiac and liver involvement.  It is noteworthy that there did 
not appear to be an association between light chain concentration in the serum and 
presence of extra-renal disease.  In all such cases, the extra-renal disease course mirrored 
that in the kidneys following chemotherapy, such that improvements in both cardiac and 
renal function were observed in association with haematologic complete responses.   
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In conclusion, renal and patient survival, as well as tolerance of high dose chemotherapy is 
markedly better in LCDD than in systemic AL amyloidosis, where median patient survival 
from diagnosis is 35.2 months as compared to greater than 58% of patients with LCDD 
surviving for more than 15 years; native renal survival in AL amyloidosis from the point of 
diagnosis is 26.8 months as compared to 5.8 years in LCDD [282].  LCDD should be 
aggressively treated, even in patients who have advanced renal impairment.  Achieving a 
very good or complete haematologic response prevents early renal allograft failure from 
recurrent LCDD.   
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Chapter 8: General Conclusions and Further Studies 
 
The studies described in this thesis outline several novel findings concerning the diagnosis 
and treatment of amyloidosis and the related disorder, light chain deposition disease. 
 
The first study was a review of current methods, in the UK of amyloid diagnosis and pitfalls 
that may lead to misdiagnosis, specifically misdiagnosing amyloidosis as one of the 
commoner proteinuric disorders i.e. minimal change disease. If a thorough panel of staining 
had been performed, including Congo red staining, then in 65% of cases, amyloid could 
correctly have been identified. Furthermore, had electron microscopy been performed in all 
available samples, characteristic amyloid fibrils would have been identified. The median 
delay before reaching the correct diagnosis was 8 months, which of course has important 
implications in terms of initiating the correct treatment and the prognosis, especially as 78% 
of patients had cardiac involvement which we now recognise as being the main prognostic 
determinant. In fact, by the time of diagnosis, SAP scintigraphy revealed a moderate or large 
total body amyloid burden in a third of patients. Such a study evaluating current UK 
histological practice had not previously been undertaken. 
 
The subsequent study proceeded on from this and hoped to establish a relatively new and 
previously unused diagnostic method in the UK, that is proteomics, to diagnose amyloidosis 
and to specify the particular subtype in a sensitive manner. To this end, Fibrinogen A α- 
chain amyloidosis was investigated and again this had not previously been researched and 
a database of fibrinogen variants was initiated. The presence of amyloid was successfully 
identified through the presence of ‘signature’ proteins and, once sufficient variants have 
been identified, gene sequencing may also become redundant. Mass spectrometry and 
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subsequent proteomic analysis have now been established at the NAC and are used for 
every amyloid subtype although, as yet, this technique is in addition to and not instead of 
the more conventional techniques, such as IHC and genotyping. Issues that need to be 
overcome and investigated in further studies include limiting the presence of background 
contaminants, modifying the fixation process so that the subsequent cleavage and the mass 
of resulting peptides is not affected and modifying the rate limiting overnight trypsin digestion 
step. Another important issue is that proteomics remains a semi-quantitative technique and 
therefore larger proteins generating more peptides and therefore appearing more 
prominently in the list generated, are not necessarily the causative proteins. 
 
In order to further stratify renal damage non-invasively, specifically tubular damage and 
perhaps interstitial fibrosis and tubular atrophy and to help prognosticate renal outcome, I 
investigated a biomarker that has not yet been established as a bedside test for amyloidosis. 
Urinary retinol binding protein, usually standardised to the urine creatinine and termed as 
the RBP:Creatinine Ratio that is RCR, has only been analysed very recently in amyloidosis 
by Li et al. Furthermore, this study was only in patients with AL amyloidosis. I found that 
higher RCR values are correlated with a worsening eGFR, greater degree of glucosuria, 
decreased tubular phosphate reabsorption and more severe tubular atrophy across 
subytpes generally and higher levels of LCs for AL amyloid. Although increasing proteinuria, 
and therefore a lower serum albumin by association, is used as a marker of worsening renal 
function in amyloidosis- this did not correlate with RCR values. Interestingly, some of the 
RCR values obtained were higher than in any previously reported studies. In terms of further 
studies, some of the trends observed in the less common subtypes i.e. the hereditary 
amyloidoses or related disorders, such as LCDD failed to become significant and therefore 
including a greater number of these patients in any further studies would be useful. A more 
recent study has found that RBP is a significant prognostic marker in LCDD [338]. 
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Additionally, the patients included could be followed up for longer to see whether or not any 
prognostic values arise or if uRBP values indicate the degree of reversibility following acute 
on chronic kidney damage- as observed in non-amyloid patients [339]. 
 
  
An important theme that underlies much of the clinical care in amyloid patients and this 
research, is the importance of early diagnosis and treatment, primarily to reduce the burden 
of amyloid deposition and especially where cardiac involvement features. In order to address 
whether or not specific interventions i.e. the use of an implantable cardiac defibrillator, 
pacemaker and/ or certain medications could affect outcome once cardiac disease has been 
established, I undertook a prospective cohort study into the most severely affected cardiac 
amyloid patients. This provided an insight into the nature of arrhythmias and, in some cases, 
the pre-terminal events which, in all cases, was found to be asystole/ pulseless electrical 
activity preceded by the development of marked bradycardia. Additionally, once patients 
have been resuscitated from an episode of cardiac ‘arrest’ the insertion of a pacemaker does 
not seem to convey the same prognostic advantage as that inferred by pacemaker insertion 
prior to an episode of cardiac ‘arrest’ or ventricular standstill. There is no indication that 
patients with severe cardiac amyloid would benefit from prophylactic ICD insertion and 
further studies are needed to determine whether rate limiting medication, including beta-
blockers, should be avoided in severe cardiac amyloid.  
 
AL amyloidosis is the most prevalent form of amyloidosis in the developed world and it has 
been proposed that the light chains responsible possess some inherent amyloidogenic 
properties; LCDD also arises from the deposition of monotypic immunoglobulin light and/or 
heavy chains although these chains lack the inherent amyloidogenic property seen in 
amyloidosis. Treatment for LCDD is similarly through using chemotherapy although a 
comprehensive study of this disorder has not previously been undertaken. We found that 
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patients had to have achieved at least a very good partial response to chemotherapy in order 
for their renal function to improve and this stood true even for those patients who were 
already at CKD Stage 4, which differs to treatment response in patients with AL amyloidosis 
who were already at CKD Stage 4. However, renal outcome was better in LCDD when 
treatment was started with a greater renal reserve.  Additionally, autologous stem cell 
transplant related patient mortality and irreversible renal decline was lower in LCDD than in 
AL amyloid, even when undertaken at CKD Stage 4. Whatever the method or chemotherapy 
regimen, renal transplants failed rapidly from LCDD recurrence when a haematologic 
response was not achieved.  
 
To summarise, the research undertaken has: improved our understanding and need to 
employ best practise in order to avoid the misdiagnosis of renal amyloid, helped establish 
the use of proteomics in diagnosing amyloidosis and its subtypes in the UK for the first time, 
explored the value of urinary biomarkers in amyloidosis, investigated arrhythmias and, in 
particular, pre-terminal events and provided a comprehensive review of a previously 
understudied related disease. 
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